NCT,Subject,Predicate,Object
NCT02227108,"Leukemia, B-Cell, Acute",PROCESS_OF,Participant
NCT02227108,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Participant
NCT02227108,B-Cell Lymphomas,PROCESS_OF,Participant
NCT02227108,lymphoblast,LOCATION_OF,B-Cell Lymphomas
NCT02227108,lymphoblast,LOCATION_OF,B-Cell Lymphomas
NCT03022747,6-Mercaptopurine,INTERACTS_WITH,Thioguanine
NCT03022747,6-Mercaptopurine,INTERACTS_WITH,6-methylthiopurine
NCT03022747,6-Mercaptopurine,ISA,Therapeutic procedure
NCT03022747,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03022747,Methotrexate,ISA,Therapeutic procedure
NCT03022747,Therapeutic procedure,USES,6-Mercaptopurine
NCT03022747,Therapeutic procedure,USES,Methotrexate
NCT03022747,Thiopurine S-Methyltransferase,PART_OF,"Leukemia, Lymphocytic, Acute"
NCT03022747,Allopurinol,TREATS,Toxic effect
NCT03022747,Liver,LOCATION_OF,Toxic effect
NCT03022747,Allopurinol,ISA,Therapeutic procedure
NCT03022747,Hemoglobin,ISA,Therapeutic procedure
NCT03022747,Hemoglobin,USES(SPEC),Allopurinol
NCT03022747,Therapeutic procedure,USES,Allopurinol
NCT03022747,Allopurinol,ISA,Therapeutic procedure
NCT03022747,Therapeutic procedure,USES,Allopurinol
NCT03022747,6-Mercaptopurine,ISA,Therapeutic procedure
NCT03022747,6-Mercaptopurine,TREATS(SPEC),"Leukemia, Lymphocytic, Acute, L1"
NCT03022747,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT03022747,Therapeutic procedure,USES,6-Mercaptopurine
NCT03022747,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00991133,Cyclophosphamide,INTERACTS_WITH,clofarabine
NCT00991133,Etoposide,INTERACTS_WITH,clofarabine
NCT00991133,Vincristine,INTERACTS_WITH,clofarabine
NCT00991133,pegaspargase,INTERACTS_WITH,clofarabine
NCT00991133,pegaspargase,TREATS,Patients
NCT00991133,Treatment Protocols,USES,Pharmaceutical Preparations
NCT00991133,Cyclophosphamide,TREATS,Patients
NCT00991133,Cyclophosphamide,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00991133,Etoposide,TREATS,Patients
NCT00991133,Etoposide,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00991133,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00991133,Vincristine,TREATS,Patients
NCT00991133,Vincristine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00991133,pegaspargase,TREATS,Patients
NCT00991133,pegaspargase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00991133,clofarabine,TREATS,Patients
NCT00991133,clofarabine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03390387,Intermittent administration,USES,Dexamethasone
NCT03390387,Induction,TREATS,Toxic effect
NCT03390387,"Leukemia, B-Cell, Acute",PROCESS_OF,Adolescent
NCT03390387,"Leukemia, B-Cell, Acute",PROCESS_OF,Young adult
NCT03390387,Maintenance therapy,PREVENTS,Infection
NCT03390387,Induction,PREVENTS,Infection
NCT03390387,Compliance behavior,PROCESS_OF,Adolescent
NCT03390387,Compliance behavior,PROCESS_OF,Young adult
NCT03390387,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT03390387,bortezomib,TREATS,Patients
NCT03390387,bortezomib,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT03390387,Daunorubicin,TREATS,Patients
NCT03390387,Induction,TREATS,Patients
NCT03390387,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03390387,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT03390387,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
NCT01655875,Blood,LOCATION_OF,AMD 3100
NCT01655875,Acute leukemia,PROCESS_OF,Adult
NCT01655875,Marrow,LOCATION_OF,Transplanted organ and tissue status
NCT01655875,Marrow,LOCATION_OF,AMD 3100
NCT01655875,AMD 3100,TREATS,Acute leukemia
NCT01655875,AMD 3100,TREATS,Adult
NCT01655875,AMD 3100,TREATS(INFER),Acute leukemia
NCT01655875,Treatment Protocols,ISA,Therapeutic procedure
NCT01655875,AMD 3100,AFFECTS,Cells
NCT01655875,Participant,INTERACTS_WITH,Patients
NCT01655875,AMD 3100,ADMINISTERED_TO,Patients
NCT01655875,Bone Marrow,LOCATION_OF,AMD 3100
NCT01655875,Bone Marrow,LOCATION_OF,AMD 3100
NCT01655875,Bone Marrow,LOCATION_OF,Does push
NCT01655875,Pharmacotherapy,TREATS,Acute leukemia
NCT01655875,Blood,LOCATION_OF,AMD 3100
NCT01655875,Transplantation,TREATS,Acute leukemia
NCT01953770,Anthracycline Antibiotics,TREATS,Patients
NCT01953770,Methotrexate,TREATS,Patients
NCT01953770,Toxic effect,PROCESS_OF,Patients
NCT01953770,Late effect of,PROCESS_OF,Patients
NCT01953770,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01953770,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01503632,6-Mercaptopurine,ISA,Therapeutic procedure
NCT01503632,6-Mercaptopurine,TREATS,Patients
NCT01503632,6-Mercaptopurine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01503632,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01503632,Therapeutic procedure,USES,6-Mercaptopurine
NCT01503632,Pharmaceutical Preparations,ADMINISTERED_TO,Patients
NCT01503632,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01503632,6-Mercaptopurine,TREATS,Child
NCT01503632,6-Mercaptopurine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01503632,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01503632,Intervention regimes,COEXISTS_WITH,intervention program
NCT01503632,ethylene diurea,TREATS,Patients
NCT01503632,ethylene diurea,TREATS,pharmacist
NCT01503632,CAP - NOS,PROCESS_OF,Patients
NCT01216332,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01216332,trivalent influenza vaccine,TREATS,Patients
NCT01216332,trivalent influenza vaccine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01216332,Influenza virus vaccine,TREATS,Patients
NCT01216332,Influenza virus vaccine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01216332,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02451774,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
NCT02451774,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02451774,Bone marrow specimen,LOCATION_OF,"Neoplasm, Residual"
NCT02451774,Bone marrow specimen,LOCATION_OF,"Neoplasm, Residual"
NCT02451774,Pentoxifylline,INHIBITS,phosphoric diester hydrolase
NCT02451774,Pharmaceutical Preparations,CAUSES,Apoptosis
NCT02451774,Antineoplastic Agents,INHIBITS,Disease remission
NCT02451774,Disease remission,PROCESS_OF,Patients
NCT02451774,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02451774,Pentoxifylline,ADMINISTERED_TO,Patients
NCT02451774,Placebos,ADMINISTERED_TO,Patients
NCT02451774,Therapeutic procedure,TREATS,Patients
NCT02451774,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02451774,Pentoxifylline,AFFECTS,Apoptosis
NCT02451774,Senility,PROCESS_OF,Patients
NCT02451774,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02451774,Pentoxifylline,compared_with,Placebos
NCT03020030,Malignant Neoplasms,PROCESS_OF,Child
NCT03020030,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
NCT03020030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03020030,"Leukemia, Lymphocytic, Acute",PROCESS_OF(SPEC),Child
NCT03020030,Cells,LOCATION_OF,Malignant Neoplasms
NCT03020030,Disease,PROCESS_OF,Child
NCT03020030,Disease,PROCESS_OF,Adolescent
NCT03020030,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03020030,Pharmaceutical Preparations,NEG_TREATS,Child
NCT03020030,Pharmaceutical Preparations,NEG_TREATS,Adolescent
NCT03020030,Pharmaceutical Preparations,NEG_TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03020030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03020030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT03020030,Therapeutic procedure,ADMINISTERED_TO,Child
NCT03020030,Therapeutic procedure,ADMINISTERED_TO,Adolescent
NCT03020030,Blood,LOCATION_OF,pegaspargase
NCT03020030,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03020030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03020030,Therapeutic procedure,TREATS,Child
NCT03020030,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03020030,Blood,LOCATION_OF,leukemia
NCT03020030,Cells,LOCATION_OF,Genetic Materials
NCT03020030,Chromosomes,LOCATION_OF,leukemia
NCT03020030,Leukemic Cell,LOCATION_OF,leukemia
NCT03020030,Marrow,LOCATION_OF,leukemia
NCT03020030,leukemia,PROCESS_OF,Child
NCT03020030,Genes,PART_OF,Leukemic Cell
NCT03020030,Therapeutic procedure,TREATS,Participant
NCT03020030,Therapeutic procedure,TREATS,Participant
NCT03020030,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03020030,pegaspargase,ISA,Pharmaceutical Preparations
NCT03020030,pegaspargase,TREATS(SPEC),"Leukemia, Lymphocytic, Acute"
NCT03020030,Therapeutic procedure,CAUSES,Adverse effects
NCT03020030,Blood,LOCATION_OF,pegaspargase
NCT03020030,Pharmaceutical Preparations,compared_with,pegaspargase
NCT03020030,Pharmaceutical Preparations,higher_than,pegaspargase
NCT03020030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03020030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT00042341,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
NCT00042341,clofarabine,ISA,Therapeutic procedure
NCT00042341,clofarabine,ISA,Injection procedure
NCT00042341,clofarabine,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00042341,Medication Management,METHOD_OF,Therapeutic procedure
NCT00042341,clofarabine,TREATS,Patients
NCT00042341,clofarabine,TREATS,Patients
NCT01901367,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01901367,Metabolic syndrome,PROCESS_OF,Patients
NCT01901367,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01901367,Body Weight decreased,PROCESS_OF,Patients
NCT01901367,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
NCT01901367,Intervention regimes,TREATS,Patients
NCT01901367,Glucose,TREATS,Patients
NCT01901367,Insulin,TREATS,Patients
NCT01901367,Serum,LOCATION_OF,Glucose
NCT01901367,Leptin,TREATS,Patients
NCT01901367,Fatigue,PROCESS_OF,Participant
NCT01901367,Acute leukemia,PROCESS_OF,Patients
NCT00439296,Pharmacotherapy,USES,Pharmaceutical Preparations
NCT00439296,ABT751,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00439296,Pharmacotherapy,ISA,Therapeutic procedure
NCT00439296,Pharmacotherapy,TREATS(SPEC),Child
NCT00439296,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00439296,Therapeutic procedure,TREATS,Child
NCT00439296,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00439296,Dexamethasone,ISA,Pharmaceutical Preparations
NCT00439296,Ara-C,ISA,Cytarabine
NCT00439296,Antineoplastic Agents,ISA,Pharmaceutical Preparations
NCT00439296,Antineoplastic Agents,TREATS,Malignant Neoplasms
NCT00439296,ABT751,ADMINISTERED_TO,Child
NCT00439296,Dexamethasone,COEXISTS_WITH,ABT751
NCT00439296,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00439296,Doxorubicin,COEXISTS_WITH,ABT751
NCT00439296,Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00439296,pegaspargase,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00439296,pegaspargase,COEXISTS_WITH,ABT751
NCT00440726,Pharmacotherapy,USES,Pharmaceutical Preparations
NCT00440726,bortezomib,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00440726,Multiple Myeloma,ISA,Hematopoietic Neoplasms
NCT00440726,Multiple Myeloma,PROCESS_OF,Adult
NCT00440726,Medication Management,TREATS,Adult
NCT00440726,bortezomib,ISA,Pharmaceutical Preparations
NCT00440726,Animals,LOCATION_OF,bortezomib
NCT00440726,Mus,ISA,Animals
NCT00440726,Mus,LOCATION_OF(SPEC),bortezomib
NCT00440726,Malignant Neoplasms,PROCESS_OF,Adult
NCT00440726,Malignant Neoplasms,PROCESS_OF,Child
NCT00440726,Ara-C,ISA,Cytarabine
NCT00440726,bortezomib,ISA,Pharmaceutical Preparations
NCT00440726,bortezomib,ADMINISTERED_TO,Child
NCT00440726,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT02046694,6-Mercaptopurine,TREATS,Child
NCT02046694,6-Mercaptopurine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02046694,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02046694,6-Mercaptopurine,TREATS,Child
NCT02046694,6-Mercaptopurine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02046694,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02046694,6-Mercaptopurine,CAUSES,Adverse effects
NCT02046694,6-Mercaptopurine,PREVENTS,Adverse effects
NCT02046694,Allopurinol,STIMULATES,6-Mercaptopurine
NCT02046694,Inflammatory Bowel Diseases,PROCESS_OF,Child
NCT02046694,Tumor Lysis Syndrome,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
NCT02046694,Medication Management,TREATS,Tumor Lysis Syndrome
NCT02046694,6-Mercaptopurine,TREATS,Child
NCT02046694,6-Mercaptopurine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02046694,Allopurinol,TREATS,Child
NCT02046694,Allopurinol,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02046694,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02046694,Physical Examination,USES,6-Mercaptopurine
NCT02046694,Physical Examination,USES,Methotrexate
NCT02046694,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT03187977,brief intervention,TREATS,Patients
NCT03187977,brief intervention,TREATS,Survivors
NCT03187977,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03187977,Therapeutic procedure,TREATS,cohort
NCT03187977,Therapeutic procedure,TREATS,Participant
NCT03187977,Intervention regimes,TREATS,Survivors
NCT03187977,Intervention regimes,TREATS,Survivors
NCT03265106,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT03265106,Lymphoma,PROCESS_OF,Patients
NCT03265106,Chemotherapy-Oncologic Procedure,METHOD_OF,Stem cell transplant
NCT02906371,CD19 gene,INTERACTS_WITH(INFER),tocilizumab
NCT02906371,CD19 gene,PART_OF,Patients
NCT02906371,tocilizumab,TREATS,Patients
NCT02906371,CD19 gene,PART_OF,Patients
NCT02906371,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
NCT02906371,Management procedure,TREATS,Patients
NCT02906371,CD19 gene,TREATS,Cytokine release syndrome
NCT02906371,tocilizumab,TREATS,Cytokine release syndrome
NCT01574274,Oncaspar,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
NCT01574274,Oncaspar,ASSOCIATED_WITH,Large Cell Lymphoblastic Lymphoma
NCT01574274,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01574274,ASPARAGINASE,TREATS,Large Cell Lymphoblastic Lymphoma
NCT01574274,Muscle,LOCATION_OF,Elspar
NCT01574274,Elspar,ISA,ASPARAGINASE
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01574274,Muscle,LOCATION_OF,Elspar
NCT01574274,Veins,LOCATION_OF,Oncaspar
NCT01574274,Oncaspar,ADMINISTERED_TO,Research Personnel
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01574274,Therapeutic procedure,TREATS,Child
NCT01574274,Therapeutic procedure,TREATS,Adolescent
NCT01574274,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01574274,"Neoplasm, Residual",ISA,Disease
NCT01574274,Leukemic Cell,LOCATION_OF,Disease
NCT01574274,Leukemic Cell,LOCATION_OF(SPEC),"Neoplasm, Residual"
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01574274,leukemia,PROCESS_OF,Participant
NCT01574274,Therapeutic procedure,TREATS,Participant
NCT01574274,Therapeutic procedure,TREATS(INFER),leukemia
NCT01574274,"Tumor cells, malignant",PART_OF,Marrow
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01574274,Blood,LOCATION_OF,Infection
NCT01574274,Therapeutic procedure,PREVENTS,Infection
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01574274,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
NCT01574274,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Adolescent
NCT01574274,Therapeutic procedure,ADMINISTERED_TO,Child
NCT01574274,Therapeutic procedure,ADMINISTERED_TO,Adolescent
NCT01574274,Vascular infections,PROCESS_OF,Child
NCT01574274,Vascular infections,PROCESS_OF,Adolescent
NCT01574274,Antibiotics,ISA,Pharmaceutical Preparations
NCT01574274,Fever,PROCESS_OF,Child
NCT01574274,leukemia,PROCESS_OF,Child
NCT01574274,Lymphoma,PROCESS_OF,Child
NCT01574274,Fever,PROCESS_OF,Participant
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01574274,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01574274,Pharmaceutical Preparations,TREATS,Large Cell Lymphoblastic Lymphoma
NCT01574274,Blood,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
NCT01574274,Blood,LOCATION_OF,Large Cell Lymphoblastic Lymphoma
NCT01574274,Bone marrow specimen,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
NCT01574274,Bone marrow specimen,LOCATION_OF,Large Cell Lymphoblastic Lymphoma
NCT01574274,leukemia,PROCESS_OF,Child
NCT01574274,Therapeutic procedure,TREATS,Child
NCT01574274,Therapeutic procedure,TREATS(INFER),leukemia
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01574274,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01574274,pegaspargase,TREATS,Child
NCT01574274,pegaspargase,TREATS,Adolescent
NCT01574274,pegaspargase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01574274,pegaspargase,TREATS(INFER),Large Cell Lymphoblastic Lymphoma
NCT01574274,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
NCT01574274,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Adolescent
NCT01574274,Oncaspar,TREATS,Child
NCT01574274,Oncaspar,TREATS,Adolescent
NCT01574274,Oncaspar,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01574274,Oncaspar,TREATS(INFER),Large Cell Lymphoblastic Lymphoma
NCT03157323,Therapeutic procedure,TREATS,Child
NCT03157323,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03157323,Therapeutic procedure,TREATS,Adolescent
NCT03157323,dietary intervention,TREATS,Child
NCT03157323,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
NCT03157323,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03157323,Intervention regimes,TREATS,Child
NCT03157323,Cancer Treatment,TREATS,Vulnerable Populations
NCT03157323,Therapeutic procedure,TREATS,Child
NCT03157323,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03157323,Therapeutic procedure,TREATS,Adolescent
NCT03157323,dietary intervention,TREATS,Child
NCT03157323,dietary intervention,TREATS,Adolescent
NCT03157323,Malignant Neoplasms,PROCESS_OF,Child
NCT03157323,Malignant Neoplasms,PROCESS_OF,Patients
NCT03157323,Therapeutic procedure,TREATS,Child
NCT03157323,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03157323,Therapeutic procedure,TREATS,Adolescent
NCT01423747,Hematopoietic Stem Cell Transplantation,compared_with,Hematopoietic Stem Cell Transplantation
NCT01423747,Stem cell transplant,TREATS,Child
NCT01423747,Stem cell transplant,TREATS,Adolescent
NCT01423747,Pharmacotherapy,PRECEDES,Hematopoietic Stem Cell Transplantation
NCT01423747,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01423747,Stem cell transplant,AFFECTS,leukemia
NCT01423747,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01423747,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01423747,Stem cell transplant,TREATS,Child
NCT01423747,Stem cell transplant,TREATS,Adolescent
NCT01423747,Stem cell transplant,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01423500,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01423500,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01423500,Hematopoietic Stem Cell Transplantation,TREATS,Child
NCT01423500,Hematopoietic Stem Cell Transplantation,TREATS,Adolescent
NCT01423500,Hematopoietic Stem Cell Transplantation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01423500,Hematopoietic Stem Cell Transplantation,compared_with,Hematopoietic Stem Cell Transplantation
NCT01423500,Pharmacotherapy,PRECEDES,Hematopoietic Stem Cell Transplantation
NCT01423500,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01423500,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01423500,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01423500,Stem cell transplant,TREATS,Child
NCT01423500,Stem cell transplant,TREATS,Adolescent
NCT01423500,Stem cell transplant,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02314273,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02314273,Thrombocytopenia,AFFECTS,Patients
NCT02314273,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT02314273,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT02314273,Thrombocytopenia,PROCESS_OF,Patients
NCT02314273,Therapeutic procedure,USES,Oprelvekin
NCT02314273,Oprelvekin,ADMINISTERED_TO,Patients
NCT02314273,Oprelvekin,TREATS,Patients
NCT02314273,Oprelvekin,TREATS(INFER),Thrombocytopenia
NCT03223753,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03223753,Therapeutic procedure,TREATS,Malignant Neoplasms
NCT03223753,regular physical activity,TREATS,Energy level
NCT03223753,School attendance,AFFECTS,Webbing
NCT03223753,Patients,INTERACTS_WITH,member
NCT03223753,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03223753,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT02091245,Pharmaceutical Preparations,DISRUPTS,Leukemic Cell
NCT02091245,Pharmaceutical Preparations,ADMINISTERED_TO,Research Personnel
NCT02091245,Pharmaceutical Preparations,ADMINISTERED_TO,Participant
NCT02091245,Pharmaceutical Preparations,ADMINISTERED_TO,Participant
NCT02091245,Intrathecal Chemotherapy,ADMINISTERED_TO,Participant
NCT02091245,CNS disorder,PROCESS_OF,Participant
NCT02091245,Chemotherapy-Oncologic Procedure,ADMINISTERED_TO,Participant
NCT02336282,Therapeutic procedure,TREATS,Functional disorder
NCT02336282,Functional disorder,PROCESS_OF,Survivors
NCT02336282,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,cohort
NCT02336282,Functional disorder,PROCESS_OF,Survivors
NCT02336282,Malignant Childhood Neoplasm,PROCESS_OF,Survivors
NCT02336282,Stimulation procedure,TREATS,Survivors
NCT02336282,Brain stimulation,ISA,Stimulation procedure
NCT02336282,Intervention regimes,COEXISTS_WITH,Stimulation procedure
NCT02336282,Intervention regimes,COEXISTS_WITH(SPEC),Brain stimulation
NCT02336282,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
NCT02336282,Stimulation procedure,TREATS,Survivors
NCT02336282,Stimulation procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02336282,Entire scalp,PART_OF,Participant
NCT02336282,Stimulation procedure,ADMINISTERED_TO,Research Personnel
NCT02336282,Wanted,PROCESS_OF,Long-Term Survivors
NCT02336282,Intervention regimes,ADMINISTERED_TO,Survivors
NCT02336282,Functional disorder,PROCESS_OF,Survivors
NCT02336282,Stimulation procedure,TREATS,Functional disorder
NCT00846703,"Cam, topical lotion",TREATS,Patients
NCT00846703,Berlin-Frankfort-Munster protocol,TREATS,Obstruction
NCT00846703,6-Mercaptopurine,TREATS,Patients
NCT00846703,Methotrexate,TREATS,Patients
NCT00902213,Intervention regimes,TREATS,Child
NCT01506453,Vincristine,ISA,Therapeutic procedure
NCT01506453,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT01506453,Vincristine,TREATS(SPEC),Patients
NCT01506453,Therapeutic procedure,TREATS,Pain
NCT01506453,Therapeutic procedure,TREATS,Patients
NCT01506453,Therapeutic procedure,USES,Vincristine
NCT01506453,Morphine,TREATS,Pain
NCT01506453,Morphine,TREATS,Pain score
NCT01506453,Vincristine,ADMINISTERED_TO,Patients
NCT01506453,gabapentin,TREATS,Patients
NCT01506453,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01506453,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01506453,Placebos,ADMINISTERED_TO,Participant
NCT01506453,gabapentin,ADMINISTERED_TO,Participant
NCT01506453,Morphine,TREATS,Pain
NCT01506453,Pain Measurement,USES,Pharmaceutical Preparations
NCT01506453,Therapeutic procedure,TREATS,Pain
NCT01506453,Analgesics,COEXISTS_WITH,gabapentin
NCT01506453,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Participant
NCT01506453,Treatment Protocols,TREATS,Participant
NCT01506453,Treatment Protocols,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01506453,gabapentin,TREATS,Participant
NCT01506453,gabapentin,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01506453,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
NCT01506453,Vincristine,ISA,Therapeutic procedure
NCT01506453,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT01506453,Therapeutic procedure,TREATS,Peripheral neuropathic pain
NCT01506453,Therapeutic procedure,USES,Vincristine
NCT00098839,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00098839,hLL2 agent,TREATS,Patients
NCT00098839,hLL2 agent,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00098839,hLL2 agent,AFFECTS,Growth
NCT00098839,hLL2 agent,ISA,Monoclonal Antibodies
NCT00098839,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00098839,Combination Drug Therapy,TREATS,Patients
NCT00098839,Remission Induction,TREATS,Patients
NCT00098839,hLL2 agent,ADMINISTERED_TO,Patients
NCT00098839,Drug Kinetics,PROCESS_OF,Patients
NCT00098839,Antibody Formation,PROCESS_OF,Patients
NCT00098839,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00098839,Methotrexate,TREATS,CNS disorder
NCT00098839,Neoadjuvant Therapy,NEG_ADMINISTERED_TO,Patients
NCT00098839,CNS disorder,PROCESS_OF,Patients
NCT00098839,CNS disorder,PROCESS_OF,Patients
NCT00098839,Methotrexate,ADMINISTERED_TO,Patients
NCT00098839,CNS disorder,PROCESS_OF,Patients
NCT00098839,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00098839,Filgrastim,ADMINISTERED_TO,Patients
NCT00098839,Cytarabine,ADMINISTERED_TO,Patients
NCT00098839,Doxorubicin,ADMINISTERED_TO,Patients
NCT00098839,Methotrexate,ADMINISTERED_TO,Patients
NCT00098839,Prednisone,ADMINISTERED_TO,Patients
NCT00098839,Vincristine,ADMINISTERED_TO,Patients
NCT00098839,pegaspargase,ADMINISTERED_TO,Patients
NCT00098839,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00098839,hLL2 agent,ADMINISTERED_TO,Patients
NCT00098839,CNS disorder,PROCESS_OF,Patients
NCT00098839,Methotrexate,ADMINISTERED_TO,Patients
NCT00098839,CNS disorder,PROCESS_OF,Patients
NCT00098839,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00098839,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00098839,hLL2 agent,PART_OF,Pilot
NCT00089349,6-Mercaptopurine,TREATS,Patients
NCT00089349,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00089349,Methotrexate,TREATS,Patients
NCT00089349,Methotrexate,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00089349,alemtuzumab,ADMINISTERED_TO,Patients
NCT00089349,alemtuzumab,TREATS,Patients
NCT00089349,alemtuzumab,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00089349,alemtuzumab,ISA,Monoclonal Antibodies
NCT00089349,6-Mercaptopurine,DISRUPTS,"Tumor cells, malignant"
NCT00089349,Methotrexate,DISRUPTS,"Tumor cells, malignant"
NCT00089349,6-Mercaptopurine,TREATS,Child
NCT00089349,6-Mercaptopurine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00089349,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00089349,Methotrexate,TREATS,Child
NCT00089349,Methotrexate,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00089349,Drug Kinetics,PROCESS_OF,Patients
NCT00089349,Immune response,PROCESS_OF,Patients
NCT00089349,alemtuzumab,TREATS,Patients
NCT00089349,Blood,PART_OF,Patients
NCT00089349,Marrow,PART_OF,Patients
NCT00089349,CNS disorder,PROCESS_OF,Patients
NCT00089349,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00089349,Methotrexate,ADMINISTERED_TO,Patients
NCT00089349,alemtuzumab,ADMINISTERED_TO,Patients
NCT00089349,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00089349,Induction,TREATS,Child
NCT00089349,Induction,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00089349,Campath 1H,TREATS,Child
NCT00089349,Campath 1H,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03467256,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
NCT03467256,"Leukemia, B-Cell, Acute",PROCESS_OF,Young adult
NCT03467256,Prophylactic treatment,TREATS,Child
NCT03467256,Prophylactic treatment,TREATS,Young adult
NCT03467256,Prophylactic treatment,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT03467256,Infusion procedures,PRECEDES,T cell therapy
NCT03467256,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00103285,Combination Drug Therapy,TREATS,Patients
NCT00103285,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00103285,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00103285,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00103285,ASPARAGINASE,TREATS,Child
NCT00103285,Therapeutic procedure,TREATS,Patients
NCT00103285,Patient identification,METHOD_OF,Therapeutic procedure
NCT00103285,Therapeutic procedure,TREATS,"Neoplasm, Residual"
NCT00103285,Upper arm,LOCATION_OF,"Neoplasm, Residual"
NCT00103285,Cytarabine,ADMINISTERED_TO,Patients
NCT00103285,Disease,PROCESS_OF,Patients
NCT00103285,Down Syndrome,PROCESS_OF,Patients
NCT00103285,Bone Marrow,PART_OF,Patients
NCT00103285,Bone Marrow,PART_OF,Patients
NCT00103285,Bone Marrow,PART_OF,Patients
NCT00103285,Bone Marrow,PART_OF,Patients
NCT00103285,Down Syndrome,PROCESS_OF,Patients
NCT00103285,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00103285,Down Syndrome,PROCESS_OF,Patients
NCT00103285,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00103285,Down Syndrome,PROCESS_OF,Patients
NCT00103285,Methotrexate,ADMINISTERED_TO,Patients
NCT00103285,Vincristine,ADMINISTERED_TO,Patients
NCT00103285,pegaspargase,ADMINISTERED_TO,Patients
NCT00103285,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00103285,Upper Extremity,LOCATION_OF,Methotrexate
NCT00103285,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00103285,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT00103285,Down Syndrome,PROCESS_OF,Patients
NCT00103285,Dexamethasone,ADMINISTERED_TO,Patients
NCT00103285,Down Syndrome,PROCESS_OF,Patients
NCT00103285,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00103285,Disease,PROCESS_OF,Patients
NCT00103285,Down Syndrome,PROCESS_OF,Patients
NCT00103285,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00103285,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00103285,Maintenance therapy,ADMINISTERED_TO,Patients
NCT00103285,Maintenance therapy,NEG_ADMINISTERED_TO,Patients
NCT00103285,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT00103285,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00103285,Disease,PROCESS_OF,Patients
NCT00103285,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00103285,Radiation therapy,TREATS,Patients
NCT00103285,Radiation therapy,TREATS(INFER),Disease
NCT00103285,Therapeutic procedure,TREATS,Male gender
NCT00103285,Maintenance therapy,TREATS,Female
NCT00103285,Maintenance therapy,TREATS,Patients
NCT00022737,Combination Drug Therapy,NEG_TREATS,Child
NCT00022737,Combination Drug Therapy,TREATS,Child
NCT00022737,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00022737,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00022737,Bone Marrow,PART_OF,Patients
NCT00022737,Toxic effect,PROCESS_OF,Child
NCT00022737,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00022737,Treatment Protocols,TREATS,Patients
NCT00022737,Imatinib mesylate,TREATS,Philadelphia chromosome positive
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Toxic effect,PROCESS_OF,Patients
NCT00022737,Methotrexate,ADMINISTERED_TO,Patients
NCT00022737,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00022737,Filgrastim,ADMINISTERED_TO,Patients
NCT00022737,Cytarabine,ADMINISTERED_TO,Patients
NCT00022737,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00022737,Methotrexate,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Radiation therapy,TREATS,Patients
NCT00022737,Radiation therapy,TREATS(INFER),Testicular Leukemia
NCT00022737,Testicular Leukemia,PROCESS_OF,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00022737,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00022737,Oral form dexamethasone,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00022737,Daunorubicin,ADMINISTERED_TO,Patients
NCT00022737,Dexamethasone,ADMINISTERED_TO,Patients
NCT00022737,Vincristine,ADMINISTERED_TO,Patients
NCT00022737,pegaspargase,ADMINISTERED_TO,Patients
NCT00022737,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00022737,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00022737,Cytarabine,ADMINISTERED_TO,Patients
NCT00022737,Etoposide,ADMINISTERED_TO,Patients
NCT00022737,Methotrexate,ADMINISTERED_TO,Patients
NCT00022737,Filgrastim,ADMINISTERED_TO,Patients
NCT00022737,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Dexamethasone,ADMINISTERED_TO,Patients
NCT00022737,Vincristine,ADMINISTERED_TO,Patients
NCT00022737,Radiation therapy,TREATS,Patients
NCT00022737,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00022737,Methotrexate,ADMINISTERED_TO,Patients
NCT00022737,Dexamethasone,ADMINISTERED_TO,Patients
NCT00022737,Vincristine,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00022737,Methotrexate,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00022737,Central Nervous System Leukemia,PROCESS_OF,Patients
NCT00022737,Radiation therapy,TREATS,Patients
NCT00022737,Methotrexate,ADMINISTERED_TO,Patients
NCT00022737,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00022737,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00022737,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00022737,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT00022737,STI571,ISA,imatinib
NCT00022737,Children's Oncology Group,LOCATION_OF,Pilot Projects
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00268528,long-term care,TREATS,Patients
NCT00268528,long-term care,USES,6-Mercaptopurine
NCT00268528,Pharmaceutical Preparations,NEG_ADMINISTERED_TO,Patients
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00268528,6-Mercaptopurine,TREATS,cohort
NCT00268528,Caucasoid Race,ISA,Racial group
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Racial group
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF(SPEC),Caucasoid Race
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF(SPEC),Asians
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF(SPEC),African American
NCT00268528,Asians,ISA,Racial group
NCT00268528,African American,ISA,Racial group
NCT00268528,Monitoring Systems,TREATS,cohort
NCT00268528,Monitoring Systems,compared_with,6-Mercaptopurine
NCT00268528,6-Mercaptopurine,TREATS,cohort
NCT00268528,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00268528,Methotrexate,ADMINISTERED_TO,Patients
NCT00268528,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00268528,ethnic,PROCESS_OF,Child
NCT00268528,racial differences,PROCESS_OF,Child
NCT00016302,Combination Drug Therapy,TREATS,Patients
NCT00016302,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00016302,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00016302,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00016302,Pharmacotherapy,TREATS,Patients
NCT00016302,Cytarabine,ADMINISTERED_TO,Patients
NCT00016302,Methotrexate,ADMINISTERED_TO,Patients
NCT00016302,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00016302,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00016302,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00016302,Cranial Irradiation,ADMINISTERED_TO,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00016302,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00016302,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00016302,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00016302,Methotrexate,ADMINISTERED_TO,Patients
NCT00016302,CNS disorder,PROCESS_OF,Patients
NCT00016302,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00016302,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT00016302,Consolidation Therapy,ISA,Therapeutic procedure
NCT00016302,Nelarabine,ADMINISTERED_TO,Patients
NCT00016302,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT00016302,Consolidation Therapy,ISA,Therapeutic procedure
NCT00016302,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, T-Cell"
NCT00016302,GW506U78,ISA,Nelarabine
NCT01656512,Malignant Neoplasms,PROCESS_OF,Child
NCT01656512,Glucocorticoids,ASSOCIATED_WITH,Fracture
NCT01656512,Osteoporosis,AFFECTS,Adolescent
NCT01700946,Therapeutic procedure,TREATS,Large Cell Lymphoblastic Lymphoma
NCT01700946,Therapeutic procedure,TREATS,Precursor B-cell lymphoblastic leukemia
NCT01700946,Therapeutic procedure,TREATS,Lymphoblastic Leukemia
NCT01700946,Therapeutic procedure,TREATS,Lymphoma
NCT01700946,Therapeutic procedure,ADMINISTERED_TO,Participant
NCT01700946,Pharmacotherapy,TREATS,Participant
NCT01700946,Hemopoietic stem cell transplant,METHOD_OF,Therapeutic procedure
NCT01700946,Pharmacotherapy,ADMINISTERED_TO,Participant
NCT01700946,Therapeutic procedure,TREATS,Large Cell Lymphoblastic Lymphoma
NCT01700946,Therapeutic procedure,TREATS,Precursor B-cell lymphoblastic leukemia
NCT01700946,Pharmacotherapy,TREATS,Participant
NCT01700946,Therapeutic procedure,USES,rituximab
NCT01700946,Therapeutic procedure,compared_with,Pharmacotherapy
NCT01700946,"Neoplasm, Residual",PRODUCES,MS4A1 gene
NCT01700946,rituximab,ISA,Therapeutic procedure
NCT01700946,Hemopoietic stem cell transplant,METHOD_OF,Remission Induction Therapy
NCT01700946,Hemopoietic stem cell transplant,TREATS,Participant
NCT01700946,Precursor B-cell lymphoblastic leukemia,PROCESS_OF,Participant
NCT01700946,Remission Induction Therapy,TREATS,Participant
NCT01700946,Remission Induction Therapy,TREATS(INFER),Precursor B-cell lymphoblastic leukemia
NCT01700946,Remission Induction,TREATS,Participant
NCT01700946,Treatment Protocols,ISA,Therapeutic procedure
NCT01700946,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT01700946,"Neoplasm, Residual",ISA,Residual Tumor
NCT01700946,Lymphoma,PROCESS_OF,Participant
NCT01700946,Blood Component Removal,TREATS,Donor person
NCT01700946,Dexamethasone,ADMINISTERED_TO,Patients
NCT01700946,Cytarabine,ADMINISTERED_TO,Patients
NCT01700946,Hydrocortisone,ADMINISTERED_TO,Patients
NCT01700946,Methotrexate,ADMINISTERED_TO,Patients
NCT01700946,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT01700946,"Neoplasm, Residual",PROCESS_OF,Patients
NCT01700946,"Neoplasm, Residual",PROCESS_OF,Patients
NCT01700946,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT01700946,Etoposide,ADMINISTERED_TO,Patients
NCT01700946,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT01700946,clofarabine,ADMINISTERED_TO,Patients
NCT01700946,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT01700946,Remission Induction,ADMINISTERED_TO,Patients
NCT01700946,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT01700946,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT01700946,"Neoplasm, Residual",PROCESS_OF,Patients
NCT02011022,Drug Kinetics,AFFECTS,Patients
NCT02011022,lymphoblast,LOCATION_OF,Malignant Neoplasms
NCT02011022,Drug Kinetics,AFFECTS,Patients
NCT02011022,Serum,LOCATION_OF,Creatinine
NCT02011022,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02011022,Methotrexate,TREATS,Child
NCT02011022,Methotrexate,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02011022,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT01990807,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT01990807,"Leukemia, Lymphocytic, Acute",PROCESS_OF,high-risk group
NCT01990807,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01990807,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
NCT03385681,educational intervention,TREATS,"Pain, Postoperative"
NCT03385681,Intervention regimes,METHOD_OF,Supervision
NCT03369847,Asthma,PROCESS_OF,Child
NCT03369847,Steroids,TREATS,Asthma
NCT03369847,Accident and Emergency department,LOCATION_OF,Clinical Research
NCT03369847,prescription procedure,ADMINISTERED_TO,Patients
NCT03369847,Physicians,DIAGNOSES,Asthma
NCT03369847,Adrenal Cortex Hormones,ADMINISTERED_TO,Child
NCT03369847,Pharmaceutical Preparations,ADMINISTERED_TO,Patients
NCT03369847,Pulmicort,ISA,Budesonide
NCT03369847,Pharmaceutical Preparations,NEG_ADMINISTERED_TO,Control Groups
NCT03369847,Asthma,ISA,Symptoms
NCT01861002,Cytarabine,ISA,Chemotherapy-Oncologic Procedure
NCT01861002,Pharmacotherapy,TREATS,Child
NCT01861002,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01861002,leukemia,AFFECTS,Hypermethylation
NCT01861002,Azacitidine,TREATS,Aberrant DNA Methylation
NCT01861002,5-aza-2'-deoxycytidine,TREATS,Aberrant DNA Methylation
NCT01861002,Tumor Suppressor Genes,AFFECTS,Apoptosis
NCT01861002,Cytarabine,AUGMENTS,"Leukemia, Myelocytic, Acute"
NCT01861002,Pharmacotherapy,TREATS,Aberrant DNA Methylation
NCT01861002,fludarabine,AUGMENTS,"Leukemia, Myelocytic, Acute"
NCT01861002,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01861002,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT01861002,Treatment Protocols,TREATS,leukemia
NCT01861002,Cytarabine,PREVENTS,Complication
NCT01861002,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Myelocytic, Acute"
NCT01861002,Children's Oncology Group,LOCATION_OF,Clinical Trials
NCT01861002,Pharmacotherapy,TREATS,Child
NCT01411267,Cytarabine,TREATS,Patients
NCT01411267,Etoposide,TREATS,Patients
NCT01411267,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01411267,leukemia,PROCESS_OF,Persons
NCT01411267,FLT3 gene,AFFECTS,Cells
NCT01411267,Extrinsic,LOCATION_OF,Normal cell
NCT01411267,FLT3 gene,PART_OF,Cells
NCT01411267,FLT3 gene,PART_OF,Leukemic Cell
NCT01411267,FLT3 gene,PART_OF,Leukemic Cell
NCT01411267,Leukemic Cell,PART_OF,Persons
NCT01411267,FLT3 gene,ISA,Pharmaceutical Preparations
NCT01411267,Cytarabine,TREATS,leukemia
NCT01411267,Etoposide,TREATS,leukemia
NCT01411267,Cytarabine,ISA,Pharmaceutical Preparations
NCT02879643,Pharmacotherapy,TREATS,Child
NCT02879643,Pharmacotherapy,TREATS,Adolescent
NCT02879643,Pharmacotherapy,TREATS,Young adult
NCT02879643,vincristine sulfate liposomes,ISA,Injection procedure
NCT02879643,Injection procedure,USES,vincristine sulfate liposomes
NCT02879643,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02879643,Induction,TREATS,Child
NCT02879643,Induction,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02879643,Treatment Protocols,compared_with,Vincristine
NCT02879643,Pharmacotherapy,TREATS,Child
NCT02879643,Pharmacotherapy,TREATS,Adolescent
NCT02879643,Pharmacotherapy,TREATS,Young adult
NCT02879643,vincristine sulfate liposomes,ISA,Injection procedure
NCT02879643,Injection procedure,USES,vincristine sulfate liposomes
NCT00537030,Hypersensitivity,PROCESS_OF,Patients
NCT00537030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00537030,Adverse effects,PROCESS_OF,Patients
NCT00537030,Pharmaceutical Preparations,DISRUPTS,Cells
NCT00537030,Erwinia asparaginase,DISRUPTS,Growth
NCT00537030,Erwinia asparaginase,ISA,Pharmacotherapy
NCT00537030,Asparagine,compared_with,Erwinase
NCT00537030,Child,LOCATION_OF,"Antibodies, Anti-Idiotypic"
NCT00537030,Hypersensitivity,PROCESS_OF,Child
NCT00537030,leukemia,PROCESS_OF,Child
NCT00537030,Drug Kinetics,PROCESS_OF,Child
NCT00537030,Plasma,LOCATION_OF,Asparagine
NCT00537030,pegaspargase,TREATS,Toxic effect
NCT00537030,Therapeutic procedure,USES,Erwinase
NCT00537030,Erwinase,ISA,Therapeutic procedure
NCT00537030,Erwinase,TREATS,Patients
NCT00537030,Erwinia asparaginase,ADMINISTERED_TO,Patients
NCT00537030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00537030,pegaspargase,TREATS,Child
NCT00537030,pegaspargase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02361047,Inflammation,PROCESS_OF,Survivors
NCT02361047,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
NCT02361047,Oxidative Stress,PROCESS_OF,Survivors
NCT02361047,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
NCT02361047,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT02361047,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
NCT02361047,Physical activity,PREVENTS,Weight Gain
NCT02361047,Weight Gain,PROCESS_OF,Survivors
NCT02361047,Physical activity,ISA,Behavior
NCT01733953,Therapeutic procedure,TREATS,Survivors
NCT01733953,Therapeutic procedure,USES,STN gene
NCT01733953,Pharmacotherapy,CAUSES,Atherosclerosis
NCT01733953,Pharmacotherapy,CAUSES,Cardiovascular Diseases
NCT01733953,Therapeutic procedure,TREATS,Malignant Neoplasms
NCT01733953,Hydroxymethylglutaryl-CoA Reductase Inhibitors,DISRUPTS,arterial stiffness
NCT01733953,Pharmaceutical Preparations,TREATS,Cancer Survivor
NCT01733953,Therapeutic procedure,TREATS,Survivors
NCT01733953,Therapeutic procedure,USES,STN gene
NCT01733953,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
NCT01733953,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Survivors
NCT01733953,Therapeutic procedure,USES,STN gene
NCT01733953,atorvastatin,compared_with,Placebos
NCT01733953,"NOS3 protein, human",PART_OF,Arteries
NCT01733953,Pathological Dilatation,PROCESS_OF,Survivors
NCT01733953,atorvastatin,AUGMENTS,Pathological Dilatation
NCT01733953,Therapeutic procedure,TREATS,Malignant Neoplasms
NCT01733953,Therapeutic procedure,PREVENTS,Atherosclerosis
NCT01733953,Therapeutic procedure,PREVENTS,Cardiovascular Diseases
NCT01733953,Risk Reduction,ADMINISTERED_TO,Survivors
NCT01733953,Intervention regimes,TREATS,Survivors
NCT01733953,Therapeutic procedure,USES,STN gene
NCT01733953,Risk Reduction,USES,Hydroxymethylglutaryl-CoA Reductase Inhibitors
NCT01733953,Therapeutic procedure,TREATS,Survivors
NCT01733953,Therapeutic procedure,USES,STN gene
NCT01733953,Vascular Diseases,PROCESS_OF,Individual
NCT01733953,Hydroxymethylglutaryl-CoA Reductase Inhibitors,TREATS,Cardiovascular Diseases
NCT01733953,Therapeutic procedure,USES,STN gene
NCT01733953,Thickened,PROCESS_OF,Survivors
NCT01733953,Pharmacotherapy,CAUSES(SPEC),Endothelial dysfunction
NCT01733953,Pharmacotherapy,ISA,Therapeutic procedure
NCT01733953,Therapeutic procedure,CAUSES,Endothelial dysfunction
NCT01733953,Endothelial dysfunction,PROCESS_OF,Individual
NCT01733953,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
NCT01733953,atorvastatin,compared_with,Placebos
NCT01733953,Therapeutic procedure,TREATS,Survivors
NCT01733953,Therapeutic procedure,USES,STN gene
NCT02981628,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02981628,Patients,LOCATION_OF,Inotuzumab Ozogamicin
NCT02981628,Antibodies,COEXISTS_WITH,Poisons
NCT02981628,Immunotoxins,COEXISTS_WITH(SPEC),Poisons
NCT02981628,Immunotoxins,ISA,Antibodies
NCT02981628,"Tumor cells, malignant",LOCATION_OF,Inotuzumab Ozogamicin
NCT02981628,"Tumor cells, malignant",PRODUCES,CD22 gene
NCT02981628,Child,LOCATION_OF,Inotuzumab Ozogamicin
NCT02981628,Therapeutic procedure,USES,Inotuzumab Ozogamicin
NCT02981628,"Neoplasm, Residual",PROCESS_OF,Patients
NCT02981628,Liver,LOCATION_OF,Venoocclusive disease
NCT02981628,Therapeutic procedure,USES,Inotuzumab Ozogamicin
NCT02981628,Venoocclusive disease,OCCURS_IN,Patients
NCT02981628,Inotuzumab Ozogamicin,ISA,Therapeutic procedure
NCT02981628,Child,LOCATION_OF,Inotuzumab Ozogamicin
NCT02981628,Young adult,LOCATION_OF,Inotuzumab Ozogamicin
NCT02228096,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT02228096,"Therapies, Investigational",TREATS,Patients
NCT02228096,"Therapies, Investigational",TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT00557193,Combination Drug Therapy,NEG_TREATS,Patients
NCT00557193,Combination Drug Therapy,TREATS,Patients
NCT00557193,lestaurtinib,NEG_TREATS,Patients
NCT00557193,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00557193,lestaurtinib,DISRUPTS,Growth
NCT00557193,Combination Drug Therapy,NEG_TREATS,"Leukemia, Lymphocytic, Acute"
NCT00557193,lestaurtinib,NEG_TREATS,"Leukemia, Lymphocytic, Acute"
NCT00557193,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00557193,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00557193,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00557193,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00557193,Pharmacodynamics,PROCESS_OF,Infant
NCT00557193,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00557193,"Neoplasm, Residual",PROCESS_OF,Infant
NCT00557193,leukemia,PROCESS_OF,Infant
NCT00557193,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00557193,Vertebral column,PART_OF,Infant
NCT00557193,Chemotherapy-Oncologic Procedure,ADMINISTERED_TO,Patients
NCT00557193,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00557193,Vertebral column,PART_OF,Patients
NCT00557193,lestaurtinib,TREATS,Patients
NCT00557193,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00557193,Pharmacotherapy,TREATS,Patients
NCT00557193,Etoposide,ADMINISTERED_TO,Patients
NCT00557193,Methotrexate,ADMINISTERED_TO,Patients
NCT00557193,Filgrastim,ADMINISTERED_TO,Patients
NCT00557193,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00557193,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00557193,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00557193,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00557193,pegaspargase,ADMINISTERED_TO,Patients
NCT00557193,Daunorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00557193,Methotrexate,ADMINISTERED_TO,Patients
NCT00557193,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00557193,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00557193,Pharmacotherapy,TREATS,Patients
NCT00557193,Etoposide,ADMINISTERED_TO,Patients
NCT00557193,Methotrexate,ADMINISTERED_TO,Patients
NCT00557193,Filgrastim,ADMINISTERED_TO,Patients
NCT00557193,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00557193,lestaurtinib,TREATS,Patients
NCT00557193,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00557193,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00557193,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00557193,pegaspargase,ADMINISTERED_TO,Patients
NCT00557193,Daunorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00557193,Methotrexate,ADMINISTERED_TO,Patients
NCT00557193,Prednisone,ADMINISTERED_TO,Patients
NCT00557193,Prednisone,ADMINISTERED_TO,Patients
NCT00557193,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00557193,Prednisone,ADMINISTERED_TO,Patients
NCT00557193,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00557193,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00557193,Therapeutic procedure,TREATS,Infant
NCT00557193,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00557193,FLT3 gene,DISRUPTS,High risk infant
NCT00056069,Ambulatory Care Facilities,LOCATION_OF,Clinical Research
NCT00056069,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00056069,Pharmacotherapy,TREATS,Malignant Neoplasms
NCT00056069,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00056069,Pharmacotherapy,TREATS,Patients
NCT00056069,Hospitals,LOCATION_OF,Clinical Research
NCT00056069,Child health care,TREATS,Child
NCT00056069,Therapeutic procedure,TREATS,Child
NCT01279096,ASPARAGINASE,TREATS,Child
NCT01279096,Dexamethasone,TREATS,Child
NCT01279096,Etoposide,TREATS,Child
NCT01279096,Mitoxantrone,TREATS,Child
NCT01279096,ASPARAGINASE,COEXISTS_WITH,Dexamethasone
NCT01279096,ASPARAGINASE,COEXISTS_WITH,Etoposide
NCT01279096,ASPARAGINASE,COEXISTS_WITH,Mitoxantrone
NCT01279096,Mitoxantrone,TREATS,Patients
NCT01279096,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01279096,Remission Induction,TREATS,Patients
NCT01279096,Remission Induction,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01279096,Therapeutic procedure,METHOD_OF,Remission Induction
NCT00707083,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00707083,Chemotherapy-Oncologic Procedure,TREATS,Child
NCT00707083,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00707083,Adverse effects,PROCESS_OF,Child
NCT00707083,"Leukemia, Lymphocytic, Acute",OCCURS_IN,Child
NCT00707083,Liver,LOCATION_OF,Toxic effect
NCT00707083,Disease,PROCESS_OF,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Therapeutic procedure,PRECEDES,Consolidation Therapy
NCT00707083,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00707083,Dexamethasone,ADMINISTERED_TO,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Methotrexate,ADMINISTERED_TO,Patients
NCT00707083,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Therapeutic procedure,TREATS,Girls
NCT00707083,Methotrexate,ADMINISTERED_TO,Patients
NCT00707083,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00707083,Dexamethasone,ADMINISTERED_TO,Patients
NCT00707083,Disease,PROCESS_OF,Patients
NCT00707083,prednisolone,ADMINISTERED_TO,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00707083,Cytarabine,ADMINISTERED_TO,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Methotrexate,ADMINISTERED_TO,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Dexamethasone,ADMINISTERED_TO,Patients
NCT00707083,Methotrexate,ADMINISTERED_TO,Patients
NCT00707083,Vincristine,ADMINISTERED_TO,Patients
NCT00707083,Upper Extremity,LOCATION_OF,Upper arm
NCT00707083,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00707083,Therapeutic procedure,TREATS,Girls
NCT00707083,Disease,PROCESS_OF,Patients
NCT00707083,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00707083,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00707083,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00707083,Dexamethasone,ADMINISTERED_TO,Patients
NCT00707083,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00707083,Dexamethasone,ADMINISTERED_TO,Patients
NCT00707083,Dexamethasone,ADMINISTERED_TO,Patients
NCT00707083,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00707083,Methotrexate,ADMINISTERED_TO,Patients
NCT00707083,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00707083,Cytarabine,ADMINISTERED_TO,Patients
NCT00707083,Dexamethasone,ADMINISTERED_TO,Patients
NCT00707083,Vincristine,ADMINISTERED_TO,Patients
NCT00707083,Radiation therapy,TREATS,Patients
NCT00707083,Stem cell transplant,TREATS,Patients
NCT00707083,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT00816049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00816049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00816049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT00816049,Treatment Protocols,TREATS,Child
NCT00816049,Treatment Protocols,TREATS,Young adult
NCT00819351,Diagnosis,TREATS,Patients
NCT00819351,Diagnosis,TREATS,Patients
NCT00819351,pegaspargase,PART_OF,Patients
NCT00819351,Treatment Protocols,TREATS,Child
NCT00819351,Treatment Protocols,TREATS,Young adult
NCT00819351,Upper arm,LOCATION_OF,Toxic effect
NCT01614197,Cyclophosphamide,TREATS,Child
NCT01614197,Cyclophosphamide,TREATS,Patients
NCT01614197,Cyclophosphamide,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01614197,Dexamethasone,TREATS,Patients
NCT01614197,Etoposide,TREATS,Child
NCT01614197,Etoposide,TREATS,Patients
NCT01614197,Etoposide,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01614197,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01614197,Growth,PROCESS_OF,Xenograft Model
NCT01614197,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Xenograft Model
NCT01614197,mTOR Inhibitor,DISRUPTS,Growth
NCT01614197,Dexamethasone,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
NCT01614197,Etoposide,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
NCT01614197,Glucocorticoids,INHIBITS,"FRAP1 protein, human"
NCT01614197,Cyclophosphamide,TREATS,Child
NCT01614197,Cyclophosphamide,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01614197,Cyclophosphamide,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT01614197,Etoposide,TREATS,Child
NCT01614197,Etoposide,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01614197,Etoposide,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT01614197,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01614197,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT00381680,Combination Drug Therapy,TREATS,Patients
NCT00381680,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00381680,Vincristine,compared_with,Vincristine
NCT00381680,Vincristine,TREATS,Patients
NCT00381680,Chemotherapy-Oncologic Procedure,ADMINISTERED_TO,Patients
NCT00381680,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00381680,Chemotherapy-Oncologic Procedure,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT00381680,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00381680,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00381680,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00381680,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00381680,Induction,METHOD_OF,Alternative Therapies
NCT00381680,Adverse effects,ASSOCIATED_WITH,Candidate Disease Gene
NCT00381680,Combination Drug Therapy,TREATS,Patients
NCT00381680,Combination Drug Therapy,compared_with,Hematopoietic Stem Cell Transplantation
NCT00381680,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,Cytarabine,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00381680,Prednisone,ADMINISTERED_TO,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,pegaspargase,ADMINISTERED_TO,Patients
NCT00381680,Doxorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00381680,Cytarabine,ADMINISTERED_TO,Patients
NCT00381680,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00381680,etoposide phosphate,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00381680,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00381680,Filgrastim,ADMINISTERED_TO,Patients
NCT00381680,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00381680,Radiation therapy,TREATS,Patients
NCT00381680,Radiation therapy,TREATS(INFER),Testicular Diseases
NCT00381680,Testicular Diseases,PROCESS_OF,Patients
NCT00381680,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00381680,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,Doxorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00381680,Dexamethasone,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,pegaspargase,ADMINISTERED_TO,Patients
NCT00381680,Doxorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00381680,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00381680,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00381680,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00381680,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00381680,Cytarabine,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,etoposide phosphate,ADMINISTERED_TO,Patients
NCT00381680,pegaspargase,ADMINISTERED_TO,Patients
NCT00381680,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00381680,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,Prednisone,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,Methotrexate,ADMINISTERED_TO,Patients
NCT00381680,Vincristine,ADMINISTERED_TO,Patients
NCT00381680,Therapeutic procedure,NEG_ADMINISTERED_TO,Patients
NCT00381680,Vincristine,PREDISPOSES,"Leukemia, Lymphocytic, Acute, L1"
NCT01195480,Immunotherapy,TREATS,"Leukemia, B-Cell, Acute"
NCT01195480,Immunotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT01195480,Immunotherapy,USES,CD19 gene
NCT01195480,Adoptive Transfer,TREATS,Patients
NCT01195480,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01195480,Stem cell transplant,PRECEDES,Immunotherapy
NCT01195480,Stem cell transplant,TREATS,Child
NCT01195480,Stem cell transplant,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03289455,Cells,LOCATION_OF,"Leukemia, B-Cell, Acute"
NCT03289455,Cells,LOCATION_OF,"Leukemia, B-Cell, Acute"
NCT03289455,Leukapheresis,TREATS,Patients
NCT00192673,ASPARAGINASE,TREATS,Lymphoblastic Leukemia
NCT00192673,ASPARAGINASE,compared_with,pegaspargase
NCT00192673,Therapeutic procedure,NEG_TREATS,Patients
NCT00192673,ASPARAGINASE,compared_with,pegaspargase
NCT00192673,pegaspargase,TREATS,Child
NCT00192673,Therapeutic procedure,USES,pegaspargase
NCT00192673,ASPARAGINASE,compared_with,pegaspargase
NCT00192673,pegaspargase,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT01324180,Dexamethasone,INTERACTS_WITH,Metformin
NCT01324180,Doxorubicin,INTERACTS_WITH,Metformin
NCT01324180,"Leukemia, Lymphocytic, Acute",ISA,Disease
NCT01324180,Metformin,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01324180,Vincristine,INTERACTS_WITH,Metformin
NCT01324180,pegaspargase,INTERACTS_WITH,Metformin
NCT01324180,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01324180,Metformin,TREATS,Child
NCT01324180,Metformin,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01324180,asparaginase/daunorubicin/prednisone/vincristine chemotherapy protocol,TREATS,Child
NCT01324180,asparaginase/daunorubicin/prednisone/vincristine chemotherapy protocol,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01324180,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01324180,Metformin,STIMULATES,Dexamethasone
NCT01324180,Metformin,STIMULATES,Doxorubicin
NCT01324180,Metformin,STIMULATES,Vincristine
NCT01324180,Metformin,STIMULATES,pegaspargase
NCT00866307,Combination Drug Therapy,TREATS,Patients
NCT00866307,pegaspargase,TREATS,Patients
NCT00866307,Adverse effects,PROCESS_OF,Patients
NCT00866307,pegaspargase,DISRUPTS,Growth
NCT00866307,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00866307,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00866307,pegaspargase,DISRUPTS,"Tumor cells, malignant"
NCT00866307,Testicular Diseases,COEXISTS_WITH,Central Nervous System Leukemia
NCT00866307,Therapeutic procedure,TREATS,Child
NCT00866307,Steroid therapy,TREATS,Child
NCT00866307,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00866307,Cytarabine,ADMINISTERED_TO,Patients
NCT00866307,Disease,PROCESS_OF,Patients
NCT00866307,Disease,PROCESS_OF,Patients
NCT00866307,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00866307,Testicular Diseases,PROCESS_OF,Patients
NCT00866307,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00866307,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00866307,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00866307,Therapeutic procedure,TREATS,Patients
NCT00866307,Methotrexate,ADMINISTERED_TO,Patients
NCT00866307,Radiation therapy,NEG_TREATS,Patients
NCT00866307,Radiation therapy,TREATS,Patients
NCT00866307,pegaspargase,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
NCT00671034,Combination Drug Therapy,TREATS,Patients
NCT00671034,pegaspargase,TREATS,Patients
NCT00671034,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00671034,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00671034,Oncaspar,ISA,pegaspargase
NCT00671034,Induction,TREATS,Patients
NCT00671034,Pharmacodynamics,PROCESS_OF,Patients
NCT00671034,ASPARAGINASE,PART_OF,Patients
NCT00671034,Cytarabine,ADMINISTERED_TO,Patients
NCT00671034,pegaspargase,ISA,Pharmaceutical Preparations
NCT00671034,pegaspargase,ADMINISTERED_TO,Patients
NCT00671034,Bone Marrow,PART_OF,Patients
NCT00671034,Marrow,PART_OF,Patients
NCT00671034,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00671034,Prednisone,ADMINISTERED_TO,Patients
NCT00671034,Vincristine,ADMINISTERED_TO,Patients
NCT00671034,Methotrexate,ADMINISTERED_TO,Patients
NCT00671034,Vincristine,ADMINISTERED_TO,Patients
NCT00671034,Prednisone,TREATS,Patients
NCT00671034,Vincristine,ADMINISTERED_TO,Patients
NCT00671034,Disease,PROCESS_OF,Patients
NCT00671034,Gene Rearrangement,PROCESS_OF,Patients
NCT00671034,Methotrexate,ISA,Pharmaceutical Preparations
NCT00671034,Steroids,ASSOCIATED_WITH(INFER),Disease
NCT00671034,Steroids,PART_OF,Patients
NCT00671034,Vincristine,ADMINISTERED_TO,Patients
NCT00671034,[M]Compound leukemia,PROCESS_OF,Gene Rearrangement
NCT00671034,Cyclophosphamide,ISA,Pharmaceutical Preparations
NCT00671034,Vincristine,ADMINISTERED_TO,Patients
NCT00671034,Doxorubicin Hydrochloride,ISA,Pharmaceutical Preparations
NCT00671034,Disease,PROCESS_OF,Patients
NCT00671034,Vincristine,ADMINISTERED_TO,Patients
NCT00671034,Methotrexate,ADMINISTERED_TO,Patients
NCT00671034,Cranial Irradiation,ADMINISTERED_TO,Patients
NCT00671034,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00671034,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00671034,pegaspargase,TREATS,Patients
NCT00671034,pegaspargase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00671034,Oncaspar,TREATS,Patients
NCT00671034,Oncaspar,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00031655,Blood stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00031655,Stem cell transplant,TREATS,Patients
NCT00031655,Pharmacotherapy,USES,Pharmaceutical Preparations
NCT00031655,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00031655,Adverse effects,PROCESS_OF,Research Personnel
NCT00031655,Transplantation,AFFECTS,leukemia
NCT00031655,Bone Marrow Transplantation,ISA,Therapeutic procedure
NCT00031655,Bone Marrow Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00031655,Stem cell transplant,ISA,Therapeutic procedure
NCT00031655,Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00031655,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00031655,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00031655,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00031655,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00031655,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00031655,Whole-Body Irradiation,TREATS,"Neoplasm, Residual"
NCT00031655,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00031655,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00031655,Allografting,TREATS,Patients
NCT00031655,Allografting,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00031655,Donor Lymphocyte Infusion,TREATS,"Neoplasm, Residual"
NCT00031655,Cyclosporine,ADMINISTERED_TO,Patients
NCT00031655,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00031655,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00031655,Cell Transplantation,TREATS,Patients
NCT00031655,Cell Transplantation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01906671,6-Mercaptopurine,TREATS,Patients
NCT01906671,Purinethol,ISA,6-Mercaptopurine
NCT01906671,Purinethol,TREATS(SPEC),Patients
NCT01906671,Well adult,PROCESS_OF,Voluntary Workers
NCT01906671,6-Mercaptopurine,TREATS,Child
NCT01906671,6-Mercaptopurine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01906671,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01906671,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
NCT01766804,Pharmacotherapy,CAUSES,Inflammation
NCT01766804,Inflammation,PROCESS_OF,Child
NCT01766804,treatment complications,COEXISTS_WITH,Toxic effect
NCT01766804,Pharmacotherapy,CAUSES,Inflammation
NCT00613457,Combination Drug Therapy,TREATS,Patients
NCT00613457,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00613457,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00613457,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00613457,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00613457,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00613457,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00613457,Chemotherapy-Oncologic Procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00613457,Dexamethasone,DISRUPTS,"Leukemia, Lymphocytic, Acute"
NCT00613457,Prednisone,DISRUPTS,"Leukemia, Lymphocytic, Acute"
NCT00613457,Anthracycline Antibiotics,TREATS,Patients
NCT00613457,Anthracycline Antibiotics,compared_with,Treatment Protocols
NCT00613457,Cyclophosphamide,compared_with,Anthracycline Antibiotics
NCT00613457,Treatment Protocols,TREATS,Patients
NCT00613457,Treatment Protocols,compared_with,Therapeutic procedure
NCT00613457,Treatment Protocols,TREATS,Patients
NCT00613457,Therapeutic procedure,TREATS,Patients
NCT00613457,Therapeutic procedure,TREATS,Patients
NCT00613457,Therapeutic procedure,compared_with,Therapeutic procedure
NCT00613457,Prednisone,ADMINISTERED_TO,Patients
NCT00613457,Dexamethasone,ADMINISTERED_TO,Patients
NCT00613457,Prednisone,ADMINISTERED_TO,Patients
NCT00613457,CNS disorder,PROCESS_OF,Patients
NCT00613457,Methotrexate,ADMINISTERED_TO,Patients
NCT00613457,Vincristine,ADMINISTERED_TO,Patients
NCT00613457,Daunorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00613457,Ara-C,ISA,Cytarabine
NCT00613457,Disease,PROCESS_OF,Patients
NCT00613457,Neoadjuvant Therapy,TREATS,Obstruction
NCT00613457,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00613457,Methotrexate,ADMINISTERED_TO,Patients
NCT00613457,Dexamethasone,ADMINISTERED_TO,Patients
NCT00613457,Dexamethasone,ADMINISTERED_TO,Patients
NCT00613457,Dexamethasone,ADMINISTERED_TO,Patients
NCT00613457,Dexamethasone,ADMINISTERED_TO,Patients
NCT00613457,Dexamethasone,ADMINISTERED_TO,Patients
NCT00613457,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00613457,Methotrexate,ADMINISTERED_TO,Patients
NCT00613457,CNS disorder,PROCESS_OF,Patients
NCT00613457,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT00957320,Research Personnel,TREATS,Patients
NCT00957320,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00957320,Adverse effects,PROCESS_OF,Patients
NCT00957320,ASPARAGINASE,COEXISTS_WITH,Pharmaceutical Preparations
NCT00957320,Pharmaceutical Preparations,NEG_CAUSES,Adverse effects
NCT00957320,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00957320,Pharmaceutical Preparations,TREATS,Patients
NCT00957320,ASPARAGINASE,TREATS,Patients
NCT00957320,Agent,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00957320,Adverse effects,PROCESS_OF,Child
NCT00957320,Pharmaceutical Preparations,CAUSES,Cell Death
NCT00957320,Laboratory,LOCATION_OF,Clinical Research
NCT00186901,Osteoporosis,PROCESS_OF,Child
NCT00186901,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
NCT00186901,Therapeutic procedure,USES,Antimetabolites
NCT00186901,Health education - diet,TREATS,Patients
NCT00186901,Calcium supplementation,TREATS,Age
NCT00186901,Dual-Energy X-Ray Absorptiometry,METHOD_OF,tomography
NCT00186901,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
NCT01253720,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
NCT01253720,Research Personnel,TREATS,Survivors
NCT01253720,Behavior,PROCESS_OF,Adolescent
NCT01253720,Behavior,PROCESS_OF,preadolescent
NCT01253720,Behavior Therapy,TREATS,preadolescent
NCT01253720,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
NCT00049569,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00049569,Combination Drug Therapy,TREATS,Child
NCT00049569,Imatinib mesylate,TREATS,Child
NCT00049569,Enzymes,TREATS,Cancer Cell Growth
NCT00049569,Imatinib mesylate,DISRUPTS,Growth
NCT00049569,Imatinib mesylate,DISRUPTS,"Tumor cells, malignant"
NCT00049569,Combination Drug Therapy,TREATS,Child
NCT00049569,Imatinib mesylate,TREATS,Child
NCT00049569,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00049569,Treatment Protocols,TREATS,Child
NCT00049569,Treatment Protocols,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00049569,Remission Induction,TREATS,Child
NCT00049569,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00049569,Diagnosis,AFFECTS,Disease recurrence
NCT00049569,Cytarabine,ADMINISTERED_TO,Patients
NCT00049569,Methotrexate,ADMINISTERED_TO,Patients
NCT00049569,"Psychotherapy, Multiple",USES,Imatinib mesylate
NCT00049569,"Psychotherapy, Multiple",USES(SPEC),STI571
NCT00049569,STI571,ISA,Imatinib mesylate
NCT00049569,Vincristine,ADMINISTERED_TO,Patients
NCT00049569,Prednisone,ADMINISTERED_TO,Patients
NCT00049569,Methotrexate,ADMINISTERED_TO,Patients
NCT00049569,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00049569,Filgrastim,ADMINISTERED_TO,Patients
NCT00049569,Prednisone,ADMINISTERED_TO,Patients
NCT00049569,Cytarabine,ADMINISTERED_TO,Patients
NCT00049569,Cytarabine,ISA,Therapeutic procedure
NCT00049569,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00049569,Hydrocortisone,ISA,Therapeutic procedure
NCT00049569,Methotrexate,ADMINISTERED_TO,Patients
NCT00049569,Methotrexate,ISA,Therapeutic procedure
NCT00049569,Prednisone,ADMINISTERED_TO,Patients
NCT00049569,Upper Extremity,LOCATION_OF,Doxorubicin
NCT00049569,Upper Extremity,LOCATION_OF,Prednisone
NCT00049569,Upper Extremity,LOCATION_OF,Vincristine
NCT00049569,Upper Extremity,LOCATION_OF,pegaspargase
NCT00049569,Upper Extremity,LOCATION_OF,Imatinib mesylate
NCT00049569,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00049569,Cytarabine,ADMINISTERED_TO,Patients
NCT00049569,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00049569,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00049569,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00049569,Etoposide,ADMINISTERED_TO,Patients
NCT00049569,Methotrexate,ADMINISTERED_TO,Patients
NCT00049569,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00049569,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00049569,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00049569,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00049569,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00049569,Neoadjuvant Therapy,TREATS,Child
NCT00049569,Neoadjuvant Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03455140,ARGINASE,PART_OF,Human
NCT03455140,Child,LOCATION_OF,ARGINASE
NCT03455140,Glioma,PROCESS_OF,Child
NCT03455140,Glioma,PROCESS_OF,Persons
NCT03455140,leukemia,PROCESS_OF,Child
NCT03455140,leukemia,PROCESS_OF,Persons
NCT03455140,Persons,LOCATION_OF,ARGINASE
NCT03455140,Neuroblastoma,PROCESS_OF,Child
NCT03455140,Neuroblastoma,PROCESS_OF,Persons
NCT03455140,sarcoma,PROCESS_OF,Child
NCT03455140,sarcoma,PROCESS_OF,Persons
NCT03455140,Pharmaceutical Preparations,INHIBITS,Arginine
NCT03455140,Glioma,PROCESS_OF,Child
NCT03455140,leukemia,PROCESS_OF,Child
NCT03455140,Neuroblastoma,PROCESS_OF,Child
NCT03455140,sarcoma,PROCESS_OF,Child
NCT03455140,Recurrent Carcinoma,PROCESS_OF,Child
NCT03455140,ARGINASE,ASSOCIATED_WITH,Recurrent Carcinoma
NCT03455140,ARGINASE,PART_OF,Human
NCT03455140,Recurrent Carcinoma,PART_OF,Child
NCT03455140,Recurrent Carcinoma,PART_OF,Young adult
NCT01186328,Pharmacotherapy,TREATS,Child
NCT01186328,Proteins,AUGMENTS,Leukemic Cell
NCT01186328,Proteins,PART_OF,Leukemic Cell
NCT01186328,Cell Death,AFFECTS,Neoplasm
NCT01186328,BIRC5 gene,AFFECTS,Cell Cycle Progression
NCT01186328,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01186328,Systemic Therapy,USES,Doxorubicin
NCT01186328,Systemic Therapy,USES,Prednisone
NCT01186328,Systemic Therapy,USES,Vincristine
NCT01186328,Systemic Therapy,USES,pegaspargase
NCT01186328,Pharmacotherapy,TREATS,Child
NCT01186328,Pharmacotherapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01186328,Pharmacotherapy,USES,BIRC5 gene
NCT01186328,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01321346,Hodgkin Disease,PROCESS_OF,Adult
NCT01321346,leukemia,PROCESS_OF,Adult
NCT01321346,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Adult
NCT01321346,Solid tumor,PROCESS_OF,Adult
NCT01321346,Pharmaceutical Preparations,AUGMENTS,Adverse effects
NCT01321346,Hodgkin Disease,PROCESS_OF,Child
NCT01321346,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01321346,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
NCT01321346,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT01321346,Refractory Hematologic Malignancy,PROCESS_OF,Child
NCT03178617,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03178617,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
NCT03178617,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
NCT03178617,intervention program,TREATS,Child
NCT03178617,intervention program,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03178617,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03178617,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
NCT03178617,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
NCT03178617,intervention program,TREATS,Child
NCT03178617,intervention program,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03178617,intervention program,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT03178617,intervention program,TREATS(INFER),Large Cell Lymphoblastic Lymphoma
NCT03178617,Malignant Childhood Neoplasm,PROCESS_OF,Survivors
NCT03178617,Malignant Neoplasms,PROCESS_OF,Child
NCT00077467,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00077467,Adverse effects,PROCESS_OF,Patients
NCT00077467,bortezomib,TREATS,Patients
NCT00077467,bortezomib,DISRUPTS,Growth
NCT00077467,bortezomib,TREATS,Child
NCT00077467,Toxic effect,PROCESS_OF,Patients
NCT00077467,Drug Kinetics,PROCESS_OF,Patients
NCT00077467,bortezomib,ADMINISTERED_TO,Patients
NCT00077467,leukemia,PROCESS_OF,Patients
NCT00077467,PS 341,TREATS,Patients
NCT00077467,PS 341,TREATS(INFER),leukemia
NCT02559557,"Leukemia, Myelocytic, Acute",PROCESS_OF,Survivors
NCT02559557,educational intervention,TREATS,parent
NCT02559557,educational intervention,TREATS,Survivors
NCT02559557,educational intervention,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT02559557,skills,PROCESS_OF,parent
NCT02559557,Intervention regimes,TREATS,parent
NCT02559557,Intervention regimes,TREATS,Survivors
NCT02559557,Therapeutic procedure,PREDISPOSES,Late effect of
NCT02559557,"Leukemia, Myelocytic, Acute",PROCESS_OF,Survivors
NCT02559557,"Leukemia, Myelocytic, Acute",PROCESS_OF,Survivors
NCT02559557,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02559557,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
NCT02559557,Intervention regimes,TREATS,parent
NCT02819804,Malignant Neoplasms,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
NCT02819804,Therapeutic procedure,TREATS,Disease
NCT02819804,Medication Management,METHOD_OF,Therapeutic procedure
NCT02819804,ABL1 gene,AUGMENTS,Cells
NCT02819804,Pharmaceutical Preparations,compared_with,Pharmaceutical Preparations
NCT02819804,Pharmaceutical Preparations,higher_than,Pharmaceutical Preparations
NCT02819804,Philadelphia chromosome positive,PROCESS_OF,Patients
NCT02819804,Toxic effect,PROCESS_OF,Patients
NCT02819804,Bone Marrow,LOCATION_OF,PDCD1 gene
NCT02819804,peripheral blood,LOCATION_OF,PDCD1 gene
NCT02819804,Peripheral,LOCATION_OF,T-Lymphocyte
NCT02819804,Therapeutic procedure,TREATS,Patients
NCT02819804,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT02819804,Hemopoietic stem cell transplant,ADMINISTERED_TO,Patients
NCT00720109,Combination Drug Therapy,TREATS,Patients
NCT00720109,Adverse effects,PROCESS_OF,Patients
NCT00720109,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00720109,Chemotherapy-Oncologic Procedure,TREATS,Child
NCT00720109,Chemotherapy-Oncologic Procedure,TREATS,Adolescent
NCT00720109,Chemotherapy-Oncologic Procedure,TREATS,Young adult
NCT00720109,Therapeutic procedure,TREATS,Patients
NCT00720109,Therapeutic procedure,USES,Protein-tyrosine kinase inhibitor
NCT00720109,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00720109,Vincristine,ADMINISTERED_TO,Patients
NCT00720109,Daunorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00720109,Bone marrow aspiration procedure,ADMINISTERED_TO,Patients
NCT00720109,Bone Marrow,PART_OF,Patients
NCT00720109,Cytarabine,ADMINISTERED_TO,Patients
NCT00720109,Diagnosis,COEXISTS_WITH,Neoadjuvant Therapy
NCT00720109,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00720109,Methotrexate,ADMINISTERED_TO,Patients
NCT00720109,Daunorubicin Hydrochloride,NEG_ADMINISTERED_TO,Patients
NCT00720109,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00720109,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00720109,Filgrastim,ADMINISTERED_TO,Patients
NCT00720109,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00720109,Bone marrow aspiration procedure,ADMINISTERED_TO,Patients
NCT00720109,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00720109,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00720109,Hematopoietic Stem Cell Transplantation,TREATS(INFER),"Neoplasm, Residual"
NCT00720109,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00720109,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00720109,Vincristine,ADMINISTERED_TO,Patients
NCT00720109,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00720109,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00720109,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00720109,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00720109,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00720109,Vincristine,ADMINISTERED_TO,Patients
NCT00720109,Therapeutic procedure,USES,Protein-tyrosine kinase inhibitor
NCT00005585,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00005585,Combination Drug Therapy,TREATS,Child
NCT00005585,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00005585,Combination Drug Therapy,TREATS,Child
NCT00005585,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00005585,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00005585,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00005585,Toxic effect,PROCESS_OF,Patients
NCT00005585,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00005585,Upper Extremity,LOCATION_OF,Methotrexate
NCT00005585,Methotrexate,ADMINISTERED_TO,Patients
NCT00005585,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00005585,Therapeutic procedure,TREATS,Patients
NCT00005585,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01228331,Cytarabine,DISRUPTS,Cells
NCT01228331,Cytarabine,TREATS,Child
NCT01228331,Pharmaceutical Preparations,DISRUPTS,Growth
NCT01228331,pegaspargase,TREATS,Child
NCT01228331,clofarabine,DISRUPTS,Cells
NCT01228331,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT01228331,Roentgen Rays,ISA,"Energy, Physics"
NCT01228331,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT01228331,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT01228331,pegaspargase,compared_with,Combination Drug Therapy
NCT01228331,clofarabine,ADMINISTERED_TO,Patients
NCT01228331,Daunorubicin Hydrochloride,TREATS,Patients
NCT01228331,Daunorubicin Hydrochloride,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT01228331,Daunorubicin Hydrochloride,TREATS(INFER),Acute T Cell Leukemia
NCT01228331,Doxorubicin Hydrochloride,TREATS,Patients
NCT01228331,Doxorubicin Hydrochloride,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT01228331,Doxorubicin Hydrochloride,TREATS(INFER),Acute T Cell Leukemia
NCT01228331,pegaspargase,COEXISTS_WITH,clofarabine
NCT01228331,pegaspargase,TREATS,Patients
NCT01228331,pegaspargase,PART_OF,"Neoplasm, Residual"
NCT01228331,pegaspargase,TREATS,Patients
NCT01228331,clofarabine,compared_with,Cytarabine
NCT01228331,pegaspargase,ASSOCIATED_WITH,"Neoplasm, Residual"
NCT01228331,pegaspargase,compared_with,Cytarabine
NCT01228331,pegaspargase,compared_with,Methotrexate
NCT01228331,clofarabine,compared_with,pegaspargase
NCT01228331,Daunorubicin Hydrochloride,compared_with,Doxorubicin Hydrochloride
NCT01228331,"Complication, infection",PROCESS_OF,Patients
NCT01228331,Disease,PROCESS_OF,Patients
NCT01228331,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT01228331,Cytarabine,ADMINISTERED_TO,Patients
NCT01228331,pegaspargase,ADMINISTERED_TO,Patients
NCT01228331,Cytarabine,ADMINISTERED_TO,Patients
NCT01228331,pegaspargase,ADMINISTERED_TO,Patients
NCT01228331,Cytarabine,ADMINISTERED_TO,Patients
NCT01228331,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT01228331,pegaspargase,ADMINISTERED_TO,Patients
NCT01228331,clofarabine,ADMINISTERED_TO,Patients
NCT01228331,Precursor B-cell lymphoblastic leukemia,PROCESS_OF,Patients
NCT01228331,Cytarabine,ADMINISTERED_TO,Patients
NCT01228331,pegaspargase,ADMINISTERED_TO,Patients
NCT01228331,Methotrexate,NEG_TREATS,Clinical Nurse Specialists
NCT01228331,Radiation therapy,TREATS,Patients
NCT01228331,Radiation therapy,TREATS(INFER),CNS metastases
NCT01228331,pegaspargase,ADMINISTERED_TO,Patients
NCT01228331,clofarabine,ADMINISTERED_TO,Patients
NCT01228331,CNS metastases,PROCESS_OF,Patients
NCT01228331,CNS metastases,NEG_PROCESS_OF,Patients
NCT01228331,CNS metastases,NEG_PROCESS_OF,Patients
NCT01228331,Therapeutic procedure,TREATS,Clinical Nurse Specialists
NCT01228331,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT01228331,Radiation therapy,TREATS,Patients
NCT01228331,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT01228331,Methotrexate,ADMINISTERED_TO,Patients
NCT01228331,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT01228331,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00382109,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00382109,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,Graft-vs-Host Disease
NCT00382109,Methotrexate,compared_with,Tacrolimus
NCT00382109,Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00382109,Stem cell transplant,TREATS,Patients
NCT00382109,Stem cell transplant,TREATS(INFER),Graft-vs-Host Disease
NCT00382109,Cyclophosphamide,DISRUPTS,Growth
NCT00382109,Thiotepa,DISRUPTS,Growth
NCT00382109,Methotrexate,NEG_TREATS,Graft-vs-Host Disease
NCT00382109,Tacrolimus,NEG_TREATS,Graft-vs-Host Disease
NCT00382109,Tacrolimus,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00382109,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00382109,Hematopoietic Stem Cell Transplantation,compared_with,Tacrolimus
NCT00382109,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00382109,Blast Cell,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
NCT00382109,Transplantation,TREATS,Patients
NCT00382109,Whole-Body Irradiation,TREATS,Patients
NCT00382109,"Receptors, Complement 3d",compared_with,"Receptors, Complement 3b"
NCT00382109,"Receptors, Complement 3d",compared_with,"Receptors, Complement 3d"
NCT00382109,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00382109,Bone Marrow,PART_OF,Patients
NCT00382109,Methotrexate,ADMINISTERED_TO,Patients
NCT00382109,Tacrolimus,ADMINISTERED_TO,Patients
NCT00382109,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01460160,Pharmacotherapy,ISA,Therapeutic procedure
NCT01460160,Pharmacotherapy,TREATS,Patients
NCT00079404,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,TREATS,Patients
NCT00079404,Adverse effects,PROCESS_OF,Patients
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,DISRUPTS,"Tumor cells, malignant"
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,ISA,Pharmacotherapy
NCT00079404,Solid tumor,PROCESS_OF,Child
NCT00079404,Drug Kinetics,PROCESS_OF,Child
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,ADMINISTERED_TO,Child
NCT00079404,Solid tumor,PROCESS_OF,Patients
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,ADMINISTERED_TO,Patients
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,ADMINISTERED_TO,Patients
NCT00079404,Toxic effect,PROCESS_OF,Patients
NCT00079404,leukemia,PROCESS_OF,Patients
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,ADMINISTERED_TO,Patients
NCT00079404,leukemia,PROCESS_OF,Patients
NCT00079404,leukemia,PROCESS_OF,Patients
NCT00079404,Solid tumor,PROCESS_OF,Patients
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,TREATS,Patients
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,TREATS(INFER),leukemia
NCT00079404,17-(allylamino)-17-demethoxygeldanamycin,TREATS(INFER),Solid tumor
NCT01492569,Pharmacotherapy,TREATS,Patients
NCT01492569,Pharmacotherapy,TREATS(INFER),Nausea
NCT01492569,Pharmacotherapy,TREATS(INFER),Vomiting
NCT01492569,Nausea,PROCESS_OF,Patients
NCT01492569,Vomiting,PROCESS_OF,Patients
NCT01492569,Point stimulation,TREATS,Nausea
NCT01492569,Acupuncture Points,LOCATION_OF,Nervousness
NCT01492569,Wrist,LOCATION_OF,Acupuncture Points
NCT01492569,Pharmacotherapy,compared_with,Point stimulation
NCT01492569,Nausea,PROCESS_OF,Child
NCT01492569,Vomiting,PROCESS_OF,Child
NCT01492569,Therapeutic procedure,USES,Antiemetics
NCT01492569,transcutaneous stimulation,TREATS,Patients
NCT01492569,transcutaneous stimulation,TREATS,Patients
NCT01492569,Point stimulation,TREATS,Nausea
NCT01492569,Point stimulation,TREATS,Vomiting
NCT01403415,Dexamethasone,TREATS,Patients
NCT01403415,Dexamethasone,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01403415,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01403415,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT01403415,Vincristine Sulfate,TREATS,Patients
NCT01403415,Vincristine Sulfate,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01403415,pegaspargase,TREATS,Patients
NCT01403415,pegaspargase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01403415,Vitelliform dystrophy,PROCESS_OF,Patients
NCT01403415,Mitoxantrone Hydrochloride,TREATS,Patients
NCT01403415,Mitoxantrone Hydrochloride,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01403415,Adverse effects,PROCESS_OF,Patients
NCT01403415,Dexamethasone,DISRUPTS,Growth
NCT01403415,Pharmaceutical Preparations,DISRUPTS,Cells
NCT01403415,Vincristine Sulfate,DISRUPTS,Growth
NCT01403415,pegaspargase,DISRUPTS,Growth
NCT01403415,Mitoxantrone Hydrochloride,DISRUPTS,Growth
NCT01403415,Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01403415,Combination Drug Therapy,TREATS,"Lymphoma, Non-Hodgkin's"
NCT01403415,Pharmacotherapy,TREATS,Child
NCT01403415,Pharmacotherapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01403415,Pharmacotherapy,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT01403415,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01403415,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT01403415,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01403415,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT01403415,Toxic effect,PROCESS_OF,Child
NCT01403415,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01403415,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT01403415,"Neoplasm, Residual",PROCESS_OF,Patients
NCT01403415,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01403415,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT01403415,Sirolimus (substance),DISRUPTS,Cells
NCT01403415,Dexamethasone,ADMINISTERED_TO,Patients
NCT01403415,Methotrexate,ADMINISTERED_TO,Patients
NCT01403415,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01403415,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT01403415,Neoadjuvant Therapy,TREATS,Child
NCT01403415,Neoadjuvant Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01403415,Neoadjuvant Therapy,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT00967057,Combination Drug Therapy,TREATS,Patients
NCT00967057,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00967057,Combination Drug Therapy,TREATS,Patients
NCT00967057,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00967057,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00967057,Disease,PROCESS_OF,Patients
NCT00967057,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00967057,Maintenance therapy,ISA,Therapeutic procedure
NCT00967057,Consolidation Therapy,ISA,Therapeutic procedure
NCT00967057,Disease,PROCESS_OF,Patients
NCT00967057,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00967057,Therapeutic procedure,METHOD_OF,Consolidation Therapy
NCT00967057,Maintenance therapy,ISA,Therapeutic procedure
NCT00967057,Maintenance therapy,METHOD_OF(SPEC),Consolidation Therapy
NCT00967057,Therapeutic procedure,METHOD_OF,Consolidation Therapy
NCT00967057,Disease,PROCESS_OF,Patients
NCT00967057,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00967057,Assessment procedure,METHOD_OF,Therapeutic procedure
NCT00967057,Assessment procedure,METHOD_OF,Consolidation Therapy
NCT00967057,Disease,PROCESS_OF,Patients
NCT00967057,Dexamethasone,ADMINISTERED_TO,Patients
NCT00967057,Methotrexate,ADMINISTERED_TO,Patients
NCT00967057,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00967057,pegaspargase,ADMINISTERED_TO,Patients
NCT00967057,Upper Extremity,LOCATION_OF,ASPARAGINASE
NCT00967057,Upper Extremity,LOCATION_OF,pegaspargase
NCT00967057,Oral form dexamethasone,ADMINISTERED_TO,Patients
NCT00967057,Oral form dexamethasone,ADMINISTERED_TO,Patients
NCT00967057,Oral form dexamethasone,ADMINISTERED_TO,Patients
NCT00967057,Cranial Irradiation,TREATS,Patients
NCT00967057,Methotrexate,NEG_ADMINISTERED_TO,Patients
NCT00967057,Radiation therapy,TREATS,Patients
NCT00967057,Cranial Irradiation,TREATS,Patients
NCT00967057,Methotrexate,ADMINISTERED_TO,Patients
NCT00967057,Cranial Irradiation,TREATS,Patients
NCT00967057,Prophylactic treatment,TREATS,Patients
NCT00967057,Stem cell transplant,TREATS,Patients
NCT00967057,Infusion procedures,METHOD_OF,Immunotherapy
NCT00967057,Stem cell transplant,TREATS,Patients
NCT00101205,Etoposide,TREATS,Patients
NCT00101205,Ifosfamide,TREATS,Patients
NCT00101205,oxaliplatin,TREATS,Patients
NCT00101205,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00101205,Adverse effects,PROCESS_OF,Patients
NCT00101205,Pharmaceutical Preparations,DISRUPTS,Cells
NCT00101205,Etoposide,DISRUPTS,Growth
NCT00101205,oxaliplatin,DISRUPTS,Growth
NCT00101205,oxaliplatin,INTERACTS_WITH,Pharmaceutical Preparations
NCT00101205,Etoposide,DISRUPTS,"Tumor cells, malignant"
NCT00101205,Etoposide,TREATS,Patients
NCT00101205,oxaliplatin,TREATS,Patients
NCT00101205,Treatment Protocols,TREATS,Patients
NCT00101205,Etoposide,ADMINISTERED_TO,Patients
NCT00101205,oxaliplatin,ADMINISTERED_TO,Patients
NCT00101205,Toxic effect,PROCESS_OF,Patients
NCT00042796,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00042796,Pharmaceutical Preparations,TREATS,Child
NCT00042796,5-aza-2'-deoxycytidine,TREATS,Child
NCT00042796,Vitelliform dystrophy,PROCESS_OF,Child
NCT00042796,Adverse effects,PROCESS_OF,Child
NCT00042796,5-aza-2'-deoxycytidine,TREATS,Child
NCT00042796,Therapeutic procedure,USES,cDNA Microarray device
NCT00042796,DNA,PART_OF,DCK gene
NCT00042796,DNA,PART_OF,CDA gene
NCT00042796,Single Nucleotide Polymorphism,COEXISTS_WITH,DNA
NCT00042796,5-aza-2'-deoxycytidine,ADMINISTERED_TO,Patients
NCT00042796,5-aza-2'-deoxycytidine,TREATS,Child
NCT00005596,Combination Drug Therapy,TREATS,Child
NCT00005596,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00005596,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00005596,Combination Drug Therapy,TREATS,Child
NCT00005596,Therapeutic procedure,TREATS,Child
NCT00005596,Methotrexate,compared_with,Methotrexate
NCT00005596,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00005596,Methotrexate,ADMINISTERED_TO,Patients
NCT00005596,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00005596,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00005596,Upper Extremity,LOCATION_OF,Methotrexate
NCT00005596,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00005596,Dexamethasone,ADMINISTERED_TO,Patients
NCT00005596,Methotrexate,ADMINISTERED_TO,Patients
NCT00005596,Vincristine,ADMINISTERED_TO,Patients
NCT00005596,Upper Extremity,LOCATION_OF,Leucovorin Calcium
NCT00005596,Methotrexate,ADMINISTERED_TO,Patients
NCT00005596,Upper Extremity,LOCATION_OF,pegaspargase
NCT00005596,Upper Extremity,LOCATION_OF,Leucovorin Calcium
NCT00005596,Methotrexate,ADMINISTERED_TO,Patients
NCT00005596,Methotrexate,ADMINISTERED_TO,Patients
NCT00005596,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00005603,Combination Drug Therapy,TREATS,Child
NCT00005603,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00005603,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00005603,Combination Drug Therapy,TREATS,Child
NCT00005603,Therapeutic procedure,TREATS,Patients
NCT00005603,Therapeutic procedure,compared_with,Therapeutic procedure
NCT00005603,Therapeutic procedure,higher_than,Therapeutic procedure
NCT00005603,Methotrexate,ADMINISTERED_TO,Patients
NCT00005603,Methotrexate,ADMINISTERED_TO,Patients
NCT00005603,Bone Marrow,PART_OF,Patients
NCT00005603,Thioguanine,ADMINISTERED_TO,Patients
NCT00005603,CNS disorder,PROCESS_OF,Patients
NCT00005603,Whole-Brain Radiotherapy,TREATS,Patients
NCT00005603,Whole-Brain Radiotherapy,TREATS(INFER),CNS disorder
NCT00005603,Methotrexate,ADMINISTERED_TO,Patients
NCT02544789,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02544789,clofarabine,TREATS,Patients
NCT02544789,clofarabine,TREATS,Patients
NCT02544789,clofarabine,TREATS,Patients
NCT00702403,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00702403,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00702403,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00702403,Stem cell transplant,TREATS,Patients
NCT00702403,Stem cell transplant,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00702403,Stem cell transplant,TREATS(INFER),"Myeloid Leukemia, Chronic"
NCT00702403,Imatinib mesylate,DISRUPTS,Growth
NCT00702403,Cell Transplantation,TREATS,Patients
NCT00702403,Cell Transplantation,TREATS(INFER),Philadelphia chromosome positive
NCT00702403,Philadelphia chromosome positive,PROCESS_OF,Patients
NCT00702403,leukemia,PROCESS_OF,Patients
NCT00702403,Therapeutic procedure,TREATS,Patients
NCT00702403,Therapeutic procedure,TREATS(INFER),leukemia
NCT00702403,Therapeutic procedure,USES,Protein-tyrosine kinase inhibitor
NCT00702403,imatinib,TREATS,leukemia
NCT00702403,Imatinib mesylate,ISA,imatinib
NCT00702403,Imatinib mesylate,TREATS(SPEC),leukemia
NCT00702403,leukemia,PROCESS_OF,Patients
NCT00702403,imatinib,ADMINISTERED_TO,Patients
NCT00702403,imatinib,TREATS,Patients
NCT00702403,leukemia,PROCESS_OF,Patients
NCT00702403,leukemia,PROCESS_OF,Patients
NCT00702403,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00702403,leukemia,PROCESS_OF,Patients
NCT00702403,Cell Transplantation,TREATS,leukemia
NCT01093586,Cord Blood Stem Cell Transplantation,TREATS,Patients
NCT01093586,Blood,PART_OF,Patients
NCT01093586,Bone Marrow,PART_OF,Patients
NCT01093586,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01093586,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT01093586,Antithymoglobulin,ADMINISTERED_TO,Patients
NCT01093586,Busulfan,ADMINISTERED_TO,Patients
NCT01093586,Transplanted tissue,LOCATION_OF,Secondary disease
NCT01093586,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01093586,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT01093586,Infusion procedures,TREATS,Transplanted organ and tissue status
NCT01093586,Cord Blood Stem Cell Transplantation,TREATS,Patients
NCT01093586,Myeloablative Chemotherapy,TREATS,Hematologic Neoplasms
NCT01093586,Cord Blood Stem Cell Transplantation,TREATS,Hematologic Neoplasms
NCT00061945,Combination Drug Therapy,ADMINISTERED_TO,Patients
NCT00061945,Combination Drug Therapy,TREATS,Patients
NCT00061945,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00061945,alemtuzumab,TREATS,Patients
NCT00061945,alemtuzumab,AFFECTS,Growth
NCT00061945,alemtuzumab,ISA,Monoclonal Antibodies
NCT00061945,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00061945,Combination Drug Therapy,AFFECTS,Growth
NCT00061945,Campath 1H,ISA,alemtuzumab
NCT00061945,Campath 1H,TREATS,Adult
NCT00061945,Therapeutic procedure,USES,Antibodies
NCT00061945,Therapeutic procedure,USES,Campath 1H
NCT00061945,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L2"
NCT00061945,Allopurinol,ADMINISTERED_TO,Patients
NCT00061945,Combination Drug Therapy,TREATS,Patients
NCT00061945,Combination Drug Therapy,TREATS(INFER),Philadelphia chromosome positive
NCT00061945,Philadelphia chromosome positive,PROCESS_OF,Patients
NCT00061945,Methotrexate,ADMINISTERED_TO,Patients
NCT00061945,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00061945,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
NCT00061945,Therapeutic procedure,TREATS,Adult
NCT00061945,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02625480,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT02625480,CD19 Antigens,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
NCT02625480,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT01471782,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01471782,Malignant Neoplasms,PART_OF,Blood
NCT01471782,Malignant Neoplasms,PART_OF,Bone Marrow
NCT01471782,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
NCT01471782,"Leukemia, Lymphocytic, Acute",PART_OF(SPEC),Blood
NCT01471782,"Leukemia, Lymphocytic, Acute",PART_OF(SPEC),Bone Marrow
NCT01471782,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
NCT01471782,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01471782,Drug Kinetics,PROCESS_OF,Patients
NCT01471782,Part,LOCATION_OF,Cells
NCT01471782,T-Cell Activation,PROCESS_OF,Patients
NCT01471782,Drug Kinetics,PROCESS_OF,cohort
NCT01471782,Pharmacotherapy,ADMINISTERED_TO,Participant
NCT01471782,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01858740,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT01858740,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01858740,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01858740,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01858740,Bone Marrow,PART_OF,Patients
NCT01858740,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT01858740,Whole-Body Irradiation,TREATS,Patients
NCT01858740,Tacrolimus,ADMINISTERED_TO,Patients
NCT01858740,Methotrexate,ADMINISTERED_TO,Patients
NCT01858740,Graft-vs-Host Disease,PROCESS_OF,Child
NCT00873093,Combination Drug Therapy,TREATS,Patients
NCT00873093,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00873093,Combination Drug Therapy,TREATS(INFER),Large Cell Lymphoblastic Lymphoma
NCT00873093,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00873093,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT00873093,bortezomib,ADMINISTERED_TO,Pilot
NCT00873093,bortezomib,TREATS,Patients
NCT00873093,bortezomib,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00873093,bortezomib,DISRUPTS,Growth
NCT00873093,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00873093,bortezomib,DISRUPTS,"Tumor cells, malignant"
NCT00873093,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00873093,bortezomib,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00873093,bortezomib,TREATS,Patients
NCT00873093,Bone Marrow,LOCATION_OF,"Neoplasm, Residual"
NCT00873093,Cytarabine,ADMINISTERED_TO,Patients
NCT00873093,CNS disorder,PROCESS_OF,Patients
NCT00873093,Methotrexate,ADMINISTERED_TO,Patients
NCT00873093,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00873093,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00873093,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00873093,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT00873093,Cerebrospinal Fluid,PART_OF,Patients
NCT00873093,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT00873093,CNS disorder,PROCESS_OF,Patients
NCT00873093,Methotrexate,ADMINISTERED_TO,Patients
NCT00873093,Disease Progression,PROCESS_OF,Patients
NCT00873093,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00873093,Neoadjuvant Therapy,TREATS,Child
NCT00873093,Neoadjuvant Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01100658,Methylphenidate,TREATS,Child
NCT01100658,Methylphenidate,TREATS(INFER),Attention deficit hyperactivity disorder
NCT01100658,Attention deficit hyperactivity disorder,PROCESS_OF,Child
NCT01100658,Pharmaceutical Preparations,TREATS,Child
NCT01100658,Methylphenidate,TREATS,Child
NCT00860574,"Leukemia, Myelocytic, Acute",ISA,Dysmyelopoietic Syndromes
NCT00860574,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00860574,"Leukemia, Myelocytic, Acute",PROCESS_OF(SPEC),Patients
NCT00860574,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00860574,Stem cell transplant,METHOD_OF,Whole-Body Irradiation
NCT00860574,Stem cell transplant,TREATS,Patients
NCT00860574,Stem cell transplant,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00860574,Fludarabine phosphate,DISRUPTS,Growth
NCT00860574,treosulfan,DISRUPTS,Growth
NCT00860574,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00860574,"Leukemia, Myelocytic, Acute",PROCESS_OF,Donor person
NCT00860574,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00860574,Dysmyelopoietic Syndromes,PROCESS_OF,Donor person
NCT00860574,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00860574,Transplanted organ and tissue status,PROCESS_OF,Donor person
NCT00860574,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00860574,Bone Marrow Transplantation,TREATS,Patients
NCT00860574,Whole-Body Irradiation,TREATS,Patients
NCT00860574,Tacrolimus,ADMINISTERED_TO,Patients
NCT00860574,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00860574,Methotrexate,ADMINISTERED_TO,Patients
NCT00860574,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00860574,Cell Transplantation,TREATS,Patients
NCT00860574,Cell Transplantation,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00860574,Cell Transplantation,USES,fludarabine
NCT00027820,Whole-Body Irradiation,TREATS,Patients
NCT00027820,Whole-Body Irradiation,TREATS(INFER),Hematologic Neoplasms
NCT00027820,Fludarabine phosphate,TREATS,Patients
NCT00027820,Fludarabine phosphate,TREATS(INFER),Hematologic Neoplasms
NCT00027820,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00027820,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00027820,Pharmacotherapy,USES,Pharmaceutical Preparations
NCT00027820,Renal Cell Carcinoma,PROCESS_OF,Patients
NCT00027820,mycophenolate mofetil,TREATS,Patients
NCT00027820,mycophenolate mofetil,TREATS(INFER),Renal Cell Carcinoma
NCT00027820,mycophenolate mofetil,TREATS(INFER),Hematologic Neoplasms
NCT00027820,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00027820,Graft acceptance,PROCESS_OF,Patients
NCT00027820,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00027820,Fludarabine phosphate,ISA,fludarabine
NCT00027820,Graft acceptance,PROCESS_OF,Patients
NCT00027820,Cyclosporine,ADMINISTERED_TO,Patients
NCT00027820,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00027820,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00027820,Renal Cell Carcinoma,PROCESS_OF,Patients
NCT00027820,Peripheral Stem Cell Transplantation,METHOD_OF,Whole-Body Irradiation
NCT00027820,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00058461,Combination Drug Therapy,TREATS,Patients
NCT00058461,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00058461,rituximab,TREATS,Patients
NCT00058461,Non-Hodgkin's lymphoma refractory,PROCESS_OF,Patients
NCT00058461,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00058461,Etoposide,DISRUPTS,"Tumor cells, malignant"
NCT00058461,Ifosfamide,DISRUPTS,"Tumor cells, malignant"
NCT00058461,Carboplatin,DISRUPTS,"Tumor cells, malignant"
NCT00058461,rituximab,ISA,Monoclonal Antibodies
NCT00058461,rituximab,DISRUPTS,"Tumor cells, malignant"
NCT00058461,Etoposide,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00058461,Etoposide,TREATS,B-cell lymphoma refractory
NCT00058461,Ifosfamide,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00058461,Ifosfamide,TREATS,B-cell lymphoma refractory
NCT00058461,Carboplatin,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00058461,Carboplatin,TREATS,B-cell lymphoma refractory
NCT00058461,Treatment Protocols,TREATS,Patients
NCT00058461,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00058461,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00058461,B-Lymphocytes,LOCATION_OF,Large-Cell Lymphomas
NCT00058461,Large-Cell Lymphomas,ISA,Disease
NCT00058461,Precursor B-cell lymphoblastic lymphoma,ISA,Disease
NCT00058461,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00058461,Filgrastim,ADMINISTERED_TO,Patients
NCT00058461,Cytarabine,ADMINISTERED_TO,Patients
NCT00058461,CHEMOTHERAPY METHOTREXATE,ADMINISTERED_TO,Patients
NCT00058461,B-Lymphocytes,LOCATION_OF,Large-Cell Lymphomas
NCT00058461,Large-Cell Lymphomas,PROCESS_OF,Patients
NCT00058461,Intrathecal Chemotherapy,ADMINISTERED_TO,Patients
NCT00058461,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00058461,"Lymphoma, Small Noncleaved-Cell",PROCESS_OF,Patients
NCT00058461,Intrathecal Chemotherapy,ADMINISTERED_TO,Patients
NCT00058461,Intrathecal Chemotherapy,ADMINISTERED_TO,Patients
NCT00058461,B-Lymphocytes,PART_OF,Child
NCT00058461,Pharmacotherapy,TREATS,Child
NCT00058461,Pharmacotherapy,USES,Etoposide
NCT00058461,Etoposide,ISA,Pharmacotherapy
NCT00058461,Etoposide,TREATS(SPEC),Child
NCT00058461,Ifosfamide,TREATS,Child
NCT00058461,Carboplatin,TREATS,Child
NCT00058461,rituximab,TREATS,Child
NCT00089011,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00089011,Whole-Body Irradiation,TREATS,Hematologic Neoplasms
NCT00089011,Fludarabine phosphate,TREATS,Hematologic Neoplasms
NCT00089011,Tacrolimus,TREATS,Graft-vs-Host Disease
NCT00089011,mycophenolate mofetil,TREATS,Graft-vs-Host Disease
NCT00089011,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00089011,Fludarabine phosphate,DISRUPTS,Growth
NCT00089011,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00089011,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00089011,Fludarabine phosphate,ISA,fludarabine
NCT00089011,Whole-Body Irradiation,TREATS,Patients
NCT00089011,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00089011,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00089011,Tacrolimus,TREATS,Hematologic Neoplasms
NCT00089011,mycophenolate mofetil,TREATS,Hematologic Neoplasms
NCT00078858,Cyclosporine,ASSOCIATED_WITH,Graft-vs-Host Disease
NCT00078858,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00078858,mycophenolate mofetil,PREDISPOSES,Graft-vs-Host Disease
NCT00078858,Metastatic renal cell carcinoma,PROCESS_OF,Patients
NCT00078858,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00078858,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00078858,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00078858,Cyclosporine,ADMINISTERED_TO,Patients
NCT00078858,Whole-Body Irradiation,TREATS,Patients
NCT00078858,Renal Cell Carcinoma,PROCESS_OF,Patients
NCT00078858,Transplantation,TREATS,Patients
NCT00078858,Transplantation,TREATS(INFER),Renal Cell Carcinoma
NCT00078858,Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00078858,mycophenolate mofetil,PREVENTS,Graft-vs-Host Disease
NCT00078858,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00014235,Fludarabine phosphate,TREATS,Patients
NCT00014235,Fludarabine phosphate,TREATS(INFER),Hematologic Neoplasms
NCT00014235,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00014235,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00014235,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00014235,Bone Marrow,PART_OF,Patients
NCT00014235,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00014235,Whole-Body Irradiation,TREATS,Patients
NCT00014235,Whole-Body Irradiation,TREATS(INFER),Graft-vs-Host Disease
NCT00014235,Fludarabine phosphate,ISA,fludarabine
NCT00014235,Cyclosporine,ADMINISTERED_TO,Patients
NCT00014235,Whole-Body Irradiation,TREATS,Patients
NCT00014235,Whole-Body Irradiation,TREATS,"Complication, infection"
NCT00014235,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00014235,mycophenolate mofetil,TREATS,Patients
NCT00014235,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00014235,Upper Extremity,LOCATION_OF,Graft-vs-Host Disease
NCT00014235,Allografting,USES,fludarabine
NCT01523977,Cells,LOCATION_OF,tumor growth
NCT01523977,Pharmacotherapy,TREATS,Patients
NCT01523977,everolimus,PREVENTS,tumor growth
NCT01523977,everolimus,STIMULATES,Pharmaceutical Preparations
NCT01523977,RAD 001,ISA,everolimus
NCT01523977,RAD 001,PREVENTS(SPEC),tumor growth
NCT01523977,Malignant neoplasm of kidney,ISA,Malignant Neoplasms
NCT01523977,Pharmaceutical Preparations,TREATS,Malignant Neoplasms
NCT01523977,Malignant Neoplasms,PROCESS_OF,Adult
NCT01523977,everolimus,ISA,Antineoplastic Agents
NCT01523977,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01523977,Laboratory,LOCATION_OF,Clinical Research
NCT01523977,Steroids,DISRUPTS,Leukemic Cell
NCT01523977,everolimus,DISRUPTS,Leukemic Cell
NCT01523977,everolimus,ISA,Pharmaceutical Preparations
NCT01523977,Pharmaceutical Preparations,TREATS,leukemia
NCT01523977,Veins,LOCATION_OF,everolimus
NCT01523977,Veins,LOCATION_OF,Entire oral cavity
NCT01523977,Veins,LOCATION_OF(SPEC),RAD 001
NCT01523977,RAD 001,ISA,everolimus
NCT01523977,Veins,LOCATION_OF,pegaspargase
NCT01523977,Erwinia asparaginase,ISA,ASPARAGINASE
NCT01523977,Muscle,LOCATION_OF,Erwinia asparaginase
NCT01523977,Intrathecal Chemotherapy,TREATS,leukemia
NCT01523977,Cytarabine,ISA,Therapeutic procedure
NCT01523977,Hydrocortisone,ISA,Therapeutic procedure
NCT01523977,Methotrexate,ISA,Therapeutic procedure
NCT01523977,Cerebrospinal Fluid,LOCATION_OF,Methotrexate
NCT01523977,Cerebrospinal Fluid,LOCATION_OF,Doxorubicin
NCT01523977,Cerebrospinal Fluid,LOCATION_OF,Vincristine
NCT01523977,Cerebrospinal Fluid,LOCATION_OF,pegaspargase
NCT01523977,Doxorubicin,ISA,Therapeutic procedure
NCT01523977,Doxorubicin,TREATS(SPEC),leukemia
NCT01523977,Prednisone,ISA,Therapeutic procedure
NCT01523977,Prednisone,TREATS(SPEC),leukemia
NCT01523977,Vincristine,ISA,Therapeutic procedure
NCT01523977,Vincristine,TREATS(SPEC),leukemia
NCT01523977,pegaspargase,ISA,Therapeutic procedure
NCT01523977,pegaspargase,TREATS(SPEC),leukemia
NCT01523977,Therapeutic procedure,TREATS,leukemia
NCT01523977,Pharmacotherapy,TREATS,Patients
NCT01523977,Pharmacotherapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01523977,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01523977,RAD 001,ISA,everolimus
NCT00052520,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00052520,"Myeloid Leukemia, Chronic",ISA,Dysmyelopoietic Syndromes
NCT00052520,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00052520,"Myeloid Leukemia, Chronic",PROCESS_OF(SPEC),Patients
NCT00052520,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00052520,Therapeutic procedure,TREATS,Patients
NCT00052520,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00052520,Therapeutic procedure,TREATS(INFER),"Myeloid Leukemia, Chronic"
NCT00052520,Therapeutic procedure,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00052520,Adverse effects,PROCESS_OF,Patients
NCT00052520,Immunotherapy,ADMINISTERED_TO,Patients
NCT00052520,"Myeloid Leukemia, Chronic",ISA,Dysmyelopoietic Syndromes
NCT00052520,Nephroblastoma,PROCESS_OF,Patients
NCT00052520,Leukapheresis,TREATS,Donor person
NCT00052520,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00052520,Therapeutic procedure,TREATS,Disease
NCT00052520,Therapeutic procedure,TREATS,Recurrent disease
NCT00052520,Disease,PROCESS_OF,high-risk group
NCT00052520,Interleukin-2,ADMINISTERED_TO,Patients
NCT00052520,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00052520,Interleukin-2,ADMINISTERED_TO,Patients
NCT00052520,Clone Cells,PART_OF,Patients
NCT00052520,Therapeutic procedure,METHOD_OF,Retreatment
NCT00052520,Progressive Disease,PROCESS_OF,Patients
NCT00052520,partial response,PROCESS_OF,Patients
NCT00052520,"Myeloid Leukemia, Chronic",ISA,Dysmyelopoietic Syndromes
NCT00052520,"Myeloid Leukemia, Chronic",PROCESS_OF(SPEC),Patients
NCT00052520,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00052520,"Immunotherapy, Adoptive",TREATS,Patients
NCT00052520,"Immunotherapy, Adoptive",TREATS(INFER),Dysmyelopoietic Syndromes
NCT00131053,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
NCT00131053,Treatment Protocols,TREATS,Patients
NCT00131053,Treatment Protocols,TREATS(INFER),"Leukemia, Lymphocytic, Acute, L2"
NCT00131053,"Leukemia, Lymphocytic, Acute, L2",ISA,"Leukemia, Lymphocytic, Acute"
NCT00131053,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00131053,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00131053,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00186875,Therapeutic procedure,USES,Etoposide
NCT00186875,Therapeutic procedure,USES,Teniposide
NCT00186875,Therapeutic procedure,TREATS,Patients
NCT00186875,Disease,PROCESS_OF,Participant
NCT00186875,Hemopoietic stem cell transplant,TREATS,Participant
NCT00186875,Hemopoietic stem cell transplant,TREATS(INFER),Disease
NCT00186875,Pharmacotherapy,TREATS,Patients
NCT00186875,Antibodies,ASSOCIATED_WITH,Hypersensitivity
NCT00186875,Antibodies,compared_with,ASPARAGINASE
NCT00186875,ASPARAGINASE,ASSOCIATED_WITH,Hypersensitivity
NCT00186875,Therapeutic procedure,TREATS,Child
NCT00186875,Serum,LOCATION_OF,Antibodies
NCT00186875,"Neoplasm, Residual",OCCURS_IN,Child
NCT00186875,Remission Induction,ADMINISTERED_TO,Patients
NCT00186875,Induction,PRECEDES,Pharmacotherapy
NCT00186875,End,LOCATION_OF,Leukocytes
NCT00186875,Induction,TREATS,Patients
NCT00186875,Induction,PRECEDES,Hemopoietic stem cell transplant
NCT00186875,Induction,METHOD_OF,Hemopoietic stem cell transplant
NCT00186875,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00186875,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00186875,Induction,METHOD_OF,Hemopoietic stem cell transplant
NCT00186875,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00186875,Pharmacotherapy,PREVENTS,"Neoplasm, Residual"
NCT00186875,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00186875,Induction,METHOD_OF,Hemopoietic stem cell transplant
NCT01860937,T-Lymphocyte,LOCATION_OF,CD19 Antigens
NCT01860937,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT01860937,Toxic effect,PROCESS_OF,Patients
NCT01860937,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT01305200,Mucositis,PROCESS_OF,Patients
NCT01305200,Oral Mucositis,PROCESS_OF,Patients
NCT01305200,Mucositis,PROCESS_OF,Patients
NCT01305200,Mouth Sore,PROCESS_OF,Patients
NCT01305200,Stem cell transplant,TREATS,Patients
NCT01305200,Stem cell transplant,TREATS(INFER),Mucositis
NCT01305200,Stem cell transplant,TREATS(INFER),Mouth Sore
NCT01305200,Hematopoietic Stem Cell Transplantation,USES,calcium phosphate
NCT01305200,Placebos,PREVENTS,Oral Mucositis
NCT01305200,Placebos,PREVENTS,Febrile neutropenia
NCT01305200,Melphalan,compared_with,Whole-Body Irradiation
NCT01305200,Mucositis,PROCESS_OF,Patients
NCT01305200,Oral Mucositis,NEG_PROCESS_OF,Patients
NCT01305200,calcium phosphate,PREVENTS,Oral Mucositis
NCT01305200,Hematopoietic Stem Cell Transplantation,TREATS,Child
NCT01305200,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Oral Mucositis
NCT01305200,Oral Mucositis,PROCESS_OF,Child
NCT02551718,Acute leukemia,PROCESS_OF,Patients
NCT02551718,Therapeutic procedure,TREATS,Patients
NCT02551718,Therapeutic procedure,TREATS(INFER),Acute leukemia
NCT02551718,Acute leukemia,PROCESS_OF,Individual
NCT02551718,Cells,PART_OF,Patients
NCT02551718,Drug Combinations,AFFECTS,Blood
NCT02551718,Pharmaceutical Preparations,AFFECTS,Blood
NCT02551718,Therapeutic procedure,TREATS,Acute leukemia
NCT00450450,Bone Marrow Transplantation,NEG_TREATS,Patients
NCT00450450,Bone Marrow Transplantation,NEG_TREATS(INFER),Hematologic Neoplasms
NCT00450450,Bone Marrow Transplantation,TREATS,Patients
NCT00450450,Bone Marrow Transplantation,TREATS(INFER),Disease
NCT00450450,Bone Marrow Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00450450,Disease,ISA,Hematologic Neoplasms
NCT00450450,Disease,PROCESS_OF,Patients
NCT00450450,Disease,PROCESS_OF(SPEC),Patients
NCT00450450,Hematologic Neoplasms,ISA,Disease
NCT00450450,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00450450,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00450450,Bone Marrow,PART_OF,Patients
NCT00450450,Disease,ISA,Hematologic Neoplasms
NCT00450450,Granulocyte Colony-Stimulating Factor,NEG_ASSOCIATED_WITH,Disease
NCT00450450,Granulocyte Colony-Stimulating Factor,NEG_ASSOCIATED_WITH,Hematologic Neoplasms
NCT00450450,Granulocyte Colony-Stimulating Factor,NEG_ASSOCIATED_WITH(SPEC),Disease
NCT00450450,Granulocyte Colony-Stimulating Factor,NEG_ASSOCIATED_WITH(SPEC),Hematologic Neoplasms
NCT00450450,Hematologic Neoplasms,ISA,Disease
NCT00450450,Disease,ISA,Hematologic Neoplasms
NCT00450450,Disease,PROCESS_OF,Patients
NCT00450450,Disease,PROCESS_OF(SPEC),Patients
NCT00450450,Filgrastim,TREATS,Disease
NCT00450450,Filgrastim,TREATS,Hematologic Neoplasms
NCT00450450,Filgrastim,TREATS(SPEC),Disease
NCT00450450,Filgrastim,TREATS(SPEC),Hematologic Neoplasms
NCT00450450,Hematologic Neoplasms,ISA,Disease
NCT00450450,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00450450,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00450450,Graft acceptance,PROCESS_OF,Patients
NCT00450450,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00450450,Bone Marrow Transplantation,TREATS,Patients
NCT00450450,Treatment Protocols,ADMINISTERED_TO,Patients
NCT00450450,Whole-Body Irradiation,TREATS,Patients
NCT00450450,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00450450,Prophylactic treatment,TREATS,Patients
NCT00450450,host,LOCATION_OF,Disease
NCT00450450,Central Nervous System Leukemia,PROCESS_OF,Patients
NCT00450450,Allogeneic bone marrow transplantation,ISA,Bone Marrow Transplantation
NCT00450450,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00450450,Filgrastim,TREATS,Patients
NCT00450450,Granulocyte Colony-Stimulating Factor,AUGMENTS,Bone Marrow
NCT02220985,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT02220985,HLA Antigens,ASSOCIATED_WITH,Graft-vs-Host Disease
NCT02220985,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02220985,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT02220985,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT02220985,Bone Marrow,PART_OF,Patients
NCT02220985,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT02220985,Whole-Body Irradiation,TREATS,Patients
NCT02220985,Cells,PART_OF,Patients
NCT02220985,Whole-Body Irradiation,TREATS,Patients
NCT02220985,Upper arm,LOCATION_OF,Transplanted organ and tissue status
NCT02220985,Peripheral Blood Stem Cell,PART_OF,Patients
NCT02220985,Methotrexate,ADMINISTERED_TO,Patients
NCT02220985,HLA Antigens,PREVENTS,Graft-vs-Host Disease
NCT02446964,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT02446964,Acute leukemia,PROCESS_OF,Patients
NCT02446964,Vitelliform dystrophy,PROCESS_OF,Patients
NCT02446964,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT02446964,Adverse effects,PROCESS_OF,Patients
NCT02446964,Lymphatic Irradiation,ISA,Radiation therapy
NCT02446964,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT02446964,Lymphatic Irradiation,USES,fludarabine
NCT02446964,Lymphatic Irradiation,USES(SPEC),Fludarabine phosphate
NCT02446964,Lymphocyte,PART_OF,Patients
NCT02446964,Fludarabine phosphate,ISA,fludarabine
NCT02446964,Cell Transplantation,TREATS,Patients
NCT02446964,Cell Transplantation,USES,Cyclophosphamide
NCT02446964,Cell Transplantation,USES,Fludarabine phosphate
NCT02446964,Bone Marrow,LOCATION_OF,"Neoplasm, Residual"
NCT02446964,Lymphatic Irradiation,TREATS,Patients
NCT02446964,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT02446964,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT02446964,Tacrolimus,ADMINISTERED_TO,Patients
NCT02446964,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT02446964,Cyclosporine,ADMINISTERED_TO,Patients
NCT02446964,Therapeutic procedure,USES,Tacrolimus
NCT02446964,Therapeutic procedure,USES,mycophenolate mofetil
NCT02446964,Cyclophosphamide,TREATS,Patients
NCT02446964,Cyclophosphamide,TREATS(INFER),Dysmyelopoietic Syndromes
NCT02446964,Cyclophosphamide,TREATS(INFER),Acute leukemia
NCT02446964,Lymphatic Irradiation,METHOD_OF,Cell Transplantation
NCT02446964,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT02446964,Acute leukemia,PROCESS_OF,Patients
NCT02446964,Cell Transplantation,USES,Cyclophosphamide
NCT00867529,B-Cell Lymphomas,PROCESS_OF,Patients
NCT00867529,rituximab,TREATS,Patients
NCT00867529,rituximab,TREATS(INFER),B-Cell Lymphomas
NCT00867529,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00867529,rituximab,ISA,Monoclonal Antibodies
NCT00867529,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00867529,rituximab,ADMINISTERED_TO,Patients
NCT00867529,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00867529,Cell Transplantation,TREATS,Patients
NCT00867529,rituximab,TREATS,Patients
NCT00693602,Hypersensitivity,PROCESS_OF,Patients
NCT00693602,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00693602,Erwinase,TREATS,Patients
NCT00693602,Erwinase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00693602,ASPARAGINASE,PART_OF,Escherichia coli
NCT00693602,Hypersensitivity,PROCESS_OF,Patients
NCT00693602,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00693602,Erwinase,TREATS,Patients
NCT00693602,Erwinase,TREATS(INFER),Adverse event
NCT00693602,Erwinase,TREATS(INFER),Allergic Reaction
NCT00693602,Adverse event,PROCESS_OF,Patients
NCT00693602,Allergic Reaction,PROCESS_OF,Patients
NCT00693602,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00693602,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00693602,Erwinase,TREATS,Patients
NCT00693602,Erwinase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00693602,Erwinase,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT01529827,Melphalan,TREATS,Patients
NCT01529827,Melphalan,TREATS(INFER),Hematologic Neoplasms
NCT01529827,Whole-Body Irradiation,TREATS,Patients
NCT01529827,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT01529827,Fludarabine phosphate,TREATS,Patients
NCT01529827,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01529827,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01529827,Melphalan,DISRUPTS,Growth
NCT01529827,Melphalan,ISA,Pharmaceutical Preparations
NCT01529827,Fludarabine phosphate,DISRUPTS,Growth
NCT01529827,Fludarabine phosphate,ISA,Pharmaceutical Preparations
NCT01529827,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01529827,Bone Marrow,PART_OF,Patients
NCT01529827,Fludarabine phosphate,ISA,fludarabine
NCT01529827,Whole-Body Irradiation,TREATS,Patients
NCT01529827,Tacrolimus,ADMINISTERED_TO,Patients
NCT01529827,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01529827,Stem cell transplant,USES,Melphalan
NCT01529827,Stem cell transplant,USES,fludarabine
NCT01427881,Cyclophosphamide,PREVENTS,Graft-vs-Host Disease
NCT01427881,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT01427881,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01427881,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT01427881,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01427881,Bone Marrow,PART_OF,Patients
NCT01427881,Cyclosporine,TREATS,Patients
NCT01427881,Acute graft-versus-host disease,ISA,Graft-vs-Host Disease
NCT01427881,Whole-Body Irradiation,ADMINISTERED_TO,Patients
NCT01427881,fludarabine,ADMINISTERED_TO,Patients
NCT01427881,Busulfan,ADMINISTERED_TO,Patients
NCT01427881,fludarabine,ADMINISTERED_TO,Patients
NCT01427881,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT01427881,Central Nervous System Prophylaxis,TREATS,Patients
NCT01427881,Cyclosporine,ADMINISTERED_TO,Patients
NCT01427881,Cyclophosphamide,PREVENTS,Chronic graft-versus-host disease
NCT01384513,Bone Marrow Transplantation,TREATS,Patients
NCT01384513,Hemopoietic stem cell transplant,TREATS,Disease
NCT01384513,Hemopoietic stem cell transplant,TREATS,Patients
NCT01384513,Disease,PROCESS_OF,Donor person
NCT01384513,Therapeutic procedure,TREATS,Patients
NCT01384513,Hematologic Neoplasms,PROCESS_OF,Donor person
NCT01384513,Disease,PROCESS_OF,Patients
NCT01384513,Lymphatic Diseases,PROCESS_OF,Patients
NCT01384513,Graft-vs-Host Disease,OCCURS_IN,Patients
NCT01384513,Graft acceptance,PROCESS_OF,Patients
NCT01384513,Whole-Body Irradiation,TREATS,Patients
NCT01384513,Tacrolimus,ADMINISTERED_TO,Patients
NCT01384513,Donor Lymphocyte Infusion,TREATS,Patients
NCT01384513,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT01384513,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT01384513,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT01384513,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00856388,Disease,PROCESS_OF,Patients
NCT00856388,Melphalan,TREATS,Patients
NCT00856388,Melphalan,TREATS(INFER),Disease
NCT00856388,Melphalan,TREATS(INFER),Hematologic Neoplasms
NCT00856388,Pancytopenia,ISA,Disease
NCT00856388,Pancytopenia,PROCESS_OF(SPEC),Patients
NCT00856388,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00856388,Stem cell transplant,METHOD_OF,Whole-Body Irradiation
NCT00856388,Stem cell transplant,TREATS,Patients
NCT00856388,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00856388,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00856388,Graft acceptance,AFFECTS,Malignant Neoplasms
NCT00856388,Whole-Body Irradiation,TREATS,Patients
NCT00856388,Stem cell transplant,TREATS,Patients
NCT00856388,Fanconi's Anemia,PROCESS_OF,Patients
NCT00856388,Syndrome,PROCESS_OF,Patients
NCT00856388,Dyskeratosis Congenita,PROCESS_OF,Patients
NCT00856388,Stem cell transplant,USES,Melphalan
NCT00856388,Stem cell transplant,USES,fludarabine
NCT01088763,Vitelliform dystrophy,PROCESS_OF,Patients
NCT01088763,Adverse effects,PROCESS_OF,Patients
NCT01088763,Drug Kinetics,PROCESS_OF,Child
NCT01088763,Dexamethasone,TREATS,Child
NCT01088763,Dexamethasone,TREATS(INFER),"Leukemia, T-Cell"
NCT01088763,"Leukemia, T-Cell",PROCESS_OF,Child
NCT01088763,Oral form dexamethasone,ADMINISTERED_TO,Patients
NCT01088763,Dexamethasone,TREATS,Child
NCT01088763,Dexamethasone,TREATS(INFER),Solid tumor
NCT01088763,Dexamethasone,ASSOCIATED_WITH(INFER),"Leukemia, Lymphocytic, Acute"
NCT01088763,Dexamethasone,PART_OF,Patients
NCT01088763,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01088763,Solid tumor,PROCESS_OF,Child
NCT01088763,Child,LOCATION_OF,gamma-secretase
NCT00536601,Solid tumor,PROCESS_OF,Patients
NCT00536601,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00536601,Stem cell transplant,METHOD_OF,Whole-Body Irradiation
NCT00536601,Stem cell transplant,METHOD_OF,high-dose chemotherapy
NCT00536601,Stem cell transplant,TREATS,Patients
NCT00536601,Stem cell transplant,TREATS(INFER),Solid tumor
NCT00536601,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00536601,Blood,PART_OF,Patients
NCT00536601,Pharmacotherapy,METHOD_OF,Stem cell transplant
NCT00536601,Patients,USES,Treats
NCT00536601,Transplantation,TREATS,Solid tumor
NCT00536601,Transplantation,TREATS,Hematologic Neoplasms
NCT00118352,Cyclosporine,TREATS,Patients
NCT00118352,mycophenolate mofetil,TREATS,Patients
NCT00118352,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00118352,Adverse effects,PROCESS_OF,Patients
NCT00118352,Stem cell transplant,TREATS,Patients
NCT00118352,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00118352,Stem cell transplant,TREATS(INFER),Vitelliform dystrophy
NCT00118352,Stem cell transplant,TREATS(INFER),Adverse effects
NCT00118352,Monoclonal Antibodies,DISRUPTS,Growth
NCT00118352,Fludarabine phosphate,DISRUPTS,Growth
NCT00118352,alemtuzumab,DISRUPTS,Growth
NCT00118352,Campath,ISA,alemtuzumab
NCT00118352,Cyclosporine,ADMINISTERED_TO,Patients
NCT00118352,Whole-Body Irradiation,TREATS,Patients
NCT00118352,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00118352,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00118352,Campath,ISA,alemtuzumab
NCT00118352,Stem cell transplant,METHOD_OF,Whole-Body Irradiation
NCT00118352,Stem cell transplant,TREATS,Patients
NCT00118352,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00105001,Tacrolimus,TREATS,Acute graft-versus-host disease
NCT00105001,mycophenolate mofetil,TREATS,Acute graft-versus-host disease
NCT00105001,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00105001,Stem cell transplant,TREATS,Patients
NCT00105001,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00105001,Stem cell transplant,TREATS(INFER),Acute graft-versus-host disease
NCT00105001,Fludarabine phosphate,DISRUPTS,Growth
NCT00105001,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00105001,Treatment Protocols,PREVENTS,Acute graft-versus-host disease
NCT00105001,Whole-Body Irradiation,TREATS,Patients
NCT00105001,Tacrolimus,ADMINISTERED_TO,Patients
NCT00105001,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00105001,Tacrolimus,ADMINISTERED_TO,Patients
NCT00105001,Tacrolimus,ADMINISTERED_TO,Patients
NCT00105001,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00105001,Transplantation,PRECEDES,Prophylactic treatment
NCT00105001,Prophylactic treatment,TREATS,Patients
NCT00105001,Prophylactic treatment,TREATS(INFER),Hematologic Neoplasms
NCT00105001,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00036738,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00036738,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00036738,Whole-Body Irradiation,TREATS,Patients
NCT00036738,Whole-Body Irradiation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00036738,Whole-Body Irradiation,TREATS(INFER),"Myeloid Leukemia, Chronic"
NCT00036738,Fludarabine phosphate,TREATS,Patients
NCT00036738,Fludarabine phosphate,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00036738,Fludarabine phosphate,TREATS(INFER),"Myeloid Leukemia, Chronic"
NCT00036738,Therapeutic procedure,USES,Imatinib mesylate
NCT00036738,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00036738,Fludarabine phosphate,DISRUPTS,Growth
NCT00036738,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00036738,Disease,PROCESS_OF,Patients
NCT00036738,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00036738,"Myeloid Leukemia, Chronic",COEXISTS_WITH,Blast Phase
NCT00036738,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00036738,Hematopoietic Stem Cell Transplantation,ADMINISTERED_TO,Patients
NCT00036738,Hematopoietic Stem Cell Transplantation,ADMINISTERED_TO,Patients
NCT00036738,BCR gene,PART_OF,Patients
NCT00036738,fludarabine,ADMINISTERED_TO,Patients
NCT00036738,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00036738,Transplantation Conditioning,PRECEDES,Neoadjuvant Therapy
NCT00036738,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00036738,Donor Lymphocyte Infusion,TREATS,Patients
NCT00036738,Cyclosporine,ADMINISTERED_TO,Patients
NCT00036738,Disease,PROCESS_OF,Patients
NCT00036738,Prophylactic treatment,NEG_PRECEDES,Donor Lymphocyte Infusion
NCT00036738,Acute leukemia,PROCESS_OF,Patients
NCT00036738,Allogeneic hematopoietic stem cell transplant,TREATS,Patients
NCT00036738,Allogeneic hematopoietic stem cell transplant,TREATS(INFER),Acute leukemia
NCT00764907,Combination Drug Therapy,TREATS,Patients
NCT00764907,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00764907,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00764907,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00764907,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00764907,Chemotherapy-Oncologic Procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00764907,Pharmaceutical Preparations,TREATS,Patients
NCT00764907,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00764907,Treatment Protocols,TREATS,Patients
NCT00764907,Therapeutic procedure,TREATS,Patients
NCT00764907,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00764907,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00764907,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Treatment Protocols,ADMINISTERED_TO,Patients
NCT00764907,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00764907,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00764907,Cytarabine,COEXISTS_WITH,RISK-1
NCT00764907,Dexamethasone,ADMINISTERED_TO,Patients
NCT00764907,Methotrexate,COEXISTS_WITH,RISK-1
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Prednisone,COEXISTS_WITH,RISK-1
NCT00764907,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00764907,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00764907,Dexamethasone,ADMINISTERED_TO,Patients
NCT00764907,Dexamethasone,ADMINISTERED_TO,Patients
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Dexamethasone,ADMINISTERED_TO,Patients
NCT00764907,Maintenance therapy,ADMINISTERED_TO,Patients
NCT00764907,Maintenance therapy,ADMINISTERED_TO,high-risk group
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Maintenance therapy,ADMINISTERED_TO,Patients
NCT00764907,Maintenance therapy,ADMINISTERED_TO,high-risk group
NCT00764907,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00764907,Radiation therapy,ADMINISTERED_TO,Patients
NCT00764907,Radiation therapy,ADMINISTERED_TO,Patients
NCT00764907,Stem cell transplant,TREATS,high-risk group
NCT00764907,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Transplantation,TREATS,Patients
NCT00764907,Maintenance therapy,ADMINISTERED_TO,Patients
NCT00764907,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00764907,Methotrexate,ADMINISTERED_TO,Patients
NCT00764907,Stem cell transplant,TREATS,high-risk group
NCT00764907,Busulfan,ADMINISTERED_TO,Patients
NCT00764907,Whole-Body Irradiation,TREATS,Patients
NCT00055718,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00055718,Silymarin,TREATS,Patients
NCT00055718,Silymarin,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00055718,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00055718,Silymarin,TREATS,Patients
NCT00055718,Silymarin,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00055718,Pharmaceutical Preparations,TREATS,Patients
NCT00055718,Pharmaceutical Preparations,TREATS,Patients
NCT00055718,Placebos,ADMINISTERED_TO,Patients
NCT00055718,Silymarin,ADMINISTERED_TO,Patients
NCT00055718,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00055718,Maintenance therapy,TREATS,Child
NCT00055718,Maintenance therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03389035,Adult,LOCATION_OF,CD19 gene
NCT00576979,Etoposide,DISRUPTS,Growth
NCT00576979,Etoposide,ISA,Pharmacotherapy
NCT00576979,Stem cell transplant,METHOD_OF,Radiation therapy
NCT00576979,Stem cell transplant,TREATS,Patients
NCT00576979,Bone Marrow,PART_OF,Patients
NCT00576979,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00576979,Adverse effects,PROCESS_OF,Patients
NCT00576979,Stem cell transplant,METHOD_OF,Radiation therapy
NCT00576979,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00576979,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00576979,Radiation therapy,USES,Cyclophosphamide
NCT00576979,Radiation therapy,USES,VP-16
NCT00576979,sibling,LOCATION_OF,Cyclophosphamide
NCT00576979,sibling,LOCATION_OF,VP-16
NCT00576979,Treatment Protocols,METHOD_OF,Hematopoietic Stem Cell Transplantation
NCT00576979,Radiation therapy,TREATS,Patients
NCT00576979,Treatment Protocols,METHOD_OF,Radiation therapy
NCT00576979,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00576979,Etoposide,ADMINISTERED_TO,Patients
NCT00576979,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00576979,Radiation therapy,USES,Etoposide
NCT00576979,Radiation therapy,USES(SPEC),VP-16
NCT00576979,Treatment Protocols,METHOD_OF,Hematopoietic Stem Cell Transplantation
NCT00576979,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00576979,Hematopoietic Stem Cell Transplantation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00576979,VP-16,ISA,Etoposide
NCT00006462,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00006462,gemcitabine,TREATS,Child
NCT00006462,gemcitabine,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00006462,gemcitabine,TREATS,"Leukemia, Myelocytic, Acute"
NCT00006462,Therapeutic procedure,TREATS,Maximum
NCT00006462,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00006462,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
NCT00006462,gemcitabine,TREATS,Child
NCT00006462,gemcitabine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00006462,gemcitabine,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00022035,Influenza,PROCESS_OF,Child
NCT00022035,Influenza virus vaccine,PREVENTS,Influenza
NCT00022035,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00022035,Vaccine Therapy,TREATS,Influenza
NCT00022035,Influenza,PROCESS_OF,Child
NCT00022035,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00022035,trivalent influenza vaccine,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00022035,Pharmacotherapy,compared_with,Therapeutic procedure
NCT00022035,trivalent influenza vaccine,ADMINISTERED_TO,Patients
NCT00022035,Vaccines,ADMINISTERED_TO,Patients
NCT00022035,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00550992,Therapeutic procedure,TREATS,Infant
NCT00550992,Bone Marrow,PART_OF,Patients
NCT00550992,Therapeutic procedure,TREATS,Infant
NCT00550992,Treatment Protocols,compared_with,Treatment Protocols
NCT00550992,Treatment Protocols,TREATS,Patients
NCT00550992,Neoadjuvant Therapy,compared_with,Treatment Protocols
NCT00550992,Methotrexate,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Prednisone,ADMINISTERED_TO,Patients
NCT00550992,Ara-C,ISA,Cytarabine
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,Methotrexate,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,CNS metastases,PROCESS_OF,Patients
NCT00550992,Methotrexate,ADMINISTERED_TO,Patients
NCT00550992,Disease,PROCESS_OF,Patients
NCT00550992,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Oral form dexamethasone,ADMINISTERED_TO,Patients
NCT00550992,Oral form dexamethasone,ISA,Dexamethasone
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Thioguanine,ADMINISTERED_TO,Patients
NCT00550992,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,VP-16,ISA,Etoposide
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Thioguanine,ADMINISTERED_TO,Patients
NCT00550992,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00550992,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00550992,prednisolone,ADMINISTERED_TO,Patients
NCT00550992,Diagnosis,METHOD_OF,Stem cell transplant
NCT00550992,Busulfan,ADMINISTERED_TO,Patients
NCT00550992,Treatment Protocols,METHOD_OF,Stem cell transplant
NCT00550992,Busulfan,ADMINISTERED_TO,Patients
NCT00550992,Cyclosporine,ADMINISTERED_TO,Patients
NCT00550992,Stem cell transplant,PRECEDES,Therapeutic procedure
NCT00550992,Stem cell transplant,PRECEDES,Prophylactic treatment
NCT00550992,Hematopoietic stem cells,PART_OF,Blood
NCT00550992,Infusion procedures,TREATS,Patients
NCT00550992,Treatment Protocols,TREATS,Infant
NCT00550992,lymphoblast,PART_OF,Infant
NCT00027547,Bone Marrow Transplantation,TREATS,Patients
NCT00027547,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00027547,Whole-Body Irradiation,TREATS,Patients
NCT00027547,Pharmacotherapy,METHOD_OF,Peripheral Stem Cell Transplantation
NCT00027547,Radiation therapy,METHOD_OF,Peripheral Stem Cell Transplantation
NCT00027547,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00027547,Peripheral Stem Cell Transplantation,METHOD_OF,Combination Drug Therapy
NCT00027547,Peripheral Stem Cell Transplantation,METHOD_OF,Whole-Body Irradiation
NCT00027547,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00027547,Peripheral Stem Cell Transplantation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00027547,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00027547,Whole-Body Irradiation,TREATS,Patients
NCT00027547,Whole-Body Irradiation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00027547,fludarabine,TREATS,Patients
NCT00027547,fludarabine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00027547,Donor Lymphocyte Infusion,TREATS,"Neoplasm, Residual"
NCT00027547,Bone Marrow Transplantation,TREATS,Child
NCT00027547,Whole-Body Irradiation,PRECEDES,Bone Marrow Transplantation
NCT00027547,Whole-Body Irradiation,PRECEDES,Peripheral Stem Cell Transplantation
NCT00027547,Peripheral Stem Cell Transplantation,TREATS,Child
NCT00027547,Whole-Body Irradiation,PRECEDES,Peripheral Stem Cell Transplantation
NCT00027547,Filgrastim,TREATS,Adult
NCT00027547,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00027547,Prophylactic treatment,ADMINISTERED_TO(SPEC),Patients
NCT00027547,Prophylactic treatment,ISA,Therapeutic procedure
NCT00027547,Prophylactic treatment,ISA,Therapeutic procedure
NCT00027547,Cytarabine,ADMINISTERED_TO,Patients
NCT00027547,Methotrexate,ADMINISTERED_TO,Patients
NCT00027547,Ara-C,ADMINISTERED_TO(SPEC),Patients
NCT00027547,Ara-C,ISA,Cytarabine
NCT00027547,Radiation,PROCESS_OF,Central Nervous System Leukemia
NCT00027547,Transplantation,PRECEDES,Treatment Protocols
NCT00027547,Radiation,PROCESS_OF,Central Nervous System Leukemia
NCT00027547,Radiation therapy,TREATS,Patients
NCT00027547,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00027547,Cell Transplantation,TREATS,Patients
NCT00027547,Cell Transplantation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02883049,Combination Drug Therapy,TREATS,Patients
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02883049,Pharmaceutical Preparations,DISRUPTS,Growth
NCT02883049,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT02883049,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
NCT02883049,Treatment Protocols,compared_with,Treatment Protocols
NCT02883049,Toxic effect,PROCESS_OF,Child
NCT02883049,Toxic effect,PROCESS_OF,Child
NCT02883049,Toxic effect,PROCESS_OF,Adolescent
NCT02883049,Toxic effect,PROCESS_OF,Young adult
NCT02883049,Down Syndrome,PROCESS_OF,Child
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02883049,Vincristine Sulfate,ISA,Vincristine
NCT02883049,Vincristine Sulfate,TREATS,Child
NCT02883049,Vincristine Sulfate,TREATS(INFER),Down Syndrome
NCT02883049,Vincristine Sulfate,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02883049,Supportive care,ISA,Vincristine
NCT02883049,Supportive care,TREATS,Child
NCT02883049,Supportive care,TREATS(INFER),Down Syndrome
NCT02883049,Supportive care,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02883049,Down Syndrome,PROCESS_OF,Child
NCT02883049,Toxic effect,PROCESS_OF,Child
NCT02883049,ASPARAGINASE,ISA,Pharmaceutical Preparations
NCT02883049,Methotrexate,ISA,Pharmaceutical Preparations
NCT02883049,Bone necrosis,PROCESS_OF,Child
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02883049,COGNITIVE DEFICIT,PROCESS_OF,Child
NCT02883049,Cytarabine,NEG_ADMINISTERED_TO,Patients
NCT02883049,Dexamethasone,compared_with,Methotrexate
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
NCT02883049,Neoadjuvant Therapy,PREVENTS,"Neoplasm, Residual"
NCT02883049,Induction,TREATS,Child
NCT02883049,Induction,TREATS,Adolescent
NCT02883049,Induction,TREATS,Young adult
NCT02883049,Induction,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02883049,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT02883049,Cytarabine,ADMINISTERED_TO,Patients
NCT02883049,Methotrexate,ADMINISTERED_TO,Patients
NCT02883049,Hydrocortisone sodium succinate,ADMINISTERED_TO,Patients
NCT02883049,Radiation therapy,TREATS,Patients
NCT02883049,Radiation therapy,TREATS(INFER),Testicular Leukemia
NCT02883049,Testicular Leukemia,PROCESS_OF,Patients
NCT02883049,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT02883049,Maintenance therapy,ADMINISTERED_TO,Patients
NCT02883049,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT02883049,Upper Extremity,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
NCT02883049,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT02883049,Maintenance therapy,ADMINISTERED_TO,Patients
NCT02883049,Upper arm,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
NCT02883049,Disease Progression,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
NCT02883049,Disease,PROCESS_OF,Patients
NCT02883049,Radiation therapy,NEG_TREATS,Patients
NCT02883049,Cytarabine,ADMINISTERED_TO,Patients
NCT02883049,Disease,PROCESS_OF,Patients
NCT02883049,Radiation therapy,NEG_TREATS,Patients
NCT02883049,Lymphoblastic Leukemia,PROCESS_OF,Patients
NCT02883049,"Leukemia, Lymphocytic, Acute",ISA,Lymphoblastic Leukemia
NCT02883049,"Leukemia, Lymphocytic, Acute",PROCESS_OF(SPEC),Patients
NCT00313053,Monoclonal Antibodies,PART_OF,Human
NCT00313053,Pharmacotherapy,METHOD_OF,Therapeutic procedure
NCT00313053,Therapeutic procedure,TREATS,Patients
NCT00313053,Pharmacotherapy,TREATS,Patients
NCT02518750,Lymphoma,PROCESS_OF,Child
NCT02518750,T-Lymphocyte,LOCATION_OF,recurrent childhood acute lymphoblastic leukemia
NCT02518750,Treatment Protocols,TREATS,Child
NCT02518750,Treatment Protocols,TREATS(INFER),Lymphoma
NCT02518750,Treatment Protocols,TREATS(INFER),T-cell lymphoma recurrent
NCT02518750,Neoadjuvant Therapy,TREATS,recurrent childhood acute lymphoblastic leukemia
NCT02518750,T-cell lymphoma recurrent,PROCESS_OF,Child
NCT02518750,Cytarabine,ISA,Pharmaceutical Preparations
NCT02518750,Dexamethasone,ISA,Pharmaceutical Preparations
NCT02518750,vincristine sulfate liposomes,ISA,Injection procedure
NCT02518750,bortezomib,ISA,Injection procedure
NCT02518750,bortezomib,USES(SPEC),vincristine sulfate liposomes
NCT02518750,vincristine liposomal,ISA,Injection procedure
NCT02518750,vincristine liposomal,USES(SPEC),vincristine sulfate liposomes
NCT02518750,Injection procedure,USES,vincristine sulfate liposomes
NCT02518750,Multiple Myeloma,PROCESS_OF,Adult
NCT02518750,leukemia,PROCESS_OF,Child
NCT02518750,Lymphoma,PROCESS_OF,Child
NCT02518750,vincristine sulfate liposomes,ISA,Injection procedure
NCT02518750,vincristine sulfate liposomes,TREATS(SPEC),Adult
NCT02518750,Injection procedure,TREATS,Adult
NCT02518750,Malignant Neoplasms,PROCESS_OF,Adult
NCT02518750,"Leukemia, T-Cell",PROCESS_OF,Patients
NCT02518750,lymphoblast,LOCATION_OF,"Leukemia, T-Cell"
NCT02518750,vincristine sulfate liposomes,ISA,Injection procedure
NCT02518750,bortezomib,TREATS,Adult
NCT02518750,bortezomib,TREATS(INFER),Malignant Neoplasms
NCT02518750,Injection procedure,USES,vincristine sulfate liposomes
NCT02518750,Therapeutic procedure,METHOD_OF,Hemopoietic stem cell transplant
NCT02518750,Vincristine,ISA,Injection procedure
NCT02518750,Vincristine,USES(SPEC),vincristine sulfate liposomes
NCT02518750,Peripheral,LOCATION_OF,Blast Cell
NCT02518750,vincristine sulfate liposomes,ISA,Injection procedure
NCT02518750,Injection procedure,USES,vincristine sulfate liposomes
NCT02518750,Lymphoblastic Leukemia,PROCESS_OF,Patients
NCT02518750,Lymphoma,PROCESS_OF,Patients
NCT02518750,Nelarabine,TREATS,Patients
NCT02518750,Nelarabine,TREATS(INFER),Lymphoblastic Leukemia
NCT02518750,Nelarabine,TREATS(INFER),Lymphoma
NCT02518750,"Hospitals, Pediatric",LOCATION_OF,Clinical Trials
NCT02518750,T-Lymphocyte,LOCATION_OF,recurrent childhood acute lymphoblastic leukemia
NCT02518750,Neoadjuvant Therapy,TREATS,Lymphoma
NCT02518750,Neoadjuvant Therapy,TREATS,recurrent childhood acute lymphoblastic leukemia
NCT01077544,Drug Kinetics,PROCESS_OF,Patients
NCT01077544,Philadelphia chromosome positive,PROCESS_OF,Patients
NCT01077544,Pharmacokinetic study,DIAGNOSES,"Leukemia, Myeloid, Chronic-Phase"
NCT01683279,leukemia,PROCESS_OF,Patients
NCT01683279,T-Lymphocyte,PRODUCES,"Receptors, Antigen"
NCT01683279,Proteins,INTERACTS_WITH,CD19 gene
NCT01683279,Surface,LOCATION_OF,Leukemic Cell
NCT01683279,Leukemic Cell,PART_OF,Patients
NCT01683279,Blood,PRODUCES,RFP2 gene
NCT01683279,Therapeutic procedure,TREATS,Oncologist
NCT01683279,Marrow aspirate,PART_OF,T-Lymphocyte
NCT01683279,Pharmacotherapy,ADMINISTERED_TO,Oncologist
NCT01683279,Stem cell transplant,ADMINISTERED_TO,Oncologist
NCT01683279,Immunotherapy,TREATS,recurrent childhood acute lymphoblastic leukemia
NCT01231919,Vitelliform dystrophy,PROCESS_OF,Patients
NCT01231919,Adverse effects,PROCESS_OF,Patients
NCT01231919,Malignant Neoplasms,PROCESS_OF,Child
NCT01231919,Toxic effect,PROCESS_OF,Child
NCT01231919,Drug Kinetics,PROCESS_OF,Child
NCT01231919,Signal Transduction,COEXISTS_WITH,Neoplasm
NCT00217412,Isotretinoin,ADMINISTERED_TO,Patients
NCT00217412,Isotretinoin,NEG_TREATS,Patients
NCT00217412,Isotretinoin,TREATS,Patients
NCT00217412,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00217412,Isotretinoin,ISA,Therapeutic procedure
NCT00217412,Isotretinoin,TREATS,Malignant Neoplasms
NCT00217412,Isotretinoin,TREATS,Patients
NCT00217412,Neuroblastoma,ISA,"Neuroectodermal Tumor, Primitive"
NCT00217412,Lymphoma,PROCESS_OF,Patients
NCT00217412,Toxic effect,PROCESS_OF,Patients
NCT00217412,leukemia,PROCESS_OF,Patients
NCT00217412,Isotretinoin,ADMINISTERED_TO,Patients
NCT00217412,Solid tumor,PROCESS_OF,Patients
NCT00217412,Isotretinoin,TREATS,Patients
NCT00217412,Isotretinoin,TREATS(INFER),Solid tumor
NCT00217412,Solid tumor,PROCESS_OF,Patients
NCT00093821,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00093821,Adverse effects,PROCESS_OF,Patients
NCT00093821,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00093821,leukemia,PROCESS_OF,Patients
NCT00093821,Toxic effect,PROCESS_OF,Patients
NCT00093821,Cell Survival,PROCESS_OF,Patients
NCT00093821,Pharmaceutical Preparations,TREATS,Patients
NCT00093821,Drug Kinetics,PROCESS_OF,Patients
NCT00093821,leukemia,PROCESS_OF,Patients
NCT00093821,Solid tumor,PROCESS_OF,Patients
NCT00093821,Toxic effect,PROCESS_OF,Patients
NCT00093821,Neuroblastoma,ISA,childhood solid tumor
NCT00093821,Neuroblastoma,PROCESS_OF(SPEC),Patients
NCT00093821,osteosarcoma,ISA,childhood solid tumor
NCT00093821,osteosarcoma,PROCESS_OF(SPEC),Patients
NCT00093821,childhood solid tumor,PROCESS_OF,Patients
NCT00093821,Desmoplastic small round cell tumor,ISA,childhood solid tumor
NCT00093821,Desmoplastic small round cell tumor,PROCESS_OF(SPEC),Patients
NCT00093821,Ewings sarcoma,ISA,childhood solid tumor
NCT00093821,Ewings sarcoma,PROCESS_OF(SPEC),Patients
NCT00093821,17-(allylamino)-17-demethoxygeldanamycin,TREATS,Patients
NCT00093821,17-(allylamino)-17-demethoxygeldanamycin,TREATS(INFER),childhood solid tumor
NCT00053963,Vitelliform dystrophy,PROCESS_OF,Child
NCT00053963,Adverse effects,PROCESS_OF,Child
NCT00053963,depsipeptide,TREATS,Child
NCT00053963,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00053963,depsipeptide,ISA,Depsipeptides
NCT00053963,depsipeptide,TREATS,Patients
NCT00053963,Toxic effect,PROCESS_OF,Patients
NCT00053963,Drug Kinetics,PROCESS_OF,Patients
NCT00053963,Pharmaceutical Preparations,TREATS,Patients
NCT00053963,depsipeptide,ISA,Depsipeptides
NCT00053963,depsipeptide,ADMINISTERED_TO,Patients
NCT00053963,Solid tumor,PROCESS_OF,Patients
NCT00053963,depsipeptide,ADMINISTERED_TO,Patients
NCT00053963,Toxic effect,PROCESS_OF,Patients
NCT00053963,leukemia,PROCESS_OF,Patients
NCT00053963,depsipeptide,ADMINISTERED_TO,cohort
NCT00053963,leukemia,PROCESS_OF,Patients
NCT00053963,Solid tumor,PROCESS_OF,Patients
NCT00053963,Depsipeptides,TREATS,Patients
NCT00053963,Depsipeptides,TREATS(INFER),leukemia
NCT00053963,Depsipeptides,TREATS(INFER),Solid tumor
NCT00941928,Antibodies,PART_OF,Natural Killer Cells
NCT00941928,Interleukin-2,ISA,Interleukins
NCT00941928,hLL2 agent,PART_OF,Natural Killer Cells
NCT00941928,Infusion procedures,TREATS,Disease
NCT00941928,Cyclophosphamide,DISRUPTS,Growth
NCT00941928,Genetic Materials,PART_OF,Cells
NCT00941928,Surface,LOCATION_OF,[M]Unspecified tumor cell NOS
NCT00941928,Blood,LOCATION_OF,immunoglobulin receptor
NCT00941928,Pharmaceutical Preparations,TREATS,Research Personnel
NCT00941928,Interleukin-2,ISA,Injection procedure
NCT00941928,Infusion procedures,PRECEDES,Injection procedure
NCT00941928,Infusion procedures,PRECEDES(SPEC),Interleukin-2
NCT00941928,Injection procedure,USES,Interleukin-2
NCT00941928,Bone marrow biopsy,USES,Anesthetics
NCT00941928,Blood,LOCATION_OF,Oxygen
NCT00941928,Systemic arterial pressure,ISA,Vital signs
NCT00941928,Pregnancy test negative,PROCESS_OF,Child
NCT00941928,Acquired Immunodeficiency Syndrome,ISA,Infection
NCT00941928,human leukocyte antigen gene,TREATS,Infection
NCT00941928,human leukocyte antigen gene,TREATS(SPEC),Acquired Immunodeficiency Syndrome
NCT00941928,Infusion procedures,TREATS,Patients
NCT00941928,Pharmacotherapy,USES,Cyclophosphamide
NCT00941928,Pharmacotherapy,USES,fludarabine
NCT00941928,Cyclophosphamide,CAUSES,Adverse effects
NCT00941928,Infusion procedures,PREVENTS,Allergic Reaction
NCT00941928,Tylenol,ISA,Acetaminophen
NCT00941928,Benadryl,ISA,Diphenhydramine
NCT00941928,Steroids,ADMINISTERED_TO,Physicians
NCT00941928,Interleukin-2,ADMINISTERED_TO(SPEC),Caregiver
NCT00941928,Interleukin-2,ISA,Injection procedure
NCT00941928,Injection procedure,ADMINISTERED_TO,Caregiver
NCT00941928,Injection procedure,USES,Interleukin-2
NCT00941928,Cyclophosphamide,TREATS,leukemia
NCT00941928,leukemia,PROCESS_OF,Adult
NCT00941928,fludarabine,TREATS,leukemia
NCT00941928,Interleukin-2,ISA,Therapeutic procedure
NCT00941928,Interleukin-2,NEG_TREATS,leukemia
NCT00941928,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Donor person
NCT00941928,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00941928,hLL2 agent,PART_OF,Natural Killer Cells
NCT00941928,hLL2 agent,TREATS,Donor person
NCT00941928,hLL2 agent,TREATS,Patients
NCT00941928,hLL2 agent,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00941928,Adoptive Transfer,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00941928,hLL2 agent,PART_OF,Natural Killer Cells
NCT01251575,Cyclosporine,ASSOCIATED_WITH,Graft-vs-Host Disease
NCT01251575,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT01251575,Hematopoietic Neoplasms,PROCESS_OF,Patients
NCT01251575,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01251575,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01251575,Bone Marrow,PART_OF,Patients
NCT01251575,Immunosuppressive Agents,COEXISTS_WITH,mycophenolate mofetil
NCT01251575,Whole-Body Irradiation,TREATS,Patients
NCT01251575,Cyclosporine,PREVENTS,Graft-vs-Host Disease
NCT01251575,mycophenolate mofetil,PREVENTS,Graft-vs-Host Disease
NCT00430118,Combination Drug Therapy,TREATS,Patients
NCT00430118,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00430118,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00430118,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00430118,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00430118,Chemotherapy-Oncologic Procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00430118,Dexamethasone,DISRUPTS,"Leukemia, Lymphocytic, Acute"
NCT00430118,Prednisone,DISRUPTS,"Leukemia, Lymphocytic, Acute"
NCT00430118,Anthracycline Antibiotics,TREATS,Patients
NCT00430118,Anthracycline Antibiotics,compared_with,Treatment Protocols
NCT00430118,Cyclophosphamide,compared_with,Anthracycline Antibiotics
NCT00430118,Treatment Protocols,TREATS,Patients
NCT00430118,Treatment Protocols,compared_with,Therapeutic procedure
NCT00430118,Treatment Protocols,TREATS,Patients
NCT00430118,Therapeutic procedure,TREATS,Patients
NCT00430118,Therapeutic procedure,TREATS,Patients
NCT00430118,Therapeutic procedure,compared_with,Therapeutic procedure
NCT00430118,Prednisone,ADMINISTERED_TO,Patients
NCT00430118,Dexamethasone,ADMINISTERED_TO,Patients
NCT00430118,Prednisone,ADMINISTERED_TO,Patients
NCT00430118,CNS disorder,PROCESS_OF,Patients
NCT00430118,Methotrexate,ADMINISTERED_TO,Patients
NCT00430118,Vincristine,ADMINISTERED_TO,Patients
NCT00430118,Daunorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00430118,Ara-C,ISA,Cytarabine
NCT00430118,Disease,PROCESS_OF,Patients
NCT00430118,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00430118,Methotrexate,ADMINISTERED_TO,Patients
NCT00430118,CNS disorder,PROCESS_OF,Patients
NCT00430118,Dexamethasone,ADMINISTERED_TO,Patients
NCT00430118,Methotrexate,ADMINISTERED_TO,Patients
NCT00430118,DNA Sequence,ADMINISTERED_TO,Patients
NCT00430118,Dexamethasone,ADMINISTERED_TO,Patients
NCT00430118,CNS disorder,PROCESS_OF,Patients
NCT00430118,Dexamethasone,ADMINISTERED_TO,Patients
NCT00430118,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00430118,Dexamethasone,ADMINISTERED_TO,Patients
NCT00430118,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00430118,Methotrexate,ADMINISTERED_TO,Patients
NCT00430118,CNS disorder,PROCESS_OF,Patients
NCT00430118,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT00430118,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00430118,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT00343369,Combination Drug Therapy,TREATS,Patients
NCT00343369,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00343369,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00343369,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00343369,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00343369,Chemotherapy-Oncologic Procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00343369,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00343369,Doxorubicin Hydrochloride,TREATS,Patients
NCT00343369,Doxorubicin Hydrochloride,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00343369,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00343369,Therapeutic procedure,TREATS,Patients
NCT00343369,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00343369,asparaginase/prednisone/vincristine protocol,TREATS,Patients
NCT00343369,asparaginase/prednisone/vincristine protocol,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00343369,Methotrexate,PREVENTS,Allergic Reaction
NCT00343369,Single Nucleotide Polymorphism,DISRUPTS,NEUROLOGIC COMPLICATION
NCT00343369,"Complication, infection",PROCESS_OF,Patients
NCT00343369,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00343369,Methotrexate,ADMINISTERED_TO,Patients
NCT00343369,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT00343369,Cranial Irradiation,TREATS,Patients
NCT00343369,Cranial Irradiation,TREATS(INFER),Acute T Cell Leukemia
NCT00343369,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00343369,Methotrexate,ADMINISTERED_TO,Patients
NCT00343369,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00096135,Combination Drug Therapy,TREATS,Patients
NCT00096135,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00096135,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00096135,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00096135,Radiation therapy,TREATS,Patients
NCT00096135,Radiation therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00096135,Roentgen Rays,ISA,"Energy, Physics"
NCT00096135,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00096135,Radiation therapy,TREATS,Patients
NCT00096135,Radiation therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00096135,Neuraxis,LOCATION_OF,Pharmacotherapy
NCT00096135,Pharmacotherapy,TREATS,Patients
NCT00096135,Pharmacotherapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00096135,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00096135,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00096135,Radiation therapy,NEG_TREATS,Patients
NCT00096135,Radiation therapy,NEG_TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00096135,Treatment Protocols,TREATS,Patients
NCT00096135,Treatment Protocols,TREATS(INFER),Bone Marrow Involvement
NCT00096135,Bone Marrow Involvement,PROCESS_OF,Patients
NCT00096135,Treatment Protocols,TREATS,Patients
NCT00096135,Treatment Protocols,TREATS(INFER),"Neoplasm, Residual"
NCT00096135,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00096135,Toxic effect,PROCESS_OF,Patients
NCT00096135,Induction,ADMINISTERED_TO,Patients
NCT00096135,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00096135,Physical findings,PROCESS_OF,Patients
NCT00096135,Biopsy of testis,ADMINISTERED_TO,Patients
NCT00096135,CNS disorder,PROCESS_OF,Patients
NCT00096135,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00096135,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00096135,Filgrastim,ADMINISTERED_TO,Patients
NCT00096135,Radiation therapy,TREATS,Patients
NCT00096135,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00096135,Methotrexate,ADMINISTERED_TO,Patients
NCT00096135,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00096135,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00096135,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00096135,pegaspargase,ADMINISTERED_TO,Patients
NCT00096135,Oral form dexamethasone,ADMINISTERED_TO,Patients
NCT00096135,Radiation therapy,TREATS,Patients
NCT00096135,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00096135,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00096135,Dexamethasone,ADMINISTERED_TO,Patients
NCT00096135,Methotrexate,ADMINISTERED_TO,Patients
NCT00096135,Vincristine,ADMINISTERED_TO,Patients
NCT00096135,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00096135,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00096135,Neuropsychological Tests,ADMINISTERED_TO,Patients
NCT00096135,Induction,ADMINISTERED_TO,Patients
NCT02116777,Neoplasm,PROCESS_OF,Patients
NCT02116777,temozolomide,TREATS,Patients
NCT02116777,Vitelliform dystrophy,PROCESS_OF,Patients
NCT02116777,Adverse effects,PROCESS_OF,Patients
NCT02116777,Pharmaceutical Preparations,DISRUPTS,Cells
NCT02116777,temozolomide,DISRUPTS,Growth
NCT02116777,temozolomide,ISA,Pharmacotherapy
NCT02116777,temozolomide,TREATS,Patients
NCT02116777,temozolomide,TREATS,"Leukemia, Lymphocytic, Acute"
NCT02116777,temozolomide,TREATS,Ewing's sarcoma recurrent
NCT02116777,temozolomide,TREATS,Patients
NCT02116777,Ewings sarcoma,PROCESS_OF,Patients
NCT02116777,temozolomide,TREATS,Child
NCT00005945,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00005945,Chemotherapy-Oncologic Procedure,TREATS,Child
NCT00005945,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00005945,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00005945,Chemotherapy-Oncologic Procedure,TREATS,Child
NCT00005945,Chemotherapy-Oncologic Procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00005945,Leucovorin Calcium,compared_with,Methotrexate
NCT00005945,Toxic effect,PROCESS_OF,Patients
NCT00005945,Therapeutic procedure,TREATS,Patients
NCT00005945,Peripheral,LOCATION_OF,lymphoblast
NCT00005945,"Chromosomes, Human, Pair 4",LOCATION_OF,Trisomy
NCT00005945,Treatment Protocols,TREATS,Patients
NCT00005945,Treatment Protocols,TREATS,Patients
NCT00005945,Bone Marrow,LOCATION_OF,"Neoplasm, Residual"
NCT00005945,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00005945,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00005945,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00005945,Bone Marrow,LOCATION_OF,CNS disorder
NCT00005945,Bone Marrow,PART_OF,Patients
NCT00005945,CNS disorder,PROCESS_OF,Patients
NCT00005945,Cranial Irradiation,TREATS,Patients
NCT00005945,Cranial Irradiation,TREATS(INFER),CNS disorder
NCT00005945,Chromosomal translocation,AFFECTS,Patients
NCT00005945,Ara-C,ISA,Cytarabine
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,CNS disorder,PROCESS_OF,Patients
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,Bone Marrow,PART_OF,Patients
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,CNS disorder,PROCESS_OF,Patients
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,Cranial Irradiation,ADMINISTERED_TO,Patients
NCT00005945,Disease,PROCESS_OF,Patients
NCT00005945,T-Lymphocyte,LOCATION_OF,Disease
NCT00005945,Testicular Diseases,PROCESS_OF,Patients
NCT00005945,Induction,NEG_ADMINISTERED_TO,Patients
NCT00005945,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00005945,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,Upper Extremity,LOCATION_OF,[V]Maintenance chemotherapy
NCT00005945,Upper Extremity,LOCATION_OF,[V]Maintenance chemotherapy
NCT00005945,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00005945,Upper Extremity,LOCATION_OF,[V]Maintenance chemotherapy
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,CNS disorder,PROCESS_OF,Patients
NCT00005945,Disease,PROCESS_OF,Patients
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,T-Lymphocyte,LOCATION_OF,Disease
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,CNS disorder,PROCESS_OF,Patients
NCT00005945,Methotrexate,ADMINISTERED_TO,Patients
NCT00005945,Cranial Irradiation,ADMINISTERED_TO,Patients
NCT00005945,Radiation therapy,ADMINISTERED_TO,Patients
NCT00005945,Testicular Leukemia,PROCESS_OF,Patients
NCT00005945,Disease,PROCESS_OF,Patients
NCT00005945,Pharmacotherapy,USES,Methotrexate
NCT00005945,T-Lymphocyte,LOCATION_OF,Disease
NCT00005945,Disease,PROCESS_OF,Patients
NCT00005945,T-Lymphocyte,LOCATION_OF,Disease
NCT00005945,Disease,PROCESS_OF,Patients
NCT00005945,T-Lymphocyte,LOCATION_OF,Disease
NCT00005945,Treatment Protocols,NEG_USES,Methotrexate
NCT00005945,[V]Maintenance chemotherapy,PROCESS_OF,Patients
NCT00005945,[V]Maintenance chemotherapy,PROCESS_OF,Patients
NCT00005945,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00005945,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00005945,Methotrexate,TREATS,Child
NCT00005945,Methotrexate,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00005945,Leukovorin rescue,TREATS,Child
NCT00005945,Leukovorin rescue,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00005945,Leukovorin rescue,compared_with,Methotrexate
NCT01154816,Adverse effects,PROCESS_OF,Patients
NCT01154816,Drug Kinetics,PROCESS_OF,Child
NCT01154816,Immunohistochemistry,DIAGNOSES,Solid tumor
NCT01154816,Neuroblastoma,ISA,Neoplasm
NCT01154816,Rhabdomyosarcoma,ISA,sarcoma
NCT01154816,Rhabdomyosarcoma,ISA,sarcoma
NCT01154816,leukemia,PROCESS_OF,Child
NCT01154816,Solid tumor,PROCESS_OF,Child
NCT01154816,kinase inhibitor,TREATS,Child
NCT01154816,kinase inhibitor,TREATS(INFER),leukemia
NCT01154816,kinase inhibitor,TREATS(INFER),Solid tumor
NCT03241940,Pharmacotherapy,ADMINISTERED_TO,Child
NCT03241940,Pharmacotherapy,ADMINISTERED_TO,Young adult
NCT03241940,Pharmacotherapy,TREATS,Child
NCT03241940,Pharmacotherapy,TREATS,Young adult
NCT03241940,Cyclophosphamide,DISRUPTS,Growth
NCT03241940,Pharmaceutical Preparations,DISRUPTS,Cells
NCT03241940,Fludarabine phosphate,DISRUPTS,Growth
NCT03241940,Pharmacotherapy,TREATS,Child
NCT03241940,Pharmacotherapy,TREATS,Young adult
NCT03241940,Pharmacotherapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03241940,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03241940,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
NCT03241940,Child,LOCATION_OF,CD19 Antigens
NCT03241940,Fludarabine phosphate,ISA,fludarabine
NCT03241940,Young adult,LOCATION_OF,CD19 Antigens
NCT03241940,Hematologic Neoplasms,PROCESS_OF,Child
NCT03241940,Hematologic Neoplasms,PROCESS_OF,Young adult
NCT03241940,Clinic Activities,TREATS,Child
NCT03241940,Clinic Activities,TREATS,Young adult
NCT03241940,Blood,LOCATION_OF,CD19 Antigens
NCT03241940,Bone Marrow,LOCATION_OF,CD19 Antigens
NCT03241940,Cerebrospinal Fluid,LOCATION_OF,CD19 Antigens
NCT03241940,Clinic Activities,TREATS,Child
NCT03241940,Clinic Activities,TREATS,Young adult
NCT03241940,B-cell lymphoma refractory,PROCESS_OF,Child
NCT03241940,B-cell lymphoma refractory,PROCESS_OF,Young adult
NCT03241940,B-cell lymphoma refractory,PROCESS_OF,cohort
NCT03241940,Adverse effects,PROCESS_OF,Patients
NCT03241940,B-Lymphocytes,LOCATION_OF,Malignant Neoplasms
NCT03241940,Child,LOCATION_OF,CD19 Antigens
NCT03241940,Young adult,LOCATION_OF,CD19 Antigens
NCT03007147,Combination Drug Therapy,TREATS,Patients
NCT03007147,Imatinib mesylate,TREATS,Patients
NCT03007147,Imatinib mesylate,DISRUPTS,Growth
NCT03007147,Pharmaceutical Preparations,DISRUPTS,Growth
NCT03007147,Combination Drug Therapy,TREATS,Patients
NCT03007147,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute, L2"
NCT03007147,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
NCT03007147,Imatinib mesylate,TREATS,Patients
NCT03007147,Imatinib mesylate,TREATS(INFER),"Leukemia, Lymphocytic, Acute, L2"
NCT03007147,Imatinib mesylate,ISA,imatinib
NCT03007147,Imatinib mesylate,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03007147,Pharmacotherapy,TREATS,Patients
NCT03007147,Pharmacotherapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute, L1"
NCT03007147,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
NCT03007147,Infection,PROCESS_OF,Patients
NCT03007147,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT03007147,Toxic effect,PROCESS_OF,Patients
NCT03007147,imatinib,TREATS,Patients
NCT03007147,imatinib,TREATS(INFER),Toxic effect
NCT03007147,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
NCT03007147,"Neoplasm, Residual",PROCESS_OF,Patients
NCT03007147,"Neoplasm, Residual",PROCESS_OF,Patients
NCT03007147,6-Mercaptopurine,ISA,Antineoplastic Agents
NCT03007147,Methotrexate,ISA,Antineoplastic Agents
NCT03007147,imatinib,ISA,Antineoplastic Agents
NCT03007147,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT03007147,Methylprednisolone,ADMINISTERED_TO,Patients
NCT03007147,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT03007147,Hematopoietic Stem Cell Transplantation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03007147,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT03007147,Cytarabine,ADMINISTERED_TO,Patients
NCT03007147,Dexamethasone,ADMINISTERED_TO,Patients
NCT03007147,Hydrocortisone,ADMINISTERED_TO,Patients
NCT03007147,Methotrexate,ADMINISTERED_TO,Patients
NCT03007147,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT03007147,pegaspargase,ADMINISTERED_TO,Patients
NCT03007147,Filgrastim,ADMINISTERED_TO,Patients
NCT03007147,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT03007147,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT03007147,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT03007147,Upper Extremity,LOCATION_OF,pegaspargase
NCT02728700,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT02728700,mycophenolate mofetil,TREATS,Patients
NCT02728700,mycophenolate mofetil,TREATS(INFER),Hematologic Neoplasms
NCT02728700,Hematologic Neoplasms,PROCESS_OF,Patients
NCT02728700,Hemopoietic stem cell transplant,TREATS,Hematologic Neoplasms
NCT02728700,Adverse effects,COEXISTS_WITH,Graft-vs-Host Disease
NCT02728700,Organism,LOCATION_OF,mycophenolate mofetil
NCT02728700,Hemopoietic stem cell transplant,TREATS,Graft-vs-Host Disease
NCT02728700,Prophylactic treatment,COEXISTS_WITH,Hospitalization
NCT02728700,Hemopoietic stem cell transplant,COEXISTS_WITH,Hospitalization
NCT02728700,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT02728700,Hemopoietic stem cell transplant,TREATS,Patients
NCT02728700,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT02728700,Prophylactic treatment,TREATS,Hematologic Neoplasms
NCT02728700,Prophylactic treatment,USES,MYCOPHENOLATE
NCT02728700,Hematopoietic Stem Cell Transplantation,TREATS,Hematologic Neoplasms
NCT02728700,Hematopoietic Stem Cell Transplantation,USES,MYCOPHENOLATE
NCT00792948,Combination Drug Therapy,ADMINISTERED_TO,Patients
NCT00792948,Combination Drug Therapy,NEG_TREATS,Patients
NCT00792948,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00792948,Stem cell transplant,NEG_TREATS,Patients
NCT00792948,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00792948,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00792948,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00792948,Chemotherapy-Oncologic Procedure,ADMINISTERED_TO,Patients
NCT00792948,Chemotherapy-Oncologic Procedure,ADMINISTERED_TO,Patients
NCT00792948,Polymerase Chain Reaction,METHOD_OF,Ablation
NCT00792948,Treatment Protocols,TREATS,Patients
NCT00792948,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00792948,Blood Platelets,PART_OF,Patients
NCT00792948,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00792948,Methotrexate,ADMINISTERED_TO,Patients
NCT00792948,Patients,LOCATION_OF,Etoposide
NCT00792948,Treatment Protocols,METHOD_OF,Regimen B
NCT00792948,Tacrolimus,ADMINISTERED_TO,Patients
NCT00792948,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00792948,Stem cell transplant,NEG_TREATS,Patients
NCT00792948,Stem cell transplant,TREATS,Patients
NCT00792948,Consolidation Therapy,NEG_PRECEDES,Transplantation
NCT00792948,Philadelphia chromosome positive,PROCESS_OF,Patients
NCT00792948,Stem cell transplant,NEG_TREATS,Patients
NCT00792948,Stem cell transplant,NEG_TREATS(INFER),Philadelphia chromosome positive
NCT03132948,Physical activity,TREATS,Child
NCT03132948,Physical activity,TREATS(INFER),[V]Maintenance chemotherapy
NCT03132948,[V]Maintenance chemotherapy,PROCESS_OF,Child
NCT03132948,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT03132948,Exercise,PREVENTS,Stress
NCT03132948,Malignant Neoplasms,PROCESS_OF,Child
NCT03132948,Malignant Neoplasms,PROCESS_OF,Child
NCT03132948,Exercise,TREATS,Child
NCT03132948,Exercise,TREATS,Adult
NCT03132948,Physical activity,TREATS,Patients
NCT03132948,Physical activity,TREATS(INFER),[V]Maintenance chemotherapy
NCT03132948,[V]Maintenance chemotherapy,PROCESS_OF,Patients
NCT02112916,Combination Drug Therapy,NEG_TREATS,Patients
NCT02112916,Combination Drug Therapy,NEG_TREATS(INFER),Acute T Cell Leukemia
NCT02112916,Combination Drug Therapy,NEG_TREATS(INFER),T-cell lymphoma stage II
NCT02112916,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT02112916,lymphoblast,LOCATION_OF,T-cell lymphoma stage II
NCT02112916,T-cell lymphoma stage II,PROCESS_OF,Patients
NCT02112916,bortezomib,NEG_TREATS,Patients
NCT02112916,bortezomib,NEG_TREATS(INFER),Acute T Cell Leukemia
NCT02112916,bortezomib,NEG_TREATS(INFER),T-cell lymphoma stage II
NCT02112916,Pharmacotherapy,TREATS,Acute T Cell Leukemia
NCT02112916,Pharmacotherapy,TREATS,T-Cell Lymphoma
NCT02112916,lymphoblast,LOCATION_OF,T-Cell Lymphoma
NCT02112916,bortezomib,TREATS,Acute T Cell Leukemia
NCT02112916,bortezomib,TREATS,T-Cell Lymphoma
NCT02112916,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT02112916,T-Cell Lymphoma,PROCESS_OF,Patients
NCT02112916,lymphoblast,LOCATION_OF,T-Cell Lymphoma
NCT02112916,Dexamethasone,TREATS,Acute T Cell Leukemia
NCT02112916,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT02112916,Pharmacotherapy,METHOD_OF,Therapeutic procedure
NCT02112916,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT02112916,"Neoplasm, Residual",PROCESS_OF,Patients
NCT02112916,partial response,PROCESS_OF,Patients
NCT02112916,"Neoplasm, Residual",PART_OF,Bone Marrow
NCT02112916,Cytarabine,ADMINISTERED_TO,Patients
NCT02112916,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT02112916,Methotrexate,ADMINISTERED_TO,Patients
NCT02112916,Upper Extremity,LOCATION_OF,Methotrexate
NCT02112916,Upper Extremity,LOCATION_OF,BID gene
NCT02112916,Radiation therapy,TREATS,Patients
NCT02112916,Radiation therapy,TREATS(INFER),Testicular Diseases
NCT02112916,Testicular Diseases,PROCESS_OF,Patients
NCT02112916,Disease,PROCESS_OF,Patients
NCT02112916,Upper Extremity,LOCATION_OF,Cyclophosphamide
NCT02112916,Upper Extremity,LOCATION_OF,Cytarabine
NCT02112916,Upper Extremity,LOCATION_OF,Dexamethasone
NCT02112916,Upper Extremity,LOCATION_OF,Methotrexate
NCT02112916,Upper Extremity,LOCATION_OF,Thioguanine
NCT02112916,Upper Extremity,LOCATION_OF,Vincristine Sulfate
NCT02112916,Upper Extremity,LOCATION_OF,pegaspargase
NCT02112916,Upper Extremity,LOCATION_OF,Doxorubicin Hydrochloride
NCT02112916,Dexamethasone,ADMINISTERED_TO,Patients
NCT02112916,Therapeutic procedure,TREATS,Obstruction
NCT02112916,Therapeutic procedure,TREATS,Obstruction
NCT02112916,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT02112916,Disease,PROCESS_OF,Patients
NCT02112916,Radiation therapy,TREATS,Patients
NCT02112916,Radiation therapy,TREATS(INFER),Disease
NCT02112916,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT02112916,Therapeutic procedure,TREATS,Patients
NCT02112916,Therapeutic procedure,TREATS(INFER),Acute T Cell Leukemia
NCT02112916,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT02112916,Therapeutic procedure,TREATS,Patients
NCT02112916,Therapeutic procedure,TREATS(INFER),Acute T Cell Leukemia
NCT02112916,Acute T Cell Leukemia,ISA,Lymphoblastic Leukemia
NCT02112916,bortezomib,TREATS,Lymphoblastic Leukemia
NCT02112916,bortezomib,TREATS(SPEC),Acute T Cell Leukemia
NCT02094794,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02094794,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT02094794,Lymphatic Irradiation,USES,Cyclophosphamide
NCT02094794,Lymphatic Irradiation,USES,Pharmaceutical Preparations
NCT02094794,Lymphatic Irradiation,USES,Etoposide
NCT02094794,Lymphocyte,PART_OF,Patients
NCT02094794,Stem cell transplant,TREATS,Patients
NCT02094794,Stem cell transplant,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT02094794,Stem cell transplant,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT02094794,VP-16,ISA,Etoposide
NCT02094794,Lymphatic Irradiation,TREATS,adiposity
NCT02094794,Magnetic Resonance Imaging,ISA,tomography
NCT02094794,Medical Imaging,ADMINISTERED_TO,Patients
NCT02094794,Lymphatic Irradiation,USES,Cyclophosphamide
NCT02094794,Lymphatic Irradiation,USES,Etoposide
NCT02094794,Lymphocyte,PART_OF,Patients
NCT02094794,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT02094794,Hematopoietic Stem Cell Transplantation,USES,Cyclophosphamide
NCT02094794,Hematopoietic Stem Cell Transplantation,USES,Etoposide
NCT01839916,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01839916,Stem cell transplant,TREATS,Patients
NCT01839916,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT01839916,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT01839916,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT01839916,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01839916,Stem cell transplant,TREATS,Patients
NCT01839916,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT01527045,Therapeutic procedure,USES,atorvastatin
NCT01527045,atorvastatin,ISA,Therapeutic procedure
NCT01527045,atorvastatin,TREATS,Acute graft-versus-host disease
NCT01527045,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01527045,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01527045,Fludarabine phosphate,DISRUPTS,Growth
NCT01527045,Fludarabine phosphate,ISA,Pharmacotherapy
NCT01527045,atorvastatin,PREVENTS,Graft-vs-Host Disease
NCT01527045,Therapeutic procedure,USES,STN gene
NCT01527045,Treatment Protocols,ADMINISTERED_TO,Patients
NCT01527045,Treatment Protocols,USES,Cyclosporine
NCT01527045,Therapeutic procedure,USES,STN gene
NCT01527045,atorvastatin,TREATS,Donor person
NCT01527045,Whole-Body Irradiation,TREATS,Transplanted organ and tissue status
NCT01527045,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT01527045,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT01527045,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01527045,Therapeutic procedure,PREVENTS,Acute graft-versus-host disease
NCT01527045,Therapeutic procedure,USES,STN gene
NCT01371656,Levofloxacin,TREATS,Patients
NCT01371656,Antibiotics,TREATS,Patients
NCT01371656,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT01371656,Pharmacotherapy,TREATS,Acute leukemia
NCT01371656,Stem cell transplant,ADMINISTERED_TO,Patients
NCT01371656,Stem cell transplant,TREATS,Acute leukemia
NCT01371656,Pharmacotherapy,TREATS,Patients
NCT01371656,Pharmacotherapy,TREATS,Acute leukemia
NCT01371656,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT01371656,Hematopoietic Stem Cell Transplantation,TREATS,Acute leukemia
NCT01371656,Levofloxacin,AFFECTS,Infection due to resistant organism
NCT01371656,Therapeutic procedure,TREATS,Child
NCT01371656,Therapeutic procedure,TREATS,Acute leukemia
NCT01371656,Prophylactic treatment,TREATS,Child
NCT01371656,Prophylactic treatment,USES,Levofloxacin
NCT01371656,Prophylactic treatment,USES,Levofloxacin
NCT01371656,Prophylactic treatment,USES,Levofloxacin
NCT01371656,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT01371656,Levofloxacin,ADMINISTERED_TO,Patients
NCT01371656,Upper Extremity,LOCATION_OF,"Diarrhoea, Clostridium difficile"
NCT01371656,Bacteremia,PROCESS_OF,Child
NCT01371656,Hematopoietic Stem Cell Transplantation,PREVENTS,Bacteremia
NCT01371656,Levofloxacin,PREVENTS,Bacteremia
NCT01190930,Pharmacotherapy,TREATS,Patients
NCT01190930,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01190930,Adverse effects,PROCESS_OF,Patients
NCT01190930,Pharmaceutical Preparations,DISRUPTS,Growth
NCT01190930,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT01190930,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT01190930,Treatment Protocols,USES,Vincristine
NCT01190930,Treatment Protocols,USES(SPEC),Vincristine Sulfate
NCT01190930,Vincristine Sulfate,ISA,Vincristine
NCT01190930,Dexamethasone,PART_OF,Patients
NCT01190930,Methotrexate,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
NCT01190930,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT01190930,Therapeutic procedure,TREATS,Child
NCT01190930,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT01190930,Therapeutic procedure,TREATS(INFER),Neuropathy
NCT01190930,Neuropathy,PROCESS_OF,Child
NCT01190930,Dexamethasone,ASSOCIATED_WITH,Disease
NCT01190930,Diagnosis,TREATS,Patients
NCT01190930,Marrow,LOCATION_OF,Disease
NCT01190930,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT01190930,Disease,PROCESS_OF,Patients
NCT01190930,Very high,PROCESS_OF,Patients
NCT01190930,Disease,PROCESS_OF,Patients
NCT01190930,Down Syndrome,PROCESS_OF,Patients
NCT01190930,Down Syndrome,PROCESS_OF,Patients
NCT01190930,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT01190930,6-Mercaptopurine,TREATS,Girls
NCT01190930,Methotrexate,TREATS,Girls
NCT01190930,Maintenance therapy,TREATS,Girls
NCT01190930,Methotrexate,ADMINISTERED_TO,Patients
NCT01190930,"Leukemia, Lymphocytic, Acute",ISA,Lymphoblastic Leukemia
NCT02435849,Cells,LOCATION_OF,"Leukemia, B-Cell, Acute"
NCT02435849,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT02435849,Cells,LOCATION_OF,"Leukemia, B-Cell, Acute"
NCT02435849,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00933985,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00933985,Doxorubicin Hydrochloride,TREATS,Patients
NCT00933985,Dexrazoxane hydrochloride,TREATS,Patients
NCT00933985,Mesylates,DISRUPTS,Growth
NCT00933985,Vincristine Sulfate,DISRUPTS,Cells
NCT00933985,Vincristine Sulfate,ISA,Pharmacotherapy
NCT00933985,Doxorubicin Hydrochloride,DISRUPTS,Growth
NCT00933985,Dexrazoxane hydrochloride,DISRUPTS,Growth
NCT00933985,Mesylates,DISRUPTS,"Tumor cells, malignant"
NCT00933985,Vincristine Sulfate,ISA,Vincristine
NCT00933985,Dexrazoxane,TREATS,Child
NCT00933985,Doxorubicin Hydrochloride,ISA,Doxorubicin
NCT00933985,Doxorubicin Hydrochloride,TREATS,Child
NCT00933985,Dexrazoxane hydrochloride,ISA,Dexrazoxane
NCT00933985,Dexrazoxane hydrochloride,TREATS(SPEC),Child
NCT00933985,Drug Kinetics,PROCESS_OF,Child
NCT00933985,Solid tumor,PROCESS_OF,Child
NCT00933985,Mesylates,ADMINISTERED_TO,Patients
NCT00933985,leukemia,PROCESS_OF,Child
NCT00933985,Dexrazoxane,TREATS,Child
NCT00933985,Dexrazoxane,TREATS(INFER),leukemia
NCT00933985,Dexrazoxane,TREATS(INFER),Solid tumor
NCT00933985,Solid tumor,PROCESS_OF,Child
NCT00022126,Bone Marrow Transplantation,NEG_TREATS,Infant
NCT00022126,Pharmacotherapy,ADMINISTERED_TO,Infant
NCT00022126,Combination Drug Therapy,NEG_TREATS,Infant
NCT00022126,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00022126,Bone Marrow Transplantation,NEG_TREATS,Infant
NCT00022126,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Physicians
NCT00022126,Pharmacotherapy,NEG_TREATS,Infant
NCT00022126,Pharmacotherapy,NEG_TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00022126,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00022126,Allogeneic bone marrow transplantation,NEG_TREATS,Infant
NCT00022126,Allogeneic bone marrow transplantation,NEG_TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00022126,Treatment Protocols,TREATS,Patients
NCT00022126,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00022126,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00022126,Methotrexate,ADMINISTERED_TO,Patients
NCT00022126,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT00022126,Bone Marrow Transplantation,NEG_ADMINISTERED_TO,Patients
NCT00022126,Methotrexate,ADMINISTERED_TO,Patients
NCT00022126,pegaspargase,ADMINISTERED_TO,Patients
NCT00022126,Vincristine,ADMINISTERED_TO,Patients
NCT00022126,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00022126,Cytarabine,ADMINISTERED_TO,Patients
NCT00022126,Dexamethasone,ADMINISTERED_TO,Patients
NCT00022126,Doxorubicin,ADMINISTERED_TO,Patients
NCT00022126,Thioguanine,ADMINISTERED_TO,Patients
NCT00022126,Vincristine,ADMINISTERED_TO,Patients
NCT00022126,pegaspargase,ADMINISTERED_TO,Patients
NCT00022126,Methotrexate,ADMINISTERED_TO,Patients
NCT00022126,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00022126,Methotrexate,ADMINISTERED_TO,Patients
NCT00022126,ASPARAGINASE,ASSOCIATED_WITH(INFER),Hypersensitivity
NCT00022126,ASPARAGINASE,PART_OF,Patients
NCT00022126,Hypersensitivity,PROCESS_OF,Patients
NCT00022126,Bone Marrow Transplantation,ADMINISTERED_TO,Patients
NCT00022126,Pharmacotherapy,TREATS,Chromosomal translocation
NCT00022126,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00022126,Whole-Body Irradiation,TREATS,Patients
NCT00022126,Allogeneic bone marrow transplantation,ADMINISTERED_TO,Patients
NCT00022126,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00022126,Therapeutic procedure,TREATS,Infant
NCT00022126,Therapeutic procedure,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01760655,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01760655,Stem cell transplant,TREATS,Patients
NCT01760655,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT01760655,Graft-vs-Host Disease,OCCURS_IN,Patients
NCT01760655,Treatment Protocols,compared_with,Hemopoietic stem cell transplant
NCT01760655,Treatment Protocols,TREATS,Patients
NCT01760655,Therapeutic procedure,TREATS,Patients
NCT01760655,Hemopoietic stem cell transplant,TREATS,Patients
NCT01760655,Whole-Body Irradiation,TREATS,Patients
NCT01760655,Tacrolimus,ADMINISTERED_TO,Patients
NCT01760655,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT01760655,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01760655,Hematopoietic Stem Cell Transplantation,TREATS,Hematologic Neoplasms
NCT00316953,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00316953,Adverse effects,PROCESS_OF,Patients
NCT00316953,Toxic effect,PROCESS_OF,Patients
NCT00316953,Toxic effect,PROCESS_OF,Patients
NCT00316953,Philadelphia chromosome positive,PROCESS_OF,Patients
NCT00316953,Drug Kinetics,PROCESS_OF,Patients
NCT00316953,Solid tumor,PROCESS_OF,Patients
NCT00316953,Solid tumor,PROCESS_OF,Patients
NCT00316953,Solid tumor,ISA,Disease
NCT00316953,Toxic effect,PROCESS_OF,Patients
NCT00316953,Toxic effect,PROCESS_OF,Patients
NCT00316953,leukemia,PROCESS_OF,Child
NCT00316953,Solid tumor,PROCESS_OF,Child
NCT00316953,BMS 354825,TREATS,Child
NCT00316953,BMS 354825,TREATS(INFER),leukemia
NCT00316953,BMS 354825,TREATS(INFER),Solid tumor
NCT01920737,Pharmaceutical Preparations,TREATS,Adult
NCT01920737,Therapeutic procedure,TREATS,Adult
NCT01920737,Pharmaceutical Preparations,TREATS,Patients
NCT01920737,Pharmaceutical Preparations,TREATS,Adult
NCT01920737,Treatment Protocols,USES,Pharmaceutical Preparations
NCT00408005,Combination Drug Therapy,TREATS,Patients
NCT00408005,Combination Drug Therapy,TREATS(INFER),Acute T Cell Leukemia
NCT00408005,Combination Drug Therapy,TREATS(INFER),Adverse effects
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT00408005,T-Cell Lymphoma,PROCESS_OF,Patients
NCT00408005,lymphoblast,LOCATION_OF,T-Cell Lymphoma
NCT00408005,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT00408005,Chemotherapy-Oncologic Procedure,TREATS(INFER),Acute T Cell Leukemia
NCT00408005,Chemotherapy-Oncologic Procedure,TREATS(INFER),T-Cell Lymphoma
NCT00408005,Adverse effects,PROCESS_OF,Patients
NCT00408005,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00408005,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00408005,lymphoblast,LOCATION_OF,T-Cell Lymphoma
NCT00408005,Chemotherapy-Oncologic Procedure,TREATS,Acute T Cell Leukemia
NCT00408005,Chemotherapy-Oncologic Procedure,TREATS,T-Cell Lymphoma
NCT00408005,GW506U78,ISA,Nelarabine
NCT00408005,Leucovorin Calcium,ISA,Leucovorin
NCT00408005,Leucovorin Calcium,compared_with,Methotrexate
NCT00408005,T-Lymphocyte,LOCATION_OF,Large Cell Lymphoblastic Lymphoma
NCT00408005,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT00408005,Nelarabine,TREATS,Patients
NCT00408005,Nelarabine,TREATS(INFER),Large Cell Lymphoblastic Lymphoma
NCT00408005,Cytarabine,ADMINISTERED_TO,Patients
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Risk Assessment,TREATS,Patients
NCT00408005,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00408005,Marrow,PART_OF,Patients
NCT00408005,Disease,PROCESS_OF,Patients
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Marrow,PART_OF,Patients
NCT00408005,Disease,PROCESS_OF,Patients
NCT00408005,Nelarabine,ADMINISTERED_TO,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,pegaspargase,ADMINISTERED_TO,Patients
NCT00408005,T-Cell Lymphoma,PROCESS_OF,Patients
NCT00408005,lymphoblast,LOCATION_OF,T-Cell Lymphoma
NCT00408005,TNFRSF6B gene,PART_OF,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Radiation therapy,TREATS,Testicular Diseases
NCT00408005,Testicular Diseases,PROCESS_OF,Patients
NCT00408005,Radiation therapy,TREATS,Disease
NCT00408005,Disease,PROCESS_OF,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Radiation therapy,TREATS,Testicular Diseases
NCT00408005,Testicular Diseases,PROCESS_OF,Patients
NCT00408005,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00408005,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00408005,Cytarabine,ADMINISTERED_TO,Patients
NCT00408005,Disease,PROCESS_OF,Patients
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Radiation therapy,TREATS,Disease
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,pegaspargase,ADMINISTERED_TO,Patients
NCT00408005,Upper Extremity,LOCATION_OF,Methotrexate
NCT00408005,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00408005,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00408005,Cytarabine,ADMINISTERED_TO,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Radiation therapy,TREATS,Testicular Diseases
NCT00408005,Testicular Diseases,PROCESS_OF,Patients
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,pegaspargase,ADMINISTERED_TO,Patients
NCT00408005,Nelarabine,ADMINISTERED_TO,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Radiation therapy,TREATS,Testicular Diseases
NCT00408005,Testicular Diseases,PROCESS_OF,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Hypersensitivity,PROCESS_OF,Patients
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,Erwinia asparaginase,ADMINISTERED_TO,Patients
NCT00408005,Upper Extremity,LOCATION_OF,Methotrexate
NCT00408005,TNFRSF6B gene,PART_OF,Patients
NCT00408005,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00408005,Cytarabine,ADMINISTERED_TO,Patients
NCT00408005,Dexamethasone,ADMINISTERED_TO,Patients
NCT00408005,Down Syndrome,PROCESS_OF,Patients
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Thioguanine,ADMINISTERED_TO,Patients
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,pegaspargase,ADMINISTERED_TO,Patients
NCT00408005,Doxorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00408005,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00408005,Cytarabine,ADMINISTERED_TO,Patients
NCT00408005,Dexamethasone,ADMINISTERED_TO,Patients
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Radiation therapy,TREATS,Disease
NCT00408005,Thioguanine,ADMINISTERED_TO,Patients
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,pegaspargase,ADMINISTERED_TO,Patients
NCT00408005,Doxorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT00408005,Nelarabine,ADMINISTERED_TO,Patients
NCT00408005,Disease,PROCESS_OF,Patients
NCT00408005,Radiation therapy,TREATS,Disease
NCT00408005,Radiation therapy,TREATS,Patients
NCT00408005,Radiation therapy,TREATS(INFER),Disease
NCT00408005,Disease,PROCESS_OF,Patients
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Boys
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Girls
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Maintenance therapy,ISA,Therapeutic procedure
NCT00408005,TNFRSF6B gene,PART_OF,Patients
NCT00408005,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00408005,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00408005,Dexamethasone,ADMINISTERED_TO,Patients
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Boys
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Girls
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,Maintenance therapy,ISA,Therapeutic procedure
NCT00408005,Disease,PROCESS_OF,Patients
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Boys
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Girls
NCT00408005,Methotrexate,ADMINISTERED_TO,Patients
NCT00408005,Vincristine Sulfate,ADMINISTERED_TO,Patients
NCT00408005,Maintenance therapy,ISA,Therapeutic procedure
NCT00408005,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Boys
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Girls
NCT00408005,Maintenance therapy,ISA,Therapeutic procedure
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Child
NCT00408005,Acute T Cell Leukemia,PROCESS_OF,Young adult
NCT00408005,Methotrexate,TREATS,Child
NCT00408005,Methotrexate,TREATS,Young adult
NCT00408005,Methotrexate,TREATS(INFER),Acute T Cell Leukemia
NCT00408005,Methotrexate,TREATS(INFER),T-Cell Lymphoma
NCT00408005,T-Cell Lymphoma,PROCESS_OF,Child
NCT00408005,T-Cell Lymphoma,PROCESS_OF,Young adult
NCT00408005,Therapeutic procedure,ISA,Nelarabine
NCT00408005,lymphoblast,LOCATION_OF,T-Cell Lymphoma
NCT00408005,GW506U78,ISA,Nelarabine
NCT01175785,Cyclosporine,PART_OF,Patients
NCT01175785,Cyclosporine,TREATS,Patients
NCT01175785,Cyclosporine,TREATS(INFER),Hematologic Neoplasms
NCT01175785,Transplantation,USES,HLA Antigens
NCT01175785,mycophenolate mofetil,TREATS,Patients
NCT01175785,mycophenolate mofetil,TREATS(INFER),Hematologic Neoplasms
NCT01175785,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01175785,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT01175785,Cyclophosphamide,DISRUPTS,Growth
NCT01175785,Fludarabine phosphate,DISRUPTS,Growth
NCT01175785,Bone Marrow,PART_OF,Patients
NCT01175785,Expanding,LOCATION_OF,Cells
NCT01175785,Blood product,AFFECTS,Graft acceptance
NCT01175785,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT01175785,Whole-Body Irradiation,TREATS,Patients
NCT01175785,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT01175785,Transplantation,TREATS,Patients
NCT01175785,Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT01175785,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00796068,Whole-Body Irradiation,TREATS,Patients
NCT00796068,Whole-Body Irradiation,TREATS(INFER),Hematologic Neoplasms
NCT00796068,Fludarabine phosphate,TREATS,Patients
NCT00796068,Fludarabine phosphate,TREATS(INFER),Hematologic Neoplasms
NCT00796068,treosulfan,TREATS,Patients
NCT00796068,treosulfan,TREATS(INFER),Hematologic Neoplasms
NCT00796068,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00796068,Fludarabine phosphate,DISRUPTS,Growth
NCT00796068,treosulfan,DISRUPTS,Growth
NCT00796068,Blood,PART_OF,Patients
NCT00796068,Bone Marrow,PART_OF,Patients
NCT00796068,Whole-Body Irradiation,TREATS,Patients
NCT00796068,Cyclosporine,ADMINISTERED_TO,Patients
NCT00796068,Treatment Protocols,ADMINISTERED_TO,Patients
NCT00796068,Prophylactic treatment,TREATS,Patients
NCT00796068,mycophenolate mofetil,TREATS,Patients
NCT00796068,Transplantation,TREATS,Patients
NCT00796068,Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00796068,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00006251,Hematopoietic Neoplasms,PROCESS_OF,Patients
NCT00006251,Donor Lymphocyte Infusion,TREATS,Patients
NCT00006251,Donor Lymphocyte Infusion,TREATS(INFER),Hematopoietic Neoplasms
NCT00006251,Fludarabine phosphate,DISRUPTS,Growth
NCT00006251,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00006251,Immune response,PROCESS_OF,Patients
NCT00006251,Graft Rejection,PROCESS_OF,Patients
NCT00006251,Treatment Protocols,TREATS,Patients
NCT00006251,Treatment Protocols,TREATS(INFER),Malignant disease
NCT00006251,Fludarabine phosphate,ISA,fludarabine
NCT00006251,Malignant disease,PROCESS_OF,Patients
NCT00006251,Cyclosporine,PART_OF,Peripheral Blood Stem Cell
NCT00006251,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00006251,Whole-Body Irradiation,TREATS,Patients
NCT00006251,Whole-Body Irradiation,TREATS(INFER),Graft-vs-Host Disease
NCT00006251,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00006251,Cyclosporine,ADMINISTERED_TO,Patients
NCT00006251,Fludarabine phosphate,NEG_ADMINISTERED_TO,Patients
NCT00006251,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00006251,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00006251,Donor Lymphocyte Infusion,TREATS,Graft-vs-Host Disease
NCT00006251,Donor Lymphocyte Infusion,TREATS,In complete remission
NCT00006251,Cyclosporine,PART_OF,Peripheral Blood Stem Cell
NCT00006251,Whole-Body Irradiation,ADMINISTERED_TO,Patients
NCT00006251,fludarabine,ADMINISTERED_TO,Patients
NCT00006251,Transplant immunosuppression,ADMINISTERED_TO,Patients
NCT00006251,Induction,TREATS,Patients
NCT00006213,Pharmaceutical Preparations,TREATS,Patients
NCT00006213,Pharmaceutical Preparations,TREATS(INFER),Acute leukemia
NCT00006213,Acute leukemia,PROCESS_OF,Patients
NCT00006213,BMS 214662,TREATS,Patients
NCT00006213,BMS 214662,TREATS(INFER),Acute leukemia
NCT00006213,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00006213,Acute leukemia,PROCESS_OF,Patients
NCT00006213,BMS 214662,TREATS,Patients
NCT00006213,BMS 214662,TREATS(INFER),"Myeloid Leukemia, Chronic"
NCT00006213,BMS 214662,TREATS(INFER),Acute leukemia
NCT00006213,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00006213,Acute leukemia,PROCESS_OF,Patients
NCT00006213,Toxic effect,PROCESS_OF,Patients
NCT00006213,Therapeutic procedure,TREATS,Maximum
NCT00006213,BMS 214662,ADMINISTERED_TO,Patients
NCT00006213,Refractory anaemia with excess blasts,COEXISTS_WITH,Blast Phase
NCT00006213,Refractory anaemia with excess blasts,ISA,Dysmyelopoietic Syndromes
NCT00006213,"Myeloid Leukemia, Chronic",COEXISTS_WITH,Blast Phase
NCT00006213,"Myeloid Leukemia, Chronic",ISA,Dysmyelopoietic Syndromes
NCT00006213,Refractory anemia with excess blasts in transformation (clinical),COEXISTS_WITH,Blast Phase
NCT00006213,Refractory anemia with excess blasts in transformation (clinical),ISA,Dysmyelopoietic Syndromes
NCT00006213,BMS 214662,TREATS,Acute leukemia
NCT00057811,Combination Drug Therapy,TREATS,Patients
NCT00057811,Chronic Lymphocytic Leukemia,PROCESS_OF,Patients
NCT00057811,Lymphoma,PROCESS_OF,Patients
NCT00057811,rituximab,TREATS,Patients
NCT00057811,Rasburicase,TREATS,Patients
NCT00057811,rituximab,ISA,Monoclonal Antibodies
NCT00057811,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00057811,rituximab,DISRUPTS,"Tumor cells, malignant"
NCT00057811,Rasburicase,ISA,Miscellaneous Chemoprotective Agent
NCT00057811,leukemia,PROCESS_OF,Child
NCT00057811,Lymphoma,PROCESS_OF,Child
NCT00057811,Toxic effect,PROCESS_OF,Child
NCT00057811,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00057811,Rasburicase,ADMINISTERED_TO,Patients
NCT00057811,Glucosephosphate Dehydrogenase Deficiency,PROCESS_OF,Patients
NCT00057811,Neoadjuvant Therapy,PREVENTS,Neoplasm
NCT00057811,Rasburicase,NEG_ADMINISTERED_TO,Patients
NCT00057811,Cyclophosphamide,PREVENTS,Neoplasm
NCT00057811,Treatment Protocols,PREVENTS,Neoplasm
NCT00057811,Treatment Protocols,USES,Doxorubicin
NCT00057811,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00057811,Excision,TREATS,Patients
NCT00057811,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00057811,Doxorubicin,ADMINISTERED_TO,Patients
NCT00057811,Treatment Protocols,ADMINISTERED_TO,Patients
NCT00057811,Treatment Protocols,USES,Doxorubicin
NCT00057811,Treatment Protocols,USES,Cymer
NCT00057811,Disease,PROCESS_OF,Patients
NCT00057811,Neoadjuvant Therapy,ISA,Therapeutic procedure
NCT00057811,Treatment Protocols,ADMINISTERED_TO,Patients
NCT00057811,Excision,TREATS,Patients
NCT00057811,Etoposide,ADMINISTERED_TO,Patients
NCT00057811,Methotrexate,ADMINISTERED_TO,Patients
NCT00057811,Treatment Protocols,ADMINISTERED_TO,Patients
NCT00057811,Maintenance therapy,ADMINISTERED_TO,Patients
NCT00057811,Therapeutic procedure,TREATS,Lymphoma
NCT00057811,Toxic effect,PROCESS_OF,Child
NCT00357565,Bone Marrow,PART_OF,Patients
NCT00357565,Busulfan,DISRUPTS,Growth
NCT00357565,Melphalan,DISRUPTS,Growth
NCT00357565,fludarabine,DISRUPTS,Growth
NCT00357565,Bone Marrow,PART_OF,Patients
NCT00357565,Dysmyelopoietic Syndromes,PROCESS_OF,Infant
NCT00357565,Acute leukemia,PROCESS_OF,Infant
NCT00357565,Transplanted organ and tissue status,PROCESS_OF,Infant
NCT00357565,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
NCT00357565,"Leukemia, Myelocytic, Acute",PROCESS_OF,Infant
NCT00357565,Dysmyelopoietic Syndromes,PROCESS_OF,Infant
NCT00357565,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00357565,Radiation therapy,TREATS,"Leukemia, Myelocytic, Acute"
NCT00357565,Radiation therapy,TREATS,Dysmyelopoietic Syndromes
NCT00357565,Graft acceptance,PROCESS_OF,Infant
NCT00357565,leukemia,PROCESS_OF,Infant
NCT00489203,Beclomethasone Dipropionate,ASSOCIATED_WITH,Acute graft-versus-host disease
NCT00489203,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00489203,Stem cell transplant,TREATS,Patients
NCT00489203,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00489203,Stem cell transplant,TREATS(INFER),Acute graft-versus-host disease
NCT00489203,Beclomethasone Dipropionate,PREVENTS,Acute graft-versus-host disease
NCT00489203,Methotrexate,ADMINISTERED_TO,Patients
NCT00489203,Tacrolimus,ADMINISTERED_TO,Patients
NCT00489203,Methotrexate,ADMINISTERED_TO,Patients
NCT00489203,Tacrolimus,ADMINISTERED_TO,Patients
NCT00489203,Upper arm,LOCATION_OF,Transplanted organ and tissue status
NCT00489203,Treatment Protocols,PREVENTS,Acute graft-versus-host disease
NCT00040846,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00040846,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00040846,Stem cell transplant,TREATS,Patients
NCT00040846,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00040846,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00040846,"Tumor cells, malignant",LOCATION_OF,alemtuzumab
NCT00040846,alemtuzumab,ISA,Monoclonal Antibodies
NCT00040846,Bone Marrow,PART_OF,Patients
NCT00040846,Treatment Protocols,ADMINISTERED_TO,Stem cell donor
NCT00040846,Graft acceptance,PROCESS_OF,Patients
NCT00040846,Campath,ISA,alemtuzumab
NCT00040846,Treatment Protocols,PREDISPOSES,Disease Progression
NCT00040846,Fludarabine phosphate,PREDISPOSES,Disease Progression
NCT00040846,Cyclosporine,ADMINISTERED_TO,Patients
NCT00040846,Whole-Body Irradiation,TREATS,Patients
NCT00040846,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00040846,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00040846,Stem cell transplant,TREATS,Patients
NCT00040846,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00005811,Pharmaceutical Preparations,DISRUPTS,[M]Unspecified tumor cell NOS
NCT00005811,Malignant neoplasm of meninges,PROCESS_OF,Child
NCT00005811,Topotecan Hydrochloride,TREATS,Child
NCT00005811,Topotecan Hydrochloride,TREATS(INFER),Malignant neoplasm of meninges
NCT00005811,Malignant neoplasm of meninges,PROCESS_OF,Child
NCT00005811,Topotecan Hydrochloride,TREATS,Child
NCT00005811,Topotecan Hydrochloride,TREATS(INFER),Malignant neoplasm of meninges
NCT00005811,Topotecan,TREATS,Patients
NCT00005811,Toxic effect,PROCESS_OF,Patients
NCT00005811,Cerebrospinal Fluid,LOCATION_OF,Matrix Metalloproteinases
NCT00005811,Malignant Neoplasms,PROCESS_OF,Patients
NCT00005811,Topotecan,TREATS,Patients
NCT00005811,Topotecan,TREATS(INFER),Malignant Neoplasms
NCT00343798,Cyclosporine,TREATS,Patients
NCT00343798,Cyclosporine,TREATS(INFER),Hematologic Neoplasms
NCT00343798,Transplantation,USES,Cyclophosphamide
NCT00343798,Transplantation,USES,fludarabine
NCT00343798,mycophenolate mofetil,TREATS,Patients
NCT00343798,mycophenolate mofetil,TREATS(INFER),Hematologic Neoplasms
NCT00343798,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00343798,Cyclophosphamide,DISRUPTS,Growth
NCT00343798,fludarabine,DISRUPTS,Growth
NCT00343798,Bone Marrow,PART_OF,Patients
NCT00343798,Expanding,LOCATION_OF,Cells
NCT00343798,Toxic effect,PROCESS_OF,Patients
NCT00343798,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00343798,Infusion procedures,TREATS,Patients
NCT00343798,Cyclosporine,ADMINISTERED_TO,Patients
NCT00343798,Whole-Body Irradiation,TREATS,Patients
NCT00343798,Infusion procedures,METHOD_OF,Transplantation
NCT00343798,umbilical cord blood transplantation,TREATS,Patients
NCT00343798,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00343798,Pilot Projects,USES,Biological blood vessel prosthesis
NCT00343798,Biological blood vessel prosthesis,TREATS,Patients
NCT00343798,umbilical cord blood transplantation,TREATS,Patients
NCT00343798,umbilical cord blood transplantation,TREATS,Hematologic Neoplasms
NCT00049504,Bone Marrow Transplantation,TREATS,Patients
NCT00049504,Bone Marrow Transplantation,TREATS(INFER),High-Risk Cancer
NCT00049504,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00049504,Whole-Body Irradiation,ADMINISTERED_TO,Patients
NCT00049504,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00049504,Tacrolimus,ADMINISTERED_TO,Patients
NCT00049504,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00049504,High-Risk Cancer,PROCESS_OF,Patients
NCT00049504,Cyclophosphamide,DISRUPTS,Growth
NCT00049504,Fludarabine phosphate,DISRUPTS,Growth
NCT00049504,Bone Marrow Transplantation,TREATS,Hematologic Neoplasms
NCT00049504,Graft acceptance,PROCESS_OF,Patients
NCT00049504,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00049504,Bone Marrow Transplantation,TREATS,Patients
NCT00049504,Whole-Body Irradiation,TREATS,Patients
NCT00049504,Tacrolimus,ADMINISTERED_TO,Patients
NCT00049504,Prophylactic treatment,ADMINISTERED_TO,Patients
NCT00049504,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00049504,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00049504,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01028716,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01028716,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01028716,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT01028716,Transplantation,TREATS,Hematologic Neoplasms
NCT01028716,Tacrolimus,TREATS,Graft-vs-Host Disease
NCT01028716,mycophenolate mofetil,TREATS,Graft-vs-Host Disease
NCT01028716,Hematologic Neoplasms,PROCESS_OF,Patients
NCT01028716,"Tumor cells, malignant",PART_OF,Patients
NCT01028716,Cyclophosphamide,ISA,Pharmacotherapy
NCT01028716,Fludarabine phosphate,ISA,Pharmacotherapy
NCT01028716,Disease,PROCESS_OF,Patients
NCT01028716,Place,LOCATION_OF,Peripheral Blood Stem Cell
NCT01028716,Whole-Body Irradiation,TREATS,Patients
NCT01028716,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT01028716,Tacrolimus,ADMINISTERED_TO,Patients
NCT01028716,Cell Transplantation,TREATS,Patients
NCT01028716,Cell Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT01028716,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00719888,Hematological Disease,PROCESS_OF,Patients
NCT00719888,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00719888,Cyclophosphamide,DISRUPTS,Growth
NCT00719888,Fludarabine phosphate,DISRUPTS,Growth
NCT00719888,Bone Marrow,PART_OF,Patients
NCT00719888,Treatment Protocols,TREATS,Patients
NCT00719888,Fludarabine phosphate,ISA,fludarabine
NCT00719888,Whole-Body Irradiation,TREATS,Patients
NCT00719888,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00719888,Hematological Disease,PROCESS_OF,Patients
NCT00719888,Transplantation,TREATS,Patients
NCT00719888,Transplantation,TREATS(INFER),Hematological Disease
NCT00643240,"Tumor cells, malignant",LOCATION_OF,Chronic Lymphocytic Leukemia
NCT00643240,"Tumor cells, malignant",LOCATION_OF,"Leukemia, Lymphocytic, Acute"
NCT00643240,Chronic Lymphocytic Leukemia,PROCESS_OF,Patients
NCT00643240,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00643240,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00643240,leukemia,PROCESS_OF,Patients
NCT00021242,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00021242,docetaxel,ADMINISTERED_TO(SPEC),Child
NCT00021242,docetaxel,DISRUPTS,"Tumor cells, malignant"
NCT00021242,docetaxel,ISA,Pharmacotherapy
NCT00021242,docetaxel,TREATS,Child
NCT00021242,docetaxel,TREATS,"Leukemia, Myelocytic, Acute"
NCT00021242,Therapeutic procedure,TREATS,Maximum
NCT00021242,leukemia,PROCESS_OF,Child
NCT00021242,docetaxel,TREATS,Child
NCT00021242,docetaxel,TREATS(INFER),leukemia
NCT00021242,Taxotere,ISA,docetaxel
NCT00021242,Taxotere,TREATS(SPEC),Child
NCT00075725,Dexamethasone,DISRUPTS,"Tumor cells, malignant"
NCT00075725,Dexamethasone,compared_with,Prednisone
NCT00075725,Methotrexate,DISRUPTS,"Tumor cells, malignant"
NCT00075725,Prednisone,DISRUPTS,"Tumor cells, malignant"
NCT00075725,Maintenance therapy,TREATS,Patients
NCT00075725,Leucovorin Calcium,DISRUPTS,"Tumor cells, malignant"
NCT00075725,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00075725,Dexamethasone,compared_with,Prednisone
NCT00075725,Maintenance therapy,TREATS,Patients
NCT00075725,Leucovorin Calcium,compared_with,Methotrexate
NCT00075725,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00075725,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00075725,Treatment Protocols,TREATS,Patients
NCT00075725,Neoadjuvant Therapy,TREATS,Patients
NCT00075725,Neoadjuvant Therapy,compared_with,Treatment Protocols
NCT00075725,Methotrexate,compared_with,Leukovorin rescue
NCT00075725,Treatment Protocols,TREATS,Patients
NCT00075725,Leukovorin rescue,TREATS,Patients
NCT00075725,Leukovorin rescue,compared_with,Methotrexate
NCT00075725,Treatment Protocols,TREATS,Patients
NCT00075725,Treatment Protocols,TREATS,Patients
NCT00075725,Treatment Protocols,TREATS(INFER),"Neoplasm, Residual"
NCT00075725,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00075725,Cytarabine,ADMINISTERED_TO,Patients
NCT00075725,Dexamethasone,ADMINISTERED_TO,Patients
NCT00075725,Cytarabine,ADMINISTERED_TO,Patients
NCT00075725,Daunorubicin,ADMINISTERED_TO,Patients
NCT00075725,Disease,PROCESS_OF,Patients
NCT00075725,Methotrexate,ADMINISTERED_TO,Patients
NCT00075725,Vincristine,ADMINISTERED_TO,Patients
NCT00075725,pegaspargase,ADMINISTERED_TO,Patients
NCT00075725,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00075725,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00075725,Disease,PROCESS_OF,Patients
NCT00075725,Disease,PROCESS_OF,Patients
NCT00075725,Disease,PROCESS_OF,Patients
NCT00075725,Neoadjuvant Therapy,ADMINISTERED_TO,Patients
NCT00075725,Dexamethasone,ADMINISTERED_TO,Patients
NCT00075725,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00075725,Disease,PROCESS_OF,Patients
NCT00075725,Disease,PROCESS_OF,Patients
NCT00075725,Methotrexate,ADMINISTERED_TO,Patients
NCT00075725,Radiation therapy,ADMINISTERED_TO,Patients
NCT00075725,Testicular Diseases,PROCESS_OF,Patients
NCT00075725,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00075725,Upper Extremity,LOCATION_OF,Methotrexate
NCT00075725,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00075725,Radiation therapy,ADMINISTERED_TO,Patients
NCT00075725,Radiation therapy,ADMINISTERED_TO,Patients
NCT00075725,Steroids,PART_OF,Patients
NCT00075725,Methotrexate,ADMINISTERED_TO,Patients
NCT00075725,Therapeutic procedure,TREATS,Patients
NCT00075725,Maintenance therapy,TREATS,Patients
NCT00075725,Radiation therapy,ADMINISTERED_TO,Patients
NCT00075725,Testicular Diseases,PROCESS_OF,Patients
NCT00866281,Pharmacodynamics,PROCESS_OF,Patients
NCT00866281,Drug Kinetics,PROCESS_OF,Patients
NCT00020670,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Child
NCT00020670,Vaccine Therapy,TREATS,Patients
NCT00020670,genetic aspects,PROCESS_OF,Patients
NCT00020670,Immunity,PROCESS_OF,Patients
NCT02808442,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT02808442,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02808442,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00077493,BL22 immunotoxin,TREATS,Patients
NCT00077493,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00077493,Adverse effects,PROCESS_OF,Patients
NCT00077493,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00077493,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00077493,Toxic effect,PROCESS_OF,Patients
NCT00077493,Pharmaceutical Preparations,TREATS,Patients
NCT00077493,Pharmaceutical Preparations,TREATS,Patients
NCT00077493,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00077493,Pharmaceutical Preparations,TREATS,Patients
NCT00077493,Immunoglobulins,TREATS,Patients
NCT00077493,Serum,LOCATION_OF,cytokine
NCT00077493,BL22 immunotoxin,ADMINISTERED_TO,Patients
NCT00077493,Toxic effect,PROCESS_OF,Patients
NCT01743807,"Drugs, Investigational",TREATS,Patients
NCT01743807,agonists,AUGMENTS,Immune response
NCT01743807,Hemopoietic stem cell transplant,ADMINISTERED_TO,Patients
NCT01743807,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT01743807,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01743807,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT01066468,Gleevec,COEXISTS_WITH,"BCR protein, human"
NCT01066468,Drug Kinetics,PROCESS_OF,Patients
NCT01066468,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT01066468,Gleevec,ISA,Imatinib mesylate
NCT00136435,ASPARAGINASE,TREATS,Patients
NCT00136435,ASPARAGINASE,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00136435,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00136435,Vincristine,ADMINISTERED_TO,Patients
NCT00136435,Pharmacotherapy,USES,ASPARAGINASE
NCT00136435,Vincristine,ISA,Pharmaceutical Preparations
NCT00136435,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
NCT00400946,ASPARAGINASE,AFFECTS,"Leukemia, Lymphocytic, Acute, L1"
NCT00400946,ASPARAGINASE,ISA,Therapeutic procedure
NCT00400946,ASPARAGINASE,ISA,Therapeutic procedure
NCT00400946,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00400946,Therapeutic procedure,USES,ASPARAGINASE
NCT00400946,Hypersensitivity,PROCESS_OF,Patients
NCT00400946,Therapeutic procedure,TREATS,Patients
NCT00400946,Therapeutic procedure,TREATS(INFER),Hypersensitivity
NCT00400946,pegaspargase,ISA,ASPARAGINASE
NCT00400946,pegaspargase,compared_with,Escherichia coli asparaginase
NCT00400946,pegaspargase,lower_than,Escherichia coli asparaginase
NCT00400946,Escherichia coli asparaginase,ISA,ASPARAGINASE
NCT00400946,Blast Cell,PART_OF,Marrow
NCT00400946,Cytarabine,ADMINISTERED_TO,Patients
NCT00400946,Methylprednisolone,ADMINISTERED_TO,Patients
NCT00400946,Cytarabine,ADMINISTERED_TO,Patients
NCT00400946,Central Nervous System Leukemia,PROCESS_OF,Patients
NCT00400946,Cytarabine,ADMINISTERED_TO,Patients
NCT00400946,Steroids,ADMINISTERED_TO,Patients
NCT00400946,Steroid therapy,NEG_ADMINISTERED_TO,Patients
NCT00400946,Cranial nerve palsies,PROCESS_OF,Patients
NCT00400946,prednisolone,ADMINISTERED_TO,Patients
NCT00400946,Prednisone,ADMINISTERED_TO,Patients
NCT00400946,Methylprednisolone,ADMINISTERED_TO,Patients
NCT00400946,prednisolone,ADMINISTERED_TO,Patients
NCT00400946,Cytarabine,ADMINISTERED_TO,Patients
NCT00400946,Steroid therapy,NEG_ADMINISTERED_TO,Patients
NCT00400946,Disease,PROCESS_OF,Patients
NCT00400946,Marrow,LOCATION_OF,Disease
NCT00400946,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00400946,Methotrexate,ADMINISTERED_TO,Patients
NCT00400946,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00400946,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00400946,Methotrexate,ADMINISTERED_TO,Patients
NCT00400946,Vincristine,ADMINISTERED_TO,Patients
NCT00400946,Patients,USES,"Support, device"
NCT00400946,"Support, device",USES,Leucovorin Calcium
NCT00400946,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00400946,Methotrexate,ADMINISTERED_TO,Patients
NCT00400946,Vincristine,ADMINISTERED_TO,Patients
NCT00400946,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT00400946,Methotrexate,ADMINISTERED_TO,Patients
NCT00400946,Leucovorin Calcium,ADMINISTERED_TO,Patients
NCT00400946,Dexrazoxane hydrochloride,ADMINISTERED_TO,Patients
NCT00400946,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00400946,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT00400946,Pancreatitis,PROCESS_OF,Patients
NCT00400946,Hypersensitivity,PROCESS_OF,Patients
NCT00400946,Vincristine,ADMINISTERED_TO,Patients
NCT00400946,Neuraxis,LOCATION_OF,Therapeutic procedure
NCT00400946,Leukocytes,PART_OF,Patients
NCT00400946,Radiation therapy,TREATS,Disease
NCT00400946,T-Lymphocyte,LOCATION_OF,Disease
NCT00400946,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT00400946,Dexamethasone,ADMINISTERED_TO,Patients
NCT00400946,Vincristine,ADMINISTERED_TO,Patients
NCT00400946,ASPARAGINASE,TREATS,Child
NCT00400946,ASPARAGINASE,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00400946,Asparagine,AFFECTS,Leukemic Cell
NCT00400946,Flow Cytometry,DIAGNOSES,"Leukemia, Lymphocytic, Acute, L1"
NCT00400946,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00400946,Polymerase Chain Reaction,DIAGNOSES,"Leukemia, Lymphocytic, Acute, L1"
NCT00400946,Remission Induction,TREATS,Patients
NCT00400946,Remission Induction,TREATS(INFER),"Neoplasm, Residual"
NCT00400946,Remission Induction,compared_with,Treatment Protocols
NCT00400946,Treatment Protocols,compared_with,Intrathecal Chemotherapy
NCT00400946,Treatment Protocols,TREATS,Patients
NCT00400946,Treatment Protocols,TREATS(INFER),"Neoplasm, Residual"
NCT00400946,pegaspargase,TREATS,Child
NCT00400946,pegaspargase,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00400946,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00400946,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00400946,Therapeutic procedure,compared_with,Pharmacotherapy
NCT00400946,"Neoplasm, Residual",PROCESS_OF,Patients
NCT00400946,Toxic effect,PROCESS_OF,Patients
NCT00400946,Nutrients,AFFECTS,Dietary intake
NCT00400946,Dietary intake,ASSOCIATED_WITH,Infection
NCT00400946,Dietary intake,ASSOCIATED_WITH,Mycoses
NCT00400946,Intrathecal Chemotherapy,TREATS,Patients
NCT00400946,Leukemic Cell,LOCATION_OF,"Neoplasm, Residual"
NCT02772198,B-Lymphocytes,LOCATION_OF,Malignant Neoplasms
NCT02772198,Malignant Neoplasms,PRODUCES,CD19 gene
NCT02772198,Child,LOCATION_OF,CD19 Antigens
NCT02772198,T-Lymphocyte,PRODUCES,CD19 Antigens
NCT02772198,CD19 Antigens,PART_OF,T-Lymphocyte
NCT02772198,Health care facility,LOCATION_OF,Clinical Trials
NCT02772198,"Receptors, Antigen",PART_OF,T-Lymphocyte
NCT02772198,B-Lymphocytes,LOCATION_OF,Malignant Neoplasms
NCT02772198,Malignant Neoplasms,PROCESS_OF,Child
NCT02772198,Malignant Neoplasms,PROCESS_OF,Young adult
NCT02772198,Child,LOCATION_OF,CD19 Antigens
NCT02772198,Young adult,LOCATION_OF,CD19 Antigens
NCT02772198,Behavior,PROCESS_OF,Patients
NCT02772198,CD19+ cell,LOCATION_OF,Malignant Neoplasms
NCT02772198,Peripheral blood mononuclear cell,LOCATION_OF,CD19 Antigens
NCT02772198,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT02772198,B-Lymphocytes,LOCATION_OF,Malignant Neoplasms
NCT02772198,Malignant Neoplasms,PROCESS_OF,Patients
NCT02772198,T-Lymphocyte,PRODUCES,CD19 Antigens
NCT00287105,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00287105,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00287105,imatinib,TREATS,Child
NCT00287105,imatinib,INHIBITS,Ephrin Receptor EphA8
NCT00287105,imatinib,ADMINISTERED_TO,Patients
NCT00287105,Pharmacotherapy,TREATS,Patients
NCT00287105,Pharmacotherapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00287105,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00882206,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00882206,5-aza-2'-deoxycytidine,AFFECTS,"Tumor cells, malignant"
NCT00882206,Combination Drug Therapy,TREATS,Patients
NCT00882206,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00882206,Combination Drug Therapy,TREATS(INFER),Large Cell Lymphoblastic Lymphoma
NCT00882206,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00882206,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00882206,5-aza-2'-deoxycytidine,DISRUPTS,"Tumor cells, malignant"
NCT00882206,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT00882206,Laboratory studies,USES,Therapeutic procedure
NCT00882206,Diagnosis,USES,5-aza-2'-deoxycytidine
NCT00882206,CNS disorder,PROCESS_OF,Patients
NCT00882206,Disease,PROCESS_OF,Patients
NCT00882206,Methotrexate,ADMINISTERED_TO,Patients
NCT00882206,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00882206,Laboratory studies,USES,Therapeutic procedure
NCT00882206,Doxorubicin,ISA,Pharmacotherapy
NCT00882206,Doxorubicin,TREATS(SPEC),"Leukemia, Lymphocytic, Acute"
NCT00882206,Doxorubicin,TREATS(SPEC),Large Cell Lymphoblastic Lymphoma
NCT00882206,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00882206,Pharmacotherapy,TREATS,Large Cell Lymphoblastic Lymphoma
NCT00882206,Prednisone,ISA,Pharmacotherapy
NCT00882206,Prednisone,TREATS(SPEC),"Leukemia, Lymphocytic, Acute"
NCT00882206,Prednisone,TREATS(SPEC),Large Cell Lymphoblastic Lymphoma
NCT00882206,Vincristine,ISA,Pharmacotherapy
NCT00882206,Vincristine,TREATS(SPEC),"Leukemia, Lymphocytic, Acute"
NCT00882206,Vincristine,TREATS(SPEC),Large Cell Lymphoblastic Lymphoma
NCT00882206,pegaspargase,ISA,Pharmacotherapy
NCT00882206,pegaspargase,TREATS(SPEC),"Leukemia, Lymphocytic, Acute"
NCT00882206,pegaspargase,TREATS(SPEC),Large Cell Lymphoblastic Lymphoma
NCT00372619,Cytarabine,TREATS,Patients
NCT00372619,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00372619,clofarabine,ADMINISTERED_TO(SPEC),Patients
NCT00372619,clofarabine,DISRUPTS,Growth
NCT00372619,clofarabine,ISA,Pharmacotherapy
NCT00372619,clofarabine,TREATS,Patients
NCT00372619,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00372619,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00372619,Adverse effects,PROCESS_OF,Patients
NCT00372619,Cytarabine,TREATS,Patients
NCT00372619,cif nucleoside transporter,PART_OF,Human
NCT00372619,clofarabine,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00372619,clofarabine,TREATS,"Leukemia, Myelocytic, Acute"
NCT00372619,Blast Cell,LOCATION_OF,Cytarabine
NCT00372619,Blast Cell,LOCATION_OF,cif nucleoside transporter
NCT00372619,Blast Cell,LOCATION_OF(SPEC),hCNT2
NCT00372619,Blast Cell,LOCATION_OF(SPEC),hCNT3
NCT00372619,Blast Cell,PART_OF,Patients
NCT00372619,Somatic mutation,OCCURS_IN,Patients
NCT00372619,hCNT2,ISA,cif nucleoside transporter
NCT00372619,hCNT2,PART_OF(SPEC),Human
NCT00372619,hCNT3,ISA,cif nucleoside transporter
NCT00372619,hCNT3,PART_OF(SPEC),Human
NCT00372619,Stem cell transplant,TREATS,Patients
NCT00372619,"Leukemia, Lymphocytic, Acute",ISA,Disease
NCT00372619,Cytarabine,ADMINISTERED_TO,Patients
NCT00372619,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00372619,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Physicians
NCT00372619,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00372619,Acute leukemia,PROCESS_OF,Patients
NCT00372619,Methotrexate,ADMINISTERED_TO,Patients
NCT00372619,Bone Marrow,PART_OF,Patients
NCT00372619,Blast Cell,PART_OF,Patients
NCT00372619,Bone Marrow,PART_OF,Patients
NCT00372619,Cytarabine,ADMINISTERED_TO,Patients
NCT00372619,clofarabine,ADMINISTERED_TO,Patients
NCT00372619,Cytarabine,TREATS,Patients
NCT00372619,Cytarabine,TREATS(INFER),leukemia
NCT00372619,leukemia,PROCESS_OF,Patients
NCT00372619,Clolar,ISA,clofarabine
NCT00462787,Dexamethasone,ADMINISTERED_TO,Patients
NCT00462787,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00462787,Combination Drug Therapy,TREATS,Patients
NCT00462787,Thiotepa,ADMINISTERED_TO,Patients
NCT00462787,vinorelbine,ADMINISTERED_TO,Patients
NCT00462787,clofarabine,ADMINISTERED_TO,Patients
NCT00462787,Topotecan,ADMINISTERED_TO,Patients
NCT00462787,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00462787,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00462787,Adverse effects,PROCESS_OF,Patients
NCT00462787,Dexamethasone,TREATS,Patients
NCT00462787,Thiotepa,TREATS,Patients
NCT00462787,Vinorelbine tartrate,TREATS,Patients
NCT00462787,Topotecan Hydrochloride,TREATS,Patients
NCT00462787,Treatment Protocols,TREATS,Patients
NCT00462787,Treatment Protocols,TREATS,Patients
NCT00462787,Stem cell transplant,TREATS,Patients
NCT00462787,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00462787,Filgrastim,ADMINISTERED_TO,Patients
NCT00462787,clofarabine,ADMINISTERED_TO,Patients
NCT00462787,Toxic effect,PROCESS_OF,Patients
NCT00462787,Dexamethasone,TREATS,Patients
NCT00462787,Thiotepa,TREATS,Patients
NCT00462787,vinorelbine,TREATS,Patients
NCT00462787,Topotecan,TREATS,Patients
NCT00083070,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00083070,temozolomide,ADMINISTERED_TO(SPEC),Patients
NCT00083070,temozolomide,DISRUPTS,"Tumor cells, malignant"
NCT00083070,temozolomide,ISA,Pharmacotherapy
NCT00083070,temozolomide,TREATS,Patients
NCT00083070,temozolomide,TREATS,Patients
NCT00083070,Toxic effect,PROCESS_OF,Patients
NCT00083070,Drug Kinetics,PROCESS_OF,Patients
NCT00083070,temozolomide,ADMINISTERED_TO,Patients
NCT00083070,temozolomide,ADMINISTERED_TO,Patients
NCT00083070,leukemia,PROCESS_OF,Patients
NCT00083070,temozolomide,TREATS,Patients
NCT00083070,temozolomide,TREATS(INFER),leukemia
NCT01156883,Combination Drug Therapy,TREATS,Patients
NCT01156883,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01156883,Pharmaceutical Preparations,DISRUPTS,Growth
NCT01156883,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01156883,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT01156883,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01156883,Adverse effects,PROCESS_OF,Patients
NCT01156883,Combination Drug Therapy,TREATS,Patients
NCT01156883,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT01156883,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT01156883,Methylprednisolone,ADMINISTERED_TO(SPEC),Patients
NCT01156883,Methylprednisolone,ISA,Steroids
NCT01156883,Prednisone,ADMINISTERED_TO(SPEC),Patients
NCT01156883,Prednisone,ISA,Steroids
NCT01156883,Steroids,ADMINISTERED_TO,Patients
NCT01156883,Treatment Protocols,TREATS,Patients
NCT01156883,Neoadjuvant Therapy,TREATS,Patients
NCT01156883,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT01156883,Prednisone,ADMINISTERED_TO,Patients
NCT01156883,Vincristine,ADMINISTERED_TO,Patients
NCT01156883,Daunorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT01156883,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT01156883,6-Mercaptopurine,ADMINISTERED_TO,Patients
NCT01156883,Methotrexate,ADMINISTERED_TO,Patients
NCT01156883,Consolidation Therapy,ADMINISTERED_TO,Patients
NCT01156883,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT01156883,Cytarabine,ADMINISTERED_TO,Patients
NCT01156883,Dexamethasone,ADMINISTERED_TO,Patients
NCT01156883,Methotrexate,ADMINISTERED_TO,Patients
NCT01156883,Vincristine,ADMINISTERED_TO,Patients
NCT01156883,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT01156883,Dexamethasone,ADMINISTERED_TO,Patients
NCT01156883,Ifosfamide,ADMINISTERED_TO,Patients
NCT01156883,Methotrexate,ADMINISTERED_TO,Patients
NCT01156883,Vindesine,ADMINISTERED_TO,Patients
NCT01156883,Daunorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT01156883,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT01156883,Cytarabine,ADMINISTERED_TO,Patients
NCT01156883,Dexamethasone,ADMINISTERED_TO,Patients
NCT01156883,ASPARAGINASE,ADMINISTERED_TO,Patients
NCT01156883,Dexamethasone,ADMINISTERED_TO,Patients
NCT01156883,Vincristine,ADMINISTERED_TO,Patients
NCT01156883,Doxorubicin Hydrochloride,ADMINISTERED_TO,Patients
NCT01156883,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT01156883,Cytarabine,ADMINISTERED_TO,Patients
NCT01156883,Thioguanine,ADMINISTERED_TO,Patients
NCT00030108,Pharmaceutical Preparations,DISRUPTS,[M]Unspecified tumor cell NOS
NCT00030108,leukemia,PROCESS_OF,Patients
NCT00030108,Solid tumor,PROCESS_OF,Patients
NCT00030108,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00030108,Adverse effects,PROCESS_OF,Patients
NCT00030108,ixabepilone,TREATS,Patients
NCT00030108,ixabepilone,TREATS(INFER),leukemia
NCT00030108,ixabepilone,TREATS(INFER),Solid tumor
NCT00030108,leukemia,PROCESS_OF,Patients
NCT00030108,Solid tumor,PROCESS_OF,Patients
NCT00030108,Toxic effect,PROCESS_OF,Patients
NCT00030108,Pharmaceutical Preparations,TREATS,Patients
NCT00030108,Pharmaceutical Preparations,TREATS,Patients
NCT00030108,Pharmaceutical Preparations,TREATS,Patients
NCT00030108,Pharmacodynamics,PROCESS_OF,Patients
NCT00030108,leukemia,PROCESS_OF,cohort
NCT00030108,Solid tumor,PROCESS_OF,Adult
NCT00030108,Pharmacodynamics,PROCESS_OF,Patients
NCT00030108,Therapeutic procedure,USES,ixabepilone
NCT00030108,Paclitaxel,AFFECTS,Blast Cell
NCT00030108,ixabepilone,AFFECTS,Blast Cell
NCT00030108,ixabepilone,compared_with,Paclitaxel
NCT00030108,ixabepilone,ADMINISTERED_TO,Patients
NCT00030108,Toxic effect,PROCESS_OF,Patients
NCT00030108,Tumour pain,ISA,Symptoms
NCT00030108,leukemia,PROCESS_OF,Patients
NCT00030108,Solid tumor,PROCESS_OF,Patients
NCT00030108,epothilone B lactam,TREATS,Patients
NCT00030108,epothilone B lactam,TREATS(INFER),leukemia
NCT00030108,epothilone B lactam,TREATS(INFER),Solid tumor
NCT01431664,Vitelliform dystrophy,PROCESS_OF,Patients
NCT01431664,Adverse effects,PROCESS_OF,Patients
NCT01431664,Pharmaceutical Preparations,TREATS,Patients
NCT01431664,Therapeutic procedure,TREATS,Patients
NCT00004932,Growth,PROCESS_OF,Patients
NCT00004932,leukemia,PROCESS_OF,Patients
NCT00004932,STI571,TREATS,Patients
NCT00004932,Imatinib mesylate,DISRUPTS,Growth
NCT00004932,leukemia,PROCESS_OF,Patients
NCT00004932,Toxic effect,PROCESS_OF,Patients
NCT00004932,STI571,ADMINISTERED_TO(SPEC),Patients
NCT00004932,STI571,ISA,Imatinib mesylate
NCT00004932,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00004932,STI571,ADMINISTERED_TO,Patients
NCT00004932,Toxic effect,PROCESS_OF,Patients
NCT00004932,STI571,TREATS,leukemia
NCT00118326,Bone Marrow Transplantation,TREATS,Patients
NCT00118326,Bone Marrow Transplantation,TREATS(INFER),Malignant Neoplasms
NCT00118326,Malignant Neoplasms,PROCESS_OF,Patients
NCT00118326,Granulocyte Colony-Stimulating Factor,ISA,Colony-Stimulating Factors
NCT00118326,Bone Marrow Transplantation,USES,Granulocyte Colony-Stimulating Factor
NCT00118326,Malignant Neoplasms,ISA,Disease
NCT00118326,Malignant Neoplasms,PROCESS_OF,Patients
NCT00118326,Malignant Neoplasms,PROCESS_OF(SPEC),Patients
NCT00118326,Disease,PROCESS_OF,Patients
NCT00118326,Granulocyte Colony-Stimulating Factor,CAUSES,Adverse effects
NCT00118326,Adverse effects,PROCESS_OF,Patients
NCT00118326,Treatment Protocols,TREATS,Patients
NCT00118326,Platelet Transfusion,TREATS,Patients
NCT00118326,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00118326,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00118326,Filgrastim,TREATS,Patients
NCT00118326,Graft acceptance,PROCESS_OF,Patients
NCT00118326,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00118326,Filgrastim,ADMINISTERED_TO,Donor person
NCT00118326,Aspiration of bone marrow from donor for transplant,TREATS,Donor person
NCT00118326,Prophylactic treatment,ADMINISTERED_TO,Patients
NCT00118326,Transplantation Conditioning,ADMINISTERED_TO,Patients
NCT00118326,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00118326,Granulocyte Colony-Stimulating Factor,AUGMENTS,Bone Marrow
NCT00068302,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00068302,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00068302,Adverse effects,PROCESS_OF,Patients
NCT00068302,Toxic effect,PROCESS_OF,Patients
NCT00068302,Pharmaceutical Preparations,TREATS,Patients
NCT00068302,Toxic effect,PROCESS_OF,Patients
NCT01810120,alpha-beta T-Cell Receptor,DISRUPTS,Transplanted tissue
NCT01810120,Infusion procedures,TREATS,Patients
NCT01810120,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT01810120,Leukaemia recurrent,PROCESS_OF,Patients
NCT01810120,Cells,PART_OF,Patients
NCT01810120,Natural Killer Cells,LOCATION_OF,killer immunoglobulin-like receptor
NCT01810120,Hematological Disease,AFFECTS,leukemia
NCT01810120,Transplantation,TREATS,Adult
NCT01810120,Hematopoietic Stem Cell Transplantation,ADMINISTERED_TO,Patients
NCT01810120,Hematopoietic Stem Cell Transplantation,METHOD_OF,Therapeutic procedure
NCT01810120,Hematological Disease,AFFECTS,Patients
NCT01810120,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Transplantation,PRECEDES,Infusion procedures
NCT00281879,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00281879,Transplantation,TREATS,Patients
NCT00281879,Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00281879,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00281879,Toxic effect,PROCESS_OF,Patients
NCT00281879,Graft Rejection,PROCESS_OF,Patients
NCT00281879,Graft acceptance,PROCESS_OF,Patients
NCT00281879,Hematopoietic Neoplasms,PROCESS_OF,Patients
NCT00281879,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00281879,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00281879,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00281879,Disease recurrence,PROCESS_OF,Patients
NCT00281879,Donor leukocyte infusion,TREATS,Patients
NCT00281879,Donor leukocyte infusion,TREATS(INFER),Disease recurrence
NCT00281879,Whole-Body Irradiation,TREATS,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00281879,Filgrastim,ADMINISTERED_TO,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Whole-Body Irradiation,TREATS,Patients
NCT00281879,Cystitis,PROCESS_OF,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Cord Blood Stem Cell Transplantation,TREATS,Patients
NCT00281879,Graft-vs-Host Disease,NEG_PROCESS_OF,Patients
NCT00281879,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00281879,Whole-Body Irradiation,TREATS,Patients
NCT00281879,Stem cell transplant,TREATS,Patients
NCT00281879,Treatment Protocols,NEG_ADMINISTERED_TO,Patients
NCT00281879,Transplantation,TREATS,Hematologic Neoplasms
NCT00949117,Body Weight decreased,PROCESS_OF,Patients
NCT00949117,Cyproheptadine hydrochloride,AFFECTS,Desire for food
NCT00949117,Cyproheptadine hydrochloride,TREATS,Patients
NCT00949117,Cyproheptadine hydrochloride,TREATS(INFER),Body Weight decreased
NCT00949117,Cancer Treatment,AFFECTS,Desire for food
NCT00949117,Malignant Neoplasms,NEG_PROCESS_OF,Patients
NCT00949117,Body Weight decreased,PROCESS_OF,Patients
NCT00949117,Body Weight Changes,PROCESS_OF,Patients
NCT00949117,Malignant Neoplasms,PROCESS_OF,Patients
NCT00949117,Treatment Protocols,TREATS,Patients
NCT00949117,Treatment Protocols,TREATS(INFER),Malignant Neoplasms
NCT00949117,Therapeutic procedure,TREATS,Cachexia
NCT00949117,Dietary Supplementation,TREATS,Patients
NCT00949117,Dietary Supplementation,TREATS(INFER),Malignant Neoplasms
NCT00949117,Dietary Supplementation,compared_with,Treatment Protocols
NCT00949117,Cyproheptadine hydrochloride,TREATS,Patients
NCT00949117,Cyproheptadine hydrochloride,ADMINISTERED_TO,Patients
NCT00949117,Lean body mass,ISA,Body Composition
NCT00949117,Assessment procedure,TREATS,Patients
NCT00949117,Body Weight decreased,PROCESS_OF,Child
NCT00949117,Cyproheptadine hydrochloride,NEG_TREATS,Child
NCT00949117,Cyproheptadine hydrochloride,NEG_TREATS(INFER),Body Weight decreased
NCT00544115,Disease,PROCESS_OF,Patients
NCT00544115,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00544115,Bone Marrow,PART_OF,Patients
NCT00544115,Disease,ISA,Hematologic Neoplasms
NCT00544115,Disease,PROCESS_OF,Patients
NCT00544115,Disease,PROCESS_OF(SPEC),Patients
NCT00544115,Hematologic Neoplasms,ISA,Disease
NCT00544115,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00544115,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00544115,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00544115,Disease,ISA,Graft-vs-Host Disease
NCT00544115,Disease,ISA,Hematologic Neoplasms
NCT00544115,Disease,PROCESS_OF,Patients
NCT00544115,Disease,PROCESS_OF(SPEC),Patients
NCT00544115,Peripheral Stem Cell Transplantation,TREATS,Disease
NCT00544115,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00544115,Peripheral Stem Cell Transplantation,TREATS,Hematologic Neoplasms
NCT00544115,Peripheral Stem Cell Transplantation,TREATS(INFER),Disease
NCT00544115,Peripheral Stem Cell Transplantation,TREATS(INFER),Chronic graft-versus-host disease
NCT00544115,Peripheral Stem Cell Transplantation,TREATS(SPEC),Disease
NCT00544115,Peripheral Stem Cell Transplantation,TREATS(SPEC),Hematologic Neoplasms
NCT00544115,Graft acceptance,PROCESS_OF,Patients
NCT00544115,Hematologic Neoplasms,ISA,Disease
NCT00544115,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00544115,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00544115,Chronic graft-versus-host disease,ISA,Graft-vs-Host Disease
NCT00544115,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00544115,Whole-Body Irradiation,TREATS,Patients
NCT00544115,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00544115,Whole-Body Irradiation,TREATS,Patients
NCT00544115,Whole-Body Irradiation,TREATS,Patients
NCT00544115,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00544115,Hematological Disease,PROCESS_OF,Patients
NCT00544115,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00544115,Peripheral Stem Cell Transplantation,TREATS(INFER),Hematological Disease
NCT00544115,Peripheral Stem Cell Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00544115,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00544466,Melphalan,DISRUPTS,Growth
NCT00544466,Fludarabine phosphate,DISRUPTS,Growth
NCT00544466,Fludarabine phosphate,ISA,Pharmaceutical Preparations
NCT00544466,Stem cell transplant,TREATS,Patients
NCT00544466,Bone Marrow,PART_OF,Patients
NCT00544466,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00544466,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00544466,Treatment Protocols,METHOD_OF,Stem cell transplant
NCT00544466,Fludarabine phosphate,ISA,fludarabine
NCT00544466,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00544466,Toxic effect,PROCESS_OF,Patients
NCT00544466,Graft acceptance,PROCESS_OF,Patients
NCT00544466,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00544466,Liver,LOCATION_OF,Venoocclusive disease
NCT00544466,Melphalan,ADMINISTERED_TO,Patients
NCT00544466,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00544466,Organ,LOCATION_OF,Toxic effect
NCT00544466,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00544466,Therapeutic procedure,TREATS,Patients
NCT00544466,Prophylactic treatment,USES,Tacrolimus
NCT00544466,Melphalan,ASSOCIATED_WITH,Hematologic Neoplasms
NCT00005606,"Herpesvirus 4, Human",CAUSES,Lymphoproliferative Disorders
NCT00005606,"Herpesvirus 4, Human",PROCESS_OF,Patients
NCT00005606,Epstein-Barr Virus Infections,PROCESS_OF,Patients
NCT00005606,peripheral blood lymphocyte therapy,ISA,Therapeutic procedure
NCT00005606,peripheral blood lymphocyte therapy,ISA,Prophylactic treatment
NCT00005606,peripheral blood lymphocyte therapy,PREVENTS,Lymphoproliferative Disorders
NCT00005606,peripheral blood lymphocyte therapy,PREVENTS,Epstein-Barr Virus Infections
NCT00005606,peripheral blood lymphocyte therapy,TREATS,Patients
NCT00005606,peripheral blood lymphocyte therapy,TREATS(INFER),Epstein-Barr Virus Infections
NCT00005606,Solid organ transplant,TREATS,Patients
NCT00005606,allogeneic lymphocytes,TREATS,Patients
NCT00005606,Viremia,PROCESS_OF,"Herpesvirus 4, Human"
NCT00005606,Viremia,PROCESS_OF,Patients
NCT00005606,Therapeutic procedure,TREATS,Patients
NCT00005606,Therapeutic procedure,TREATS(INFER),Viremia
NCT00005606,Prophylactic treatment,TREATS,Patients
NCT00005606,Prophylactic treatment,TREATS(INFER),Viremia
NCT00005606,Viremia,PROCESS_OF,"Herpesvirus 4, Human"
NCT00005606,Viremia,PROCESS_OF,Patients
NCT00005606,allogeneic lymphocytes,ADMINISTERED_TO,Patients
NCT00005606,Viremia,PROCESS_OF,"Herpesvirus 4, Human"
NCT00005606,"Herpesvirus 4, Human",CAUSES,Disease
NCT00089037,Methotrexate,TREATS,Acute graft-versus-host disease
NCT00089037,Tacrolimus,TREATS,Acute graft-versus-host disease
NCT00089037,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00089037,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00089037,Adverse effects,COEXISTS_WITH,Acute graft-versus-host disease
NCT00089037,Stem cell transplant,TREATS,Patients
NCT00089037,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00089037,Stem cell transplant,TREATS(INFER),Acute graft-versus-host disease
NCT00089037,Methotrexate,PREVENTS,Acute graft-versus-host disease
NCT00089037,Drug Kinetics,PROCESS_OF,Patients
NCT00089037,Treatment Protocols,TREATS,Patients
NCT00089037,Tacrolimus,PREVENTS,Acute graft-versus-host disease
NCT00089037,Hematopoietic Stem Cell Transplantation,TREATS,Hematologic Neoplasms
NCT00089037,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00089037,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00089037,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00089037,Treatment Protocols,TREATS,Patients
NCT00089037,Treatment Protocols,TREATS(INFER),Graft-vs-Host Disease
NCT00089037,Treatment Protocols,TREATS(INFER),Toxic effect
NCT00089037,Toxic effect,PROCESS_OF,Patients
NCT00089037,Mucositis,PROCESS_OF,Patients
NCT00089037,host,LOCATION_OF,Disease
NCT00089037,Methotrexate,PREVENTS,Acute graft-versus-host disease
NCT00089037,Tacrolimus,PREVENTS,Acute graft-versus-host disease
NCT00089037,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00089037,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Acute graft-versus-host disease
NCT00089037,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00066599,Pharmacotherapy,TREATS,Aplastic Anemia
NCT00066599,Pharmacotherapy,TREATS,leukemia
NCT00066599,Pharmacotherapy,TREATS,Lymphoma
NCT00066599,Mycoses,PROCESS_OF,Child
NCT00066599,Neutropenia,PROCESS_OF,Child
NCT00066599,voriconazole,TREATS,Systemic mycosis
NCT00066599,Systemic mycosis,PROCESS_OF,Child
NCT00066599,Pharmacotherapy,PRECEDES,Prophylactic treatment
NCT00066599,Neutropenia,PROCESS_OF,Patients
NCT00066599,Systemic mycosis,PROCESS_OF,Patients
NCT00066599,Pharmaceutical Preparations,ADMINISTERED_TO,Patients
NCT00066599,Treatment Protocols,TREATS,cohort
NCT00066599,voriconazole,ADMINISTERED_TO,Patients
NCT00066599,Drug Kinetics,PROCESS_OF,"Child, Hospitalized"
NCT00066599,Therapeutic procedure,PREVENTS,Systemic mycosis
NCT00066248,Cachexia,PROCESS_OF,Child
NCT00066248,Cyproheptadine,AFFECTS,Desire for food
NCT00066248,Cyproheptadine,TREATS,Body Weight decreased
NCT00066248,Megestrol,TREATS,Body Weight decreased
NCT00066248,Body Weight decreased,PROCESS_OF,Child
NCT00066248,Cachexia,PROCESS_OF,Child
NCT00066248,Malignant Neoplasms,PROCESS_OF,Child
NCT00066248,Cyproheptadine,TREATS,Body Weight decreased
NCT00066248,Body Weight decreased,PROCESS_OF,Child
NCT00066248,Megestrol,TREATS,Body Weight decreased
NCT00066248,Body Weight decreased,PROCESS_OF,Patients
NCT00066248,Cyproheptadine,ADMINISTERED_TO,Patients
NCT00066248,Body Weight decreased,PROCESS_OF,Patients
NCT00066248,Cachexia,PROCESS_OF,Child
NCT00066248,Periactin,ISA,Cyproheptadine hydrochloride
NCT00066248,Periactin,TREATS,Child
NCT00066248,Periactin,TREATS(INFER),Cachexia
NCT00066248,Megestrol Acetate,TREATS,Child
NCT00055653,Pharmacotherapy,METHOD_OF,umbilical cord blood transplantation
NCT00055653,leukemia,PROCESS_OF,Patients
NCT00055653,Lymphoma,PROCESS_OF,Patients
NCT00055653,Radiation therapy,METHOD_OF,umbilical cord blood transplantation
NCT00055653,umbilical cord blood transplantation,TREATS,Patients
NCT00055653,umbilical cord blood transplantation,TREATS(INFER),leukemia
NCT00055653,umbilical cord blood transplantation,TREATS(INFER),Lymphoma
NCT00055653,umbilical cord blood transplantation,TREATS(INFER),Non-Neoplastic Hematologic and Lymphocytic Disorder
NCT00055653,Non-Neoplastic Hematologic and Lymphocytic Disorder,PROCESS_OF,Patients
NCT00055653,umbilical cord blood transplantation,TREATS,Hematological Disease
NCT00055653,Treatment Protocols,TREATS,Patients
NCT00055653,Treatment Protocols,TREATS,Patients
NCT00055653,Graft acceptance,PROCESS_OF,Patients
NCT00055653,Treatment Protocols,TREATS,Patients
NCT00055653,Treatment Protocols,TREATS(INFER),Chronic graft-versus-host disease
NCT00055653,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00055653,Treatment Protocols,TREATS,Patients
NCT00055653,"Pneumonitis, Interstitial",OCCURS_IN,Patients
NCT00055653,Venoocclusive disease,OCCURS_IN,Patients
NCT00055653,Malignant Neoplasms,OCCURS_IN,Patients
NCT00055653,Lymphoproliferative Disorders,OCCURS_IN,Patients
NCT00055653,Dysmyelopoietic Syndromes,OCCURS_IN,Patients
NCT00055653,Treatment Protocols,TREATS,Patients
NCT00055653,Whole-Body Irradiation,TREATS,Patients
NCT00055653,Whole-Body Irradiation,TREATS,Patients
NCT00055653,Behavior Therapy,ADMINISTERED_TO,Patients
NCT00055653,Etoposide,ADMINISTERED_TO,Patients
NCT00055653,"Histiocytosis, Langerhans-Cell",PROCESS_OF,Patients
NCT00055653,Familial Hemophagocytic Lymphocytosis,PROCESS_OF,Patients
NCT00055653,Antithymoglobulin,TREATS,Patients
NCT00055653,Antithymoglobulin,TREATS(INFER),leukemia
NCT00055653,leukemia,PROCESS_OF,Patients
NCT00055653,Methylprednisolone,TREATS,Patients
NCT00055653,Methylprednisolone,TREATS(INFER),leukemia
NCT00055653,Treatment Protocols,TREATS,Patients
NCT00055653,Treatment Protocols,TREATS(INFER),leukemia
NCT00055653,umbilical cord blood transplantation,TREATS,Patients
NCT00055653,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00055653,Filgrastim,ADMINISTERED_TO,Patients
NCT00055653,Cyclosporine,ADMINISTERED_TO,Patients
NCT00055653,Transplantation,PRECEDES,Prophylactic treatment
NCT00045292,Cytomegalovirus Infections,PROCESS_OF,Patients
NCT00045292,Cytomegalovirus,LOCATION_OF,valacyclovir
NCT00045292,valacyclovir,ISA,Antiviral Agents
NCT00045292,Cytomegalovirus,LOCATION_OF,valacyclovir
NCT00045292,Cytomegalovirus,PROCESS_OF,Patients
NCT00045292,Stem cell transplant,TREATS,Patients
NCT00045292,Bacterial Infections,PROCESS_OF,Patients
NCT00045292,valacyclovir,ADMINISTERED_TO,Patients
NCT00045292,Stem cell transplant,ADMINISTERED_TO,Patients
NCT00045292,Stem cell transplant,compared_with,valacyclovir
NCT00045292,Transplantation,TREATS,Patients
NCT00045292,Transplantation,TREATS(INFER),Primary infection NOS
NCT00045292,Transplantation,compared_with,Treatment Protocols
NCT00045292,Treatment Protocols,TREATS,Patients
NCT00045292,Treatment Protocols,TREATS(INFER),Primary infection NOS
NCT00045292,Primary infection NOS,PROCESS_OF,Cytomegalovirus
NCT00045292,Primary infection NOS,PROCESS_OF,Patients
NCT00045292,Disease,PROCESS_OF,Cytomegalovirus
NCT00045292,Disease,PROCESS_OF,Patients
NCT00045292,Transplantation,TREATS,Patients
NCT00045292,Transplantation,TREATS(INFER),Disease
NCT00045292,Transplantation,compared_with,Treatment Protocols
NCT00045292,Treatment Protocols,TREATS,Patients
NCT00045292,Treatment Protocols,TREATS(INFER),Disease
NCT00045292,Treatment Protocols,TREATS,Patients
NCT00045292,Stem cells,LOCATION_OF,Cytomegalovirus
NCT00045292,transplantation infection,PROCESS_OF,Cytomegalovirus
NCT00045292,transplantation infection,PROCESS_OF,Patients
NCT00045292,Subclinical infection,PROCESS_OF,Cytomegalovirus
NCT00045292,Subclinical infection,PROCESS_OF,specific immunity
NCT00045292,specific immunity,PROCESS_OF,Virus
NCT00045292,Treatment Protocols,TREATS,Patients
NCT00045292,Microbicides,compared_with,Filgrastim
NCT00045292,Transplantation Conditioning,ADMINISTERED_TO,Patients
NCT00045292,Acyclovir,ADMINISTERED_TO,Patients
NCT00045292,valacyclovir,ADMINISTERED_TO(SPEC),Patients
NCT00045292,valacyclovir,ISA,Acyclovir
NCT00045292,Upper Extremity,LOCATION_OF,Placebos
NCT00045292,Prophylactic treatment,USES,valacyclovir
NCT00045292,Cytomegalovirus prophylaxis,USES,valacyclovir
NCT00100152,Lymphoma,PROCESS_OF,Patients
NCT00112567,Blood,LOCATION_OF,Thiotepa
NCT00112567,Bone Marrow,LOCATION_OF,Thiotepa
NCT00112567,Thiotepa,TREATS,Patients
NCT00112567,Whole-Body Irradiation,TREATS,Patients
NCT00112567,fludarabine,ISA,Pharmacotherapy
NCT00112567,fludarabine,TREATS,Patients
NCT00112567,Stem cell transplant,TREATS,Patients
NCT00112567,Blood,PART_OF,Patients
NCT00112567,Bone Marrow,PART_OF,Patients
NCT00112567,Adverse effects,PROCESS_OF,Patients
NCT00112567,Stem cell transplant,TREATS,Patients
NCT00112567,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00112567,Stem cell transplant,TREATS(INFER),Adverse effects
NCT00112567,Disease,PROCESS_OF,Patients
NCT00112567,Treatment Protocols,TREATS,Patients
NCT00112567,Treatment Protocols,TREATS(INFER),Disease
NCT00112567,Peripheral Stem Cell Transplantation,METHOD_OF,Whole-Body Irradiation
NCT00112567,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00112567,host,LOCATION_OF,Disease
NCT00112567,Treatment Protocols,TREATS,Patients
NCT00112567,Infection,PROCESS_OF,Patients
NCT00112567,Whole-Body Irradiation,TREATS,Age
NCT00112567,Whole-Body Irradiation,TREATS,Age
NCT00112567,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00112567,CNS disorder,PROCESS_OF,Patients
NCT00112567,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00112567,Methotrexate,ADMINISTERED_TO,Patients
NCT00112567,Radiation therapy,TREATS,Patients
NCT00112567,Radiation therapy,TREATS(INFER),Malignant lymphoid neoplasm
NCT00112567,Malignant lymphoid neoplasm,PROCESS_OF,Patients
NCT00301860,Stem cell transplant,TREATS,Patients
NCT00301860,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00301860,Bone Marrow,PART_OF,Patients
NCT00301860,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00301860,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00301860,Treatment Protocols,TREATS,Complication
NCT00301860,Hematopoietic Neoplasms,PROCESS_OF,Patients
NCT00301860,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00301860,Treatment Protocols,TREATS,Patients
NCT00301860,Treatment Protocols,TREATS(INFER),Transplanted organ and tissue status
NCT00301860,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00301860,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00301860,Toxic effect,PROCESS_OF,Patients
NCT00301860,host,LOCATION_OF,Disease
NCT00301860,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00301860,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00301860,Filgrastim,ADMINISTERED_TO,Patients
NCT00301860,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00301860,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00301860,Donor Lymphocyte Infusion,METHOD_OF,Hematopoietic Stem Cell Transplantation
NCT00301860,Donor Lymphocyte Infusion,TREATS,Child
NCT00324779,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
NCT00324779,Pharmacotherapy,TREATS,B-Cell Lymphomas
NCT00324779,rituximab,AFFECTS,Growth
NCT00324779,rituximab,ISA,Monoclonal Antibodies
NCT00324779,rituximab,ISA,Pharmacotherapy
NCT00324779,rituximab,TREATS(SPEC),"Leukemia, B-Cell, Acute"
NCT00324779,rituximab,TREATS(SPEC),B-Cell Lymphomas
NCT00324779,rituximab,TREATS,Patients
NCT00324779,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
NCT00324779,Pharmacotherapy,TREATS,B-Cell Lymphomas
NCT00324779,rituximab,ISA,Therapeutic procedure
NCT00324779,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
NCT00324779,"Leukemia, B-Cell, Acute",PROCESS_OF,Adolescent
NCT00324779,B-Cell Lymphomas,PROCESS_OF,Child
NCT00324779,B-Cell Lymphomas,PROCESS_OF,Adolescent
NCT00324779,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00324779,Treatment Protocols,TREATS,Patients
NCT00324779,Treatment Protocols,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT00324779,Treatment Protocols,TREATS(INFER),Mature B-Cell Non-Hodgkin's Lymphoma
NCT00324779,Mature B-Cell Non-Hodgkin's Lymphoma,PROCESS_OF,Patients
NCT00324779,Treatment Protocols,TREATS,Patients
NCT00324779,rituximab,TREATS,Patients
NCT00324779,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
NCT00324779,Mature B-Cell Non-Hodgkin's Lymphoma,PROCESS_OF,Child
NCT00005988,Bone Marrow Transplantation,TREATS,Patients
NCT00005988,Bone Marrow Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00005988,Pharmacotherapy,METHOD_OF,Bone Marrow Transplantation
NCT00005988,Radiation therapy,METHOD_OF,Bone Marrow Transplantation
NCT00005988,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00005988,Bone Marrow Transplantation,TREATS,Patients
NCT00005988,Bone Marrow Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00005988,Leukocytes,PART_OF,Bone Marrow
NCT00005988,Leukocytes,PART_OF,Patients
NCT00005988,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00005988,"Antibodies, Anti-Idiotypic",PART_OF,Bone Marrow
NCT00005988,Pancytopenia,PROCESS_OF,Patients
NCT00005988,Graft acceptance,PROCESS_OF,Patients
NCT00005988,Refractory Hematologic Malignancy,PROCESS_OF,Patients
NCT00005988,Treatment Protocols,TREATS,Graft-vs-Host Disease
NCT00005988,Leukapheresis,TREATS,Patients
NCT00005988,Whole-Body Irradiation,ADMINISTERED_TO,Patients
NCT00005988,Bone Marrow,PART_OF,Patients
NCT00005988,"Antibodies, Anti-Idiotypic",PART_OF,Bone Marrow
NCT00005988,IDEC-114 monoclonal antibody,PART_OF,Bone Marrow
NCT00004255,Bone Marrow Transplantation,TREATS,Graft-vs-Host Disease
NCT00004255,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00004255,Therapeutic procedure,PREVENTS,Graft-vs-Host Disease
NCT00004255,Therapeutic procedure,PREVENTS,Chronic leukemia (category)
NCT00004255,Chronic leukemia (category),PROCESS_OF,Patients
NCT00004255,Bone Marrow Transplantation,TREATS,Graft-vs-Host Disease
NCT00004255,Bone Marrow Transplantation,TREATS,Dysmyelopoietic Syndromes
NCT00004255,Bone Marrow Transplantation,TREATS,Chronic leukemia (category)
NCT00004255,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00004255,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00004255,Chronic leukemia (category),PROCESS_OF,Patients
NCT00004255,Treatment Protocols,TREATS,Patients
NCT00004255,Treatment Protocols,TREATS,Patients
NCT00004255,Treatment Protocols,TREATS,Patients
NCT00004255,Graft acceptance,PROCESS_OF,Patients
NCT00004255,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00004255,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00004255,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00014469,Bone Marrow Transplantation,METHOD_OF,Combination Drug Therapy
NCT00014469,Bone Marrow Transplantation,TREATS,Patients
NCT00014469,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00014469,Bone Marrow Transplantation,METHOD_OF,Chemotherapy-Oncologic Procedure
NCT00014469,Bone Marrow Transplantation,TREATS,Patients
NCT00014469,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00014469,Treatment Protocols,TREATS,Patients
NCT00014469,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00014469,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00014469,Allogeneic bone marrow transplantation,METHOD_OF,Therapeutic procedure
NCT00014469,Busulfex,ISA,Busulfan
NCT00002757,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT00002757,Therapeutic procedure,TREATS,Child
NCT00002757,Therapeutic procedure,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT00002757,Cyclophosphamide,INHIBITS,Methotrexate
NCT00002757,leukemia,PROCESS_OF,Patients
NCT00002757,Treatment Protocols,TREATS,leukemia
NCT00002757,Treatment Protocols,TREATS,Patients
NCT00002757,CNS metastases,PROCESS_OF,Patients
NCT00002757,Patients,USES,Group C
NCT00002757,CNS metastases,PROCESS_OF,Patients
NCT00002757,Cells,PART_OF,Patients
NCT00002757,Toxic effect,PROCESS_OF,Patients
NCT00002757,Mature B-Lymphocyte,LOCATION_OF,Childhood Lymphoma
NCT00002757,Patients,USES,Group C
NCT00002757,Bone Marrow,LOCATION_OF,CNS disorder
NCT00002757,CNS metastases,PROCESS_OF,Patients
NCT00002757,Ara-C,ISA,Cytarabine
NCT00002757,Disease,PROCESS_OF,Patients
NCT00002757,Methotrexate,ADMINISTERED_TO,Patients
NCT00002757,Cymer,ADMINISTERED_TO,Patients
NCT00002757,Upper Extremity,LOCATION_OF,Methotrexate
NCT00002757,Cymer,ADMINISTERED_TO,Patients
NCT00002757,Methotrexate,ADMINISTERED_TO,Patients
NCT00002757,Cymer,ADMINISTERED_TO,Patients
NCT00002757,Methotrexate,ADMINISTERED_TO,Patients
NCT00002757,Methotrexate,ADMINISTERED_TO,Patients
NCT00002757,Cymer,ADMINISTERED_TO,Patients
NCT00002757,Maintenance therapy,ADMINISTERED_TO,Patients
NCT00002757,CNS disorder,PROCESS_OF,Patients
NCT00002757,Ara-C,TREATS,Maximum
NCT00002757,In complete remission,PROCESS_OF,Patients
NCT00002757,Methotrexate,ADMINISTERED_TO,Patients
NCT00002757,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00002757,CNS disorder,PROCESS_OF,Patients
NCT00002757,Upper Extremity,LOCATION_OF,Methotrexate
NCT00002757,In complete remission,PROCESS_OF,Patients
NCT00002757,Patients,USES,Group C
NCT00914940,Therapeutic procedure,TREATS,Dysmyelopoietic Syndromes
NCT00914940,Therapeutic procedure,TREATS,Acute leukemia
NCT00914940,Prophylactic treatment,ISA,Therapeutic procedure
NCT00914940,Prophylactic treatment,TREATS(SPEC),Dysmyelopoietic Syndromes
NCT00914940,Prophylactic treatment,TREATS(SPEC),Acute leukemia
NCT00914940,Bone Marrow,PART_OF,Patients
NCT00914940,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00914940,Whole-Body Irradiation,ADMINISTERED_TO,Patients
NCT00914940,Infection,PROCESS_OF,Patients
NCT00914940,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00914940,Acute leukemia,PROCESS_OF,Patients
NCT00914940,host,LOCATION_OF,Disease
NCT00914940,Disease,PROCESS_OF,Patients
NCT00914940,Graft-vs-Host Disease,ISA,Disease
NCT00914940,Graft-vs-Host Disease,PROCESS_OF(SPEC),Patients
NCT00914940,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00914940,Acute leukemia,PROCESS_OF,Patients
NCT00914940,Peripheral Stem Cell Transplantation,TREATS,Dysmyelopoietic Syndromes
NCT00914940,Peripheral Stem Cell Transplantation,TREATS,Acute leukemia
NCT00914940,host,LOCATION_OF,Disease
NCT00914940,host,LOCATION_OF(SPEC),Graft-vs-Host Disease
NCT00914940,Whole-Body Irradiation,TREATS,Patients
NCT00914940,Graft-vs-Host Disease,ISA,Disease
NCT00914940,Tacrolimus,ADMINISTERED_TO,Patients
NCT00914940,host,LOCATION_OF,Disease
NCT00914940,host,LOCATION_OF(SPEC),Graft-vs-Host Disease
NCT00914940,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00006379,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00006379,Aplastic Anemia,PROCESS_OF,Patients
NCT00006379,Pharmacotherapy,METHOD_OF,Peripheral Stem Cell Transplantation
NCT00006379,Peripheral Stem Cell Transplantation,METHOD_OF,Combination Drug Therapy
NCT00006379,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00006379,Peripheral Stem Cell Transplantation,TREATS(INFER),Aplastic Anemia
NCT00006379,Peripheral Stem Cell Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00006379,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00006379,anemia; profound,PROCESS_OF,Patients
NCT00006379,Graft acceptance,PROCESS_OF,Patients
NCT00006379,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00006379,Treatment Protocols,TREATS,Patients
NCT00006379,Treatment Protocols,TREATS,Patients
NCT00006379,Treatment Protocols,TREATS(INFER),Chronic graft-versus-host disease
NCT00006379,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00006379,Treatment Protocols,TREATS,Patients
NCT00006379,Filgrastim,TREATS,Patients
NCT00006379,Stem cell transplant,TREATS,anemia; profound
NCT00006379,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00006348,Nausea,PROCESS_OF,Patients
NCT00006348,Placebos,PREVENTS,Nausea
NCT00006348,Placebos,TREATS,Patients
NCT00006348,Placebos,TREATS(INFER),Advanced cancer
NCT00006348,Vomiting,PROCESS_OF,Patients
NCT00006348,Ondansetron,ISA,Antiemetics
NCT00006348,Ondansetron,compared_with,Placebos
NCT00006348,Ondansetron,PREVENTS,Nausea
NCT00006348,Ondansetron,TREATS,Patients
NCT00006348,Ondansetron,TREATS(INFER),Nausea
NCT00006348,Ondansetron,TREATS(INFER),Vomiting
NCT00006348,Ondansetron,TREATS(INFER),Advanced cancer
NCT00006348,Advanced cancer,PROCESS_OF,Patients
NCT00006348,Pharmacotherapy,ISA,Therapeutic procedure
NCT00006348,Ondansetron,compared_with,Placebos
NCT00006348,Advanced cancer,PROCESS_OF,Patients
NCT00006348,Antiemetic Effect,PROCESS_OF,Patients
NCT00006348,Toxic effect,PROCESS_OF,Patients
NCT00006348,Antiemetics,TREATS,Patients
NCT00006348,Creatinine,compared_with,Creatinine
NCT00006348,Placebos,ADMINISTERED_TO,Patients
NCT00006348,Ondansetron,ADMINISTERED_TO,Patients
NCT00006348,Placebos,ADMINISTERED_TO,Patients
NCT00006348,Ondansetron,ADMINISTERED_TO,Patients
NCT00006348,Ondansetron,TREATS,Nausea
NCT00006348,Ondansetron,TREATS,Vomiting
NCT00006348,Therapeutic procedure,TREATS,Patients
NCT00006348,Therapeutic procedure,TREATS(INFER),Advanced cancer
NCT00006348,Advanced cancer,PROCESS_OF,Patients
NCT00005892,Cyclophosphamide,TREATS,Patients
NCT00005892,Cyclophosphamide,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00005892,Cyclophosphamide,TREATS(INFER),Acute leukemia
NCT00005892,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00005892,Radiation therapy,TREATS,Patients
NCT00005892,Radiation therapy,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00005892,Radiation therapy,TREATS(INFER),Acute leukemia
NCT00005892,Acute leukemia,PROCESS_OF,Patients
NCT00005892,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00005892,Acute leukemia,PROCESS_OF,Patients
NCT00005892,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00005892,Allogeneic bone marrow transplantation,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00005892,Allogeneic bone marrow transplantation,TREATS(INFER),Acute leukemia
NCT00005892,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00450983,Hematological Disease,PROCESS_OF,Patients
NCT00450983,leukemia,PROCESS_OF,Patients
NCT00450983,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00450983,Bone Marrow,PART_OF,Patients
NCT00450983,Hematological Disease,ISA,leukemia
NCT00450983,Hematological Disease,PROCESS_OF,Patients
NCT00450983,Hematological Disease,PROCESS_OF(SPEC),Patients
NCT00450983,leukemia,ISA,Hematological Disease
NCT00450983,leukemia,PROCESS_OF,Patients
NCT00450983,leukemia,PROCESS_OF(SPEC),Patients
NCT00450983,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00450983,Disease,PROCESS_OF,Patients
NCT00450983,Hematological Disease,PROCESS_OF,Patients
NCT00450983,leukemia,PROCESS_OF,Patients
NCT00450983,Treatment Protocols,TREATS,Patients
NCT00450983,host,LOCATION_OF,Disease
NCT00450983,Graft Rejection,PROCESS_OF,Patients
NCT00450983,Treatment Protocols,TREATS,Patients
NCT00450983,Infection,PROCESS_OF,Patients
NCT00450983,Treatment Protocols,TREATS,Patients
NCT00450983,Treatment Protocols,TREATS(INFER),Infection
NCT00450983,Immunoglobulins,PART_OF,Killer Cells
NCT00450983,Whole-Body Irradiation,TREATS,Age
NCT00450983,Whole-Body Irradiation,TREATS,Age
NCT00450983,leukemia,PROCESS_OF,Patients
NCT00450983,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00450983,Methotrexate,ADMINISTERED_TO,Patients
NCT00450983,Immunoglobulins,PART_OF,Killer Cells
NCT00253513,Pharmaceutical Preparations,DISRUPTS,Cells
NCT00253513,fludarabine,TREATS,Patients
NCT00253513,treosulfan,DISRUPTS,Growth
NCT00253513,treosulfan,ISA,Pharmacotherapy
NCT00253513,treosulfan,TREATS,Patients
NCT00253513,Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00253513,Stem cell transplant,TREATS,"Leukemia, Myelocytic, Acute"
NCT00253513,Stem cell transplant,TREATS,Dysmyelopoietic Syndromes
NCT00253513,Stem cell transplant,TREATS,Patients
NCT00253513,Bone Marrow Transplantation,ISA,Therapeutic procedure
NCT00253513,fludarabine,TREATS,Patients
NCT00253513,treosulfan,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00253513,treosulfan,TREATS,"Leukemia, Myelocytic, Acute"
NCT00253513,treosulfan,TREATS,Dysmyelopoietic Syndromes
NCT00253513,Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00253513,Stem cell transplant,TREATS,"Leukemia, Myelocytic, Acute"
NCT00253513,Stem cell transplant,TREATS,Dysmyelopoietic Syndromes
NCT00253513,Stem cell transplant,TREATS,Patients
NCT00253513,Lymphoblastic Leukemia,OCCURS_IN,Patients
NCT00253513,"Leukemia, Myelocytic, Acute",OCCURS_IN,Patients
NCT00253513,Dysmyelopoietic Syndromes,OCCURS_IN,Patients
NCT00253513,fludarabine,DISRUPTS,Toxic effect
NCT00253513,Hematopoietic Stem Cell Transplantation,METHOD_OF,Treatment Protocols
NCT00253513,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00253513,Treatment Protocols,TREATS,Patients
NCT00253513,treosulfan,TREATS,Patients
NCT00253513,Toxic effect,PROCESS_OF,Patients
NCT00253513,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00253513,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00253513,Teleradiotherapy procedure,ADMINISTERED_TO,Patients
NCT00253513,Treatment Protocols,USES,fludarabine
NCT00253513,Treatment Protocols,USES,treosulfan
NCT00253513,Acute leukemia,PROCESS_OF,Patients
NCT00253513,Cell Transplantation,TREATS,Patients
NCT00253513,Cell Transplantation,TREATS(INFER),Acute leukemia
NCT00253513,Cell Transplantation,USES,fludarabine
NCT00253513,Cell Transplantation,USES,treosulfan
NCT00996359,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00996359,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00996359,Whole-Body Irradiation,PRECEDES,Stem cell transplant
NCT00996359,Adverse effects,PROCESS_OF,Patients
NCT00996359,Refractory Hematologic Malignancy,PROCESS_OF,Patients
NCT00996359,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00996359,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00996359,Transplantation,PRECEDES,Therapeutic procedure
NCT00996359,Transplantation,PRECEDES,Cell Therapy
NCT00996359,Whole-Body Irradiation,PRECEDES,Therapeutic procedure
NCT00996359,Whole-Body Irradiation,PRECEDES,Cell Therapy
NCT00996359,Whole-Body Irradiation,TREATS,Patients
NCT00996359,Toxic effect,PROCESS_OF,Patients
NCT00996359,Refractory Hematologic Malignancy,PROCESS_OF,Patients
NCT00996359,Filgrastim,ADMINISTERED_TO,Patients
NCT00996359,pegfilgrastim,ADMINISTERED_TO,Patients
NCT00996359,Disease,PROCESS_OF,Patients
NCT00996359,Donor Lymphocyte Infusion,TREATS,Patients
NCT00996359,Donor Lymphocyte Infusion,TREATS(INFER),Disease
NCT00996359,Whole-Body Irradiation,PRECEDES,Cell Therapy
NCT00423514,Melphalan,DISRUPTS,Growth
NCT00423514,Thiotepa,DISRUPTS,Growth
NCT00423514,clofarabine,DISRUPTS,Growth
NCT00423514,clofarabine,ISA,Pharmacotherapy
NCT00423514,Stem cell transplant,TREATS,Patients
NCT00423514,Bone Marrow,PART_OF,Patients
NCT00423514,Disease,ISA,Hematologic Neoplasms
NCT00423514,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00423514,Hematologic Neoplasms,ISA,Disease
NCT00423514,Adverse effects,PROCESS_OF,Patients
NCT00423514,Stem cell transplant,TREATS,Patients
NCT00423514,Treatment Protocols,TREATS,Patients
NCT00423514,Toxic effect,OCCURS_IN,Patients
NCT00423514,Graft-vs-Host Disease,OCCURS_IN,Patients
NCT00423514,clofarabine,ADMINISTERED_TO,Patients
NCT00423514,Toxic effect,PROCESS_OF,Patients
NCT00423514,mycophenolate mofetil,TREATS,Patients
NCT00423514,umbilical cord blood transplantation,TREATS,Patients
NCT00423514,umbilical cord blood transplantation,TREATS,Patients
NCT00423514,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00423514,umbilical cord blood transplantation,TREATS,Patients
NCT00423514,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00423514,Filgrastim,ADMINISTERED_TO,Patients
NCT00423514,Cytarabine,ADMINISTERED_TO,Patients
NCT00423514,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00423514,Cytarabine,ADMINISTERED_TO,Patients
NCT00423514,Therapeutic procedure,USES,Melphalan
NCT00423514,Therapeutic procedure,USES,Thiotepa
NCT00423514,Allogeneic hematopoietic stem cell transplant,METHOD_OF,Treatment Protocols
NCT00732316,Antithymoglobulin,TREATS,Patients
NCT00732316,Antithymoglobulin,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,Antithymoglobulin,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Busulfan,TREATS,Patients
NCT00732316,Busulfan,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,Busulfan,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00732316,fludarabine,TREATS,Patients
NCT00732316,fludarabine,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,fludarabine,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00732316,Malignant Neoplasms,PROCESS_OF,Patients
NCT00732316,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00732316,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00732316,Antithymoglobulin,TREATS,Patients
NCT00732316,Antithymoglobulin,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,Antithymoglobulin,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Busulfan,TREATS,Patients
NCT00732316,Busulfan,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,Busulfan,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Methotrexate,ADMINISTERED_TO,Patients
NCT00732316,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00732316,Fludarabine phosphate,TREATS,Patients
NCT00732316,Fludarabine phosphate,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,Fludarabine phosphate,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00732316,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00732316,Acute leukemia,PROCESS_OF,Patients
NCT00732316,Oral medication,ADMINISTERED_TO,Patients
NCT00732316,Blood count,DIAGNOSES,Blast Phase
NCT00732316,Antithymoglobulin,TREATS,Patients
NCT00732316,Antithymoglobulin,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,Antithymoglobulin,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Busulfan,TREATS,Patients
NCT00732316,Busulfan,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,Busulfan,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00732316,fludarabine,TREATS,Patients
NCT00732316,fludarabine,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00732316,fludarabine,TREATS(INFER),Hematologic Neoplasms
NCT00732316,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00782145,"Support, device",TREATS,Family
NCT00782145,"Support, device",TREATS,Patients
NCT00782145,skills,PROCESS_OF,Family
NCT00782145,"Information, health",TREATS,parent
NCT00782145,Stem cell transplant,TREATS,Family
NCT00782145,Stem cell transplant,TREATS,Patients
NCT00782145,skills,PROCESS_OF,parent
NCT00782145,Group education,ADMINISTERED_TO,Dyads
NCT00782145,Institutional care,ADMINISTERED_TO,Dyads
NCT00782145,Psychosocial care,TREATS,parent
NCT00782145,Institutional care,ADMINISTERED_TO,Dyads
NCT00782145,Questionnaires,ISA,Health
NCT00769613,Stem cell transplant,TREATS,Patients
NCT00769613,Cytomegalovirus Infections,PROCESS_OF,Patients
NCT00728585,Pharmacotherapy,CAUSES,Oral Mucositis
NCT00728585,Radiation therapy,TREATS,Patients
NCT00728585,"Clinical Trials, Phase II",USES,Placebos
NCT00728585,Palifermin,ASSOCIATED_WITH,Oral Mucositis
NCT00728585,Palifermin,compared_with,Placebos
NCT00728585,Palifermin,PREVENTS,Oral Mucositis
NCT00728585,Stem cell transplant,TREATS,Patients
NCT00728585,Bacterial Infections,OCCURS_IN,Patients
NCT00728585,Methotrexate,ADMINISTERED_TO,Patients
NCT00728585,"Parenteral Nutrition, Total",compared_with,Treatment Protocols
NCT00728585,Treatment Protocols,compared_with,Treatment Protocols
NCT00728585,health care utilization,TREATS,Patients
NCT00728585,Hematopoietic Stem Cell Transplantation,PRECEDES,Placebos
NCT00728585,Palifermin,compared_with,Placebos
NCT00728585,Oral Mucositis,OCCURS_IN,Patients
NCT00728585,Melphalan,compared_with,Whole-Body Irradiation
NCT00728585,Radiation therapy,CAUSES,Oral Mucositis
NCT00728585,Hematopoietic Stem Cell Transplantation,CAUSES,Oral Mucositis
NCT00728585,Oral Mucositis,PROCESS_OF,Child
NCT00641030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00641030,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00641030,Melphalan,DISRUPTS,Growth
NCT00641030,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00641030,clofarabine,DISRUPTS,Growth
NCT00641030,clofarabine,ISA,Pharmacotherapy
NCT00641030,Stem cell transplant,TREATS,Patients
NCT00641030,Stem cell transplant,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00641030,Stem cell transplant,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00641030,Stem cell transplant,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00641030,Bone Marrow,PART_OF,Patients
NCT00641030,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00641030,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00641030,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00641030,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00641030,Adverse effects,PROCESS_OF,Patients
NCT00641030,Graft acceptance,PROCESS_OF,Patients
NCT00641030,Toxic effect,PROCESS_OF,Patients
NCT00641030,Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00641030,Stem cell transplant,TREATS,"Leukemia, Myelocytic, Acute"
NCT00641030,Stem cell transplant,TREATS,Dysmyelopoietic Syndromes
NCT00641030,Stem cell transplant,TREATS,Patients
NCT00641030,Stem cell transplant,TREATS(INFER),Toxic effect
NCT00641030,clofarabine,ADMINISTERED_TO,Patients
NCT00641030,Toxic effect,PROCESS_OF,Patients
NCT00641030,Stem cell transplant,TREATS,Patients
NCT00641030,Polymerase chain reaction analysis,METHOD_OF,Flow Cytometry
NCT00641030,Ribonucleotide Reductase,DISRUPTS,Apoptosis
NCT00641030,Treatment Protocols,METHOD_OF,"Transplantation, Homologous"
NCT00589563,Antithymoglobulin,ASSOCIATED_WITH,Graft-vs-Host Disease
NCT00589563,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00589563,Stem cell transplant,TREATS,Patients
NCT00589563,Stem cell transplant,TREATS(INFER),Graft-vs-Host Disease
NCT00589563,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00589563,Antithymoglobulin,ASSOCIATED_WITH,Graft-vs-Host Disease
NCT00589563,Antithymoglobulin,ASSOCIATED_WITH,Chronic graft-versus-host disease
NCT00589563,Etoposide,compared_with,Whole-Body Irradiation
NCT00589563,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00589563,Melphalan,compared_with,Whole-Body Irradiation
NCT00589563,Transplantation,TREATS,Patients
NCT00589563,Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00589563,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00589563,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00589563,Stem cell transplant,TREATS,Patients
NCT00589563,Stem cell transplant,TREATS(INFER),Graft-vs-Host Disease
NCT00589563,Stem cell transplant,TREATS(INFER),Chronic graft-versus-host disease
NCT00589563,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00589563,Therapeutic procedure,USES,Methotrexate
NCT00589563,Prophylactic treatment,TREATS,Patients
NCT00589563,Cell Transplantation,TREATS,Patients
NCT00889408,Therapeutic procedure,USES,CD19 gene
NCT00889408,Toxic effect,PROCESS_OF,Patients
NCT00889408,Therapeutic procedure,USES,Immunotoxins
NCT00569283,Cells,LOCATION_OF,Vitelliform dystrophy
NCT00569283,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00569283,Adverse effects,PROCESS_OF,Patients
NCT00569283,Toxic effect,PROCESS_OF,Patients
NCT00569283,host,LOCATION_OF,Disease
NCT00569283,Bone Marrow Transplantation,PRECEDES,Prophylactic treatment
NCT00555048,"Tumor cells, malignant",LOCATION_OF,alemtuzumab
NCT00555048,alemtuzumab,ISA,Monoclonal Antibodies
NCT00555048,Stem cell transplant,TREATS,Patients
NCT00555048,Busulfan,DISRUPTS,Growth
NCT00555048,Cyclophosphamide,DISRUPTS,Growth
NCT00555048,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00555048,Bone Marrow,PART_OF,Patients
NCT00555048,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00555048,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00555048,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00555048,alemtuzumab,TREATS,Patients
NCT00555048,Graft-vs-Host Disease,OCCURS_IN,Patients
NCT00555048,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00555048,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00555048,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00555048,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00555048,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00555048,Filgrastim,TREATS,Patients
NCT00555048,Campath,ISA,alemtuzumab
NCT00555048,Campath,DISRUPTS,Transplanted organ and tissue status
NCT00005977,Combination Drug Therapy,TREATS,Patients
NCT00005977,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00005977,Combination Drug Therapy,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT00005977,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00005977,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00005977,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00005977,Combination Drug Therapy,TREATS,Patients
NCT00005977,Combination Drug Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00005977,Combination Drug Therapy,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT00005977,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00005977,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00005977,CNS disorder,PROCESS_OF,Patients
NCT00005977,Diagnosis,USES,Etoposide
NCT00005977,Diagnosis,USES,Ifosfamide
NCT00005977,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00005977,"Lymphoma, Small Noncleaved-Cell",PROCESS_OF,Patients
NCT00005977,Therapeutic procedure,TREATS,Patients
NCT00005977,Therapeutic procedure,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT00005977,Therapeutic procedure,TREATS(INFER),"Lymphoma, Small Noncleaved-Cell"
NCT00005977,Toxic effect,PROCESS_OF,Patients
NCT00005977,Neuraxis,LOCATION_OF,Therapeutic procedure
NCT00005977,Non-Hodgkin's lymphoma stage III,ISA,Disease
NCT00005977,Cytarabine,ADMINISTERED_TO,Patients
NCT00005977,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00005977,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00005977,Methotrexate,ADMINISTERED_TO,Patients
NCT00005977,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00005977,Filgrastim,ADMINISTERED_TO,Patients
NCT00005977,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00005977,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00005977,CNS metastases,NEG_PROCESS_OF,Patients
NCT00005977,Non-Hodgkin's lymphoma stage III,PROCESS_OF,Patients
NCT00005977,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00005977,CNS metastases,PROCESS_OF,Patients
NCT00005977,CNS metastases,PROCESS_OF,Patients
NCT00005977,Methotrexate,TREATS,Patients
NCT00521430,Behavior Therapy,PRECEDES,Stem cell transplant
NCT00521430,Behavior Therapy,TREATS,Patients
NCT00521430,Behavior Therapy,TREATS(INFER),Disease
NCT00521430,Behavior Therapy,TREATS(INFER),Solid tumor
NCT00521430,Behavior Therapy,TREATS(INFER),Hematologic Neoplasms
NCT00521430,Disease,PROCESS_OF,Patients
NCT00521430,Solid tumor,PROCESS_OF,Patients
NCT00521430,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00521430,Bone Marrow,PART_OF,Patients
NCT00521430,Disease,ISA,Solid tumor
NCT00521430,Disease,ISA,Hematologic Neoplasms
NCT00521430,Disease,PROCESS_OF,Patients
NCT00521430,Disease,PROCESS_OF(SPEC),Patients
NCT00521430,Solid tumor,ISA,Disease
NCT00521430,Solid tumor,PROCESS_OF,Patients
NCT00521430,Solid tumor,PROCESS_OF(SPEC),Patients
NCT00521430,Hematologic Neoplasms,ISA,Disease
NCT00521430,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00521430,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00521430,Adverse effects,PROCESS_OF,Patients
NCT00521430,Antithymoglobulin,TREATS,Patients
NCT00521430,Antithymoglobulin,TREATS(INFER),Disease
NCT00521430,Antithymoglobulin,TREATS(INFER),Solid tumor
NCT00521430,Antithymoglobulin,TREATS(INFER),Hematologic Neoplasms
NCT00521430,Busulfan,TREATS,Patients
NCT00521430,Busulfan,TREATS(INFER),Disease
NCT00521430,Busulfan,TREATS(INFER),Solid tumor
NCT00521430,Busulfan,TREATS(INFER),Hematologic Neoplasms
NCT00521430,Disease,PROCESS_OF,Patients
NCT00521430,Methylprednisolone,TREATS,Patients
NCT00521430,Methylprednisolone,TREATS(INFER),Disease
NCT00521430,Methylprednisolone,TREATS(INFER),Solid tumor
NCT00521430,Methylprednisolone,TREATS(INFER),Hematologic Neoplasms
NCT00521430,Fludarabine phosphate,TREATS,Patients
NCT00521430,Fludarabine phosphate,TREATS(INFER),Disease
NCT00521430,Fludarabine phosphate,TREATS(INFER),Solid tumor
NCT00521430,Fludarabine phosphate,TREATS(INFER),Hematologic Neoplasms
NCT00521430,Solid tumor,PROCESS_OF,Patients
NCT00521430,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00509691,Vaccine Therapy,TREATS,Patients
NCT00509691,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00509691,Adverse effects,PROCESS_OF,Patients
NCT00509691,Stem cell transplant,TREATS,Patients
NCT00509691,Stem cell transplant,TREATS(INFER),Vitelliform dystrophy
NCT00509691,Stem cell transplant,TREATS(INFER),Adverse effects
NCT00509691,specific immunity,PROCESS_OF,Patients
NCT00509691,Stem cell transplant,TREATS,Patients
NCT00448201,Busulfan,DISRUPTS,Growth
NCT00448201,Busulfan,ISA,Pharmacotherapy
NCT00448201,Disease,PROCESS_OF,Patients
NCT00448201,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00448201,Stem cell transplant,TREATS,Patients
NCT00448201,Stem cell transplant,TREATS(INFER),Disease
NCT00448201,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00448201,Busulfan,TREATS,Hematologic Neoplasms
NCT00448201,Disease,ISA,Hematologic Neoplasms
NCT00448201,Disease,PROCESS_OF,Patients
NCT00448201,Disease,PROCESS_OF(SPEC),Patients
NCT00448201,fludarabine,TREATS,Hematologic Neoplasms
NCT00448201,Therapeutic procedure,TREATS,Patients
NCT00448201,Therapeutic procedure,TREATS(INFER),Disease
NCT00448201,Therapeutic procedure,TREATS(INFER),Hematologic Neoplasms
NCT00448201,Hematologic Neoplasms,ISA,Disease
NCT00448201,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00448201,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00448201,Stem cell transplant,METHOD_OF,Therapeutic procedure
NCT00448201,Disease,ISA,Hematologic Neoplasms
NCT00448201,Disease,PROCESS_OF,Patients
NCT00448201,Disease,PROCESS_OF(SPEC),Patients
NCT00448201,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00448201,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Disease
NCT00448201,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00448201,Hematologic Neoplasms,ISA,Disease
NCT00448201,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00448201,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00448201,Treatment Protocols,TREATS,Patients
NCT00448201,Treatment Protocols,TREATS,Patients
NCT00448201,Treatment Protocols,TREATS,Patients
NCT00448201,Treatment Protocols,TREATS,Patients
NCT00448201,Treatment Protocols,TREATS,Patients
NCT00448201,Treatment Protocols,TREATS(INFER),Toxic effect
NCT00448201,Treatment Protocols,TREATS(INFER),Chronic graft-versus-host disease
NCT00448201,Treatment Protocols,TREATS(INFER),Pulmonary toxicity
NCT00448201,Toxic effect,PROCESS_OF,Patients
NCT00448201,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00448201,Pulmonary toxicity,PROCESS_OF,Patients
NCT00448201,HLA Antigens,PART_OF,"Leukemia, Lymphocytic, Acute"
NCT00448201,HLA Antigens,PART_OF,"Myeloid Leukemia, Chronic"
NCT00448201,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00448201,Busulfan,ADMINISTERED_TO,Patients
NCT00448201,HLA Antigens,PART_OF,"Myeloid Leukemia, Chronic"
NCT00448201,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00448201,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00448201,Antithymoglobulin,ADMINISTERED_TO,Patients
NCT00448201,Busulfan,ADMINISTERED_TO,Patients
NCT00448201,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00448201,Busulfan,ADMINISTERED_TO,Patients
NCT00448201,Fludarabine phosphate,ADMINISTERED_TO,Patients
NCT00448201,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00448201,Granulocyte-Macrophage Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00448201,Tacrolimus,ADMINISTERED_TO,Patients
NCT00448201,Stable Disease,PROCESS_OF,Patients
NCT00448201,Progressive Disease,PROCESS_OF,Patients
NCT00448201,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00448201,Hematological Disease,PROCESS_OF,Patients
NCT00448201,Cell Transplantation,TREATS,Patients
NCT00448201,Cell Transplantation,TREATS(INFER),Hematological Disease
NCT00161187,Adverse effects,PROCESS_OF,Patients
NCT00161187,Donor Lymphocyte Infusion,TREATS,Patients
NCT00161187,Solid tumor,PROCESS_OF,Patients
NCT00161187,Toxic effect,PROCESS_OF,Patients
NCT00161187,Refractory Hematologic Malignancy,PROCESS_OF,Patients
NCT00161187,Treatment Protocols,TREATS,Patients
NCT00161187,Disease,PROCESS_OF,Patients
NCT00161187,Malignant Neoplasms,PROCESS_OF,Patients
NCT00161187,allogeneic lymphocytes,TREATS,Patients
NCT00161187,allogeneic lymphocytes,TREATS(INFER),Malignant Neoplasms
NCT00365287,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00365287,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00365287,Blood,PART_OF,Patients
NCT00365287,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00365287,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00365287,Transplantation,TREATS,Renal Cell Carcinoma
NCT00365287,Transplantation,TREATS,Patients
NCT00365287,Transplantation,TREATS,Breast cancer metastatic
NCT00365287,Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00365287,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00365287,umbilical cord blood transplantation,TREATS,Renal Cell Carcinoma
NCT00365287,umbilical cord blood transplantation,TREATS,Breast cancer metastatic
NCT00365287,Whole-Body Irradiation,TREATS,Patients
NCT00365287,Antithymoglobulin,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00365287,"Leukemia, Myelocytic, Acute",COEXISTS_WITH,Blast Phase
NCT00365287,"Leukemia, Myelocytic, Acute",ISA,Dysmyelopoietic Syndromes
NCT00365287,"Myeloid Leukemia, Chronic",COEXISTS_WITH,Blast Phase
NCT00365287,"Myeloid Leukemia, Chronic",ISA,Dysmyelopoietic Syndromes
NCT00365287,umbilical cord blood transplantation,TREATS,Patients
NCT00365287,Hematological Disease,PROCESS_OF,Patients
NCT00365287,Transplantation,TREATS,Patients
NCT00365287,Transplantation,TREATS(INFER),Hematological Disease
NCT00305851,Music Therapy,TREATS,Patients
NCT00305851,Stem cell transplant,TREATS,Patients
NCT00305851,Hearing,PROCESS_OF,Patients
NCT00305851,Music Therapy,TREATS,Patients
NCT00305851,Stem cell transplant,TREATS,Patients
NCT00305851,"Transplantation, Homologous",TREATS,Malignant Neoplasms
NCT00305851,Biomedical tape,TREATS,Adolescent
NCT00305851,Biomedical tape,TREATS,Young adult
NCT00305851,Therapeutic Intervention,TREATS,Malignant Neoplasms
NCT00295997,Aplastic Anemia,PROCESS_OF,Patients
NCT00295997,Stem cells,PART_OF,Patients
NCT00295997,Metastatic renal cell carcinoma,PROCESS_OF,Patients
NCT00295997,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00295997,Stem cell transplant,TREATS,Patients
NCT00295997,Stem cell transplant,TREATS(INFER),Aplastic Anemia
NCT00295997,Stem cell transplant,TREATS(INFER),Metastatic renal cell carcinoma
NCT00295997,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00295997,Aplastic Anemia,PROCESS_OF,Patients
NCT00295997,Metastatic renal cell carcinoma,PROCESS_OF,Patients
NCT00295997,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00295997,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00295997,Aplastic Anemia,PROCESS_OF,Patients
NCT00295997,Treatment Protocols,TREATS,Patients
NCT00295997,Metastatic renal cell carcinoma,PROCESS_OF,Patients
NCT00295997,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00295997,Stem cell transplant,TREATS,Aplastic Anemia
NCT00295997,Stem cell transplant,TREATS,Metastatic renal cell carcinoma
NCT00295997,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00295997,Treatment Protocols,TREATS,Patients
NCT00295997,Graft acceptance,PROCESS_OF,Patients
NCT00295997,Aplastic Anemia,PROCESS_OF,Patients
NCT00295997,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00295997,Filgrastim,ADMINISTERED_TO,Patients
NCT00295997,Transplantation,PRECEDES,Prophylactic treatment
NCT00295997,Tacrolimus,ADMINISTERED_TO,Patients
NCT00295997,Aplastic Anemia,PROCESS_OF,Patients
NCT00295997,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00295997,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00295997,Stem cell transplant,TREATS,Aplastic Anemia
NCT00295997,Stem cell transplant,TREATS,Renal Cell Carcinoma
NCT00295997,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00265837,Bone Marrow Transplantation,TREATS,Patients
NCT00265837,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00265837,Bone Marrow,PART_OF,Patients
NCT00265837,Bone Marrow Transplantation,TREATS,Patients
NCT00265837,Bone Marrow Transplantation,TREATS,Hematologic Neoplasms
NCT00265837,Laboratory,LOCATION_OF,"Clinical Trials, Phase III"
NCT00265837,Disease,PROCESS_OF,Patients
NCT00265837,Allogeneic bone marrow transplantation,TREATS,Hematologic Neoplasms
NCT00265837,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00265837,host,LOCATION_OF,Disease
NCT00265837,Lymphocyte Depletion,METHOD_OF,Allogeneic bone marrow transplantation
NCT00255684,Cyclophosphamide,DISRUPTS,Growth
NCT00255684,Cyclosporine,TREATS,Patients
NCT00255684,fludarabine,ISA,Pharmacotherapy
NCT00255684,mycophenolate mofetil,TREATS,Patients
NCT00255684,Cyclosporine,TREATS,Hematologic Neoplasms
NCT00255684,mycophenolate mofetil,TREATS,Hematologic Neoplasms
NCT00255684,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00255684,Cyclophosphamide,TREATS,Hematologic Neoplasms
NCT00255684,Whole-Body Irradiation,TREATS,Hematologic Neoplasms
NCT00255684,fludarabine,TREATS,Hematologic Neoplasms
NCT00255684,Graft acceptance,PROCESS_OF,Patients
NCT00255684,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00255684,Treatment Protocols,TREATS,Patients
NCT00255684,Graft acceptance,PROCESS_OF,Patients
NCT00255684,Infection,PROCESS_OF,Patients
NCT00255684,Treatment Protocols,TREATS,Patients
NCT00255684,Treatment Protocols,TREATS(INFER),Infection
NCT00255684,Treatment Protocols,TREATS(INFER),Toxic effect
NCT00255684,Treatment Protocols,TREATS(INFER),Myelosuppression
NCT00255684,Treatment Protocols,TREATS(INFER),Chronic graft-versus-host disease
NCT00255684,Toxic effect,PROCESS_OF,Patients
NCT00255684,Myelosuppression,PROCESS_OF,Patients
NCT00255684,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00255684,Treatment Protocols,TREATS,Patients
NCT00255684,Whole-Body Irradiation,TREATS,Patients
NCT00255684,Disease,PROCESS_OF,Adult
NCT00255684,Disease,PROCESS_OF,Child
NCT00255684,umbilical cord blood transplantation,TREATS,Adult
NCT00255684,umbilical cord blood transplantation,TREATS,Child
NCT00255684,umbilical cord blood transplantation,TREATS(INFER),Disease
NCT00253552,Bone Marrow Transplantation,TREATS,Patients
NCT00253552,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00253552,Bone Marrow,PART_OF,Patients
NCT00253552,Bone Marrow,LOCATION_OF,Granulocyte Colony-Stimulating Factor
NCT00253552,Bone Marrow Transplantation,TREATS,Patients
NCT00253552,Bone Marrow Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00253552,Granulocyte Colony-Stimulating Factor,ISA,Colony-Stimulating Factors
NCT00253552,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00253552,Hematological Disease,PROCESS_OF,Patients
NCT00253552,Allogeneic bone marrow transplantation,USES,Filgrastim
NCT00253552,Graft acceptance,PROCESS_OF,Patients
NCT00253552,Treatment Protocols,TREATS,Patients
NCT00253552,Treatment Protocols,TREATS(INFER),Acute graft-versus-host disease
NCT00253552,Graft acceptance,PROCESS_OF,Patients
NCT00253552,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00253552,Treatment Protocols,TREATS,Patients
NCT00253552,Treatment Protocols,TREATS(INFER),Chronic graft-versus-host disease
NCT00253552,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00253552,Treatment Protocols,TREATS,Patients
NCT00253552,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00253552,Filgrastim,ADMINISTERED_TO,Donor person
NCT00253552,Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00253552,Bone Marrow Transplantation,TREATS,Patients
NCT00253552,Bone Marrow Transplantation,TREATS(INFER),Malignant Neoplasms
NCT00253552,Bone Marrow Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00253552,Malignant Neoplasms,PROCESS_OF,Patients
NCT00253552,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00134017,Bone Marrow Transplantation,TREATS,Patients
NCT00134017,Combination Drug Therapy,TREATS,Patients
NCT00134017,Tacrolimus,TREATS,Patients
NCT00134017,mycophenolate mofetil,TREATS,Patients
NCT00134017,Bone Marrow,PART_OF,Patients
NCT00134017,Bone Marrow Transplantation,TREATS,Patients
NCT00134017,Bone Marrow Transplantation,TREATS,Hematologic Neoplasms
NCT00134017,mycophenolate mofetil,TREATS,Patients
NCT00134017,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00134017,Allogeneic bone marrow transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00134017,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00134017,Transplant immunosuppression,USES,Busulfan
NCT00134017,Treatment Protocols,TREATS,Patients
NCT00134017,Acute graft-versus-host disease,OCCURS_IN,Patients
NCT00134017,Treatment Protocols,TREATS,Patients
NCT00134017,Treatment Protocols,TREATS(INFER),Toxic effect
NCT00134017,Toxic effect,PROCESS_OF,Patients
NCT00134017,disorder control,TREATS,Patients
NCT00134017,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00134017,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00134017,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00134017,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00134017,Bone Marrow Transplantation,USES,Cyclophosphamide
NCT00134017,Cyclophosphamide,TREATS,Hematologic Neoplasms
NCT03373071,"Leukemia, B-Cell, Acute",AFFECTS,Patients
NCT03373071,Patients,LOCATION_OF,TNFRSF6B gene
NCT03373071,Patients,LOCATION_OF,CD19 gene
NCT03373071,Cells,LOCATION_OF,"Leukemia, B-Cell, Acute"
NCT03373071,Leukapheresis,TREATS,Patients
NCT03373071,caspase-9,CAUSES,Apoptosis
NCT03373071,"Leukemia, Lymphocytic, Acute",AFFECTS,Patients
NCT03373071,"Lymphoma, Non-Hodgkin's",AFFECTS,Patients
NCT03373071,Patients,LOCATION_OF,CD19 Antigens
NCT00096096,Tacrolimus,ISA,Therapeutic procedure
NCT00096096,Tacrolimus,TREATS,Graft-vs-Host Disease
NCT00096096,mycophenolate mofetil,TREATS,Acute graft-versus-host disease
NCT00096096,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00096096,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00096096,Stem cell transplant,TREATS,Patients
NCT00096096,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00096096,Stem cell transplant,TREATS(INFER),Acute graft-versus-host disease
NCT00096096,Disease,PROCESS_OF,Patients
NCT00096096,Transplanted tissue,LOCATION_OF,Tacrolimus
NCT00096096,Transplanted tissue,LOCATION_OF,mycophenolate mofetil
NCT00096096,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00096096,host,LOCATION_OF,Disease
NCT00096096,host,LOCATION_OF,Disease
NCT00096096,Tacrolimus,PREVENTS,Acute graft-versus-host disease
NCT00096096,mycophenolate mofetil,PREVENTS,Acute graft-versus-host disease
NCT00084695,Malignant Neoplasms,ISA,Disease
NCT00084695,Pharmacotherapy,METHOD_OF,umbilical cord blood transplantation
NCT00084695,Stem cell transplant,TREATS,Patients
NCT00084695,Graft-vs-Host Disease,OCCURS_IN,Patients
NCT00084695,Treatment Protocols,ISA,Therapeutic procedure
NCT00084695,Graft acceptance,PROCESS_OF,Patients
NCT00084695,Antithymoglobulin,NEG_ADMINISTERED_TO,Patients
NCT00084695,Whole-Body Irradiation,NEG_ADMINISTERED_TO,Patients
NCT00084695,Disease,PROCESS_OF,Patients
NCT00084695,Fanconi's Anemia,PROCESS_OF,Patients
NCT00084695,Whole-Body Irradiation,TREATS,Patients
NCT00084695,umbilical cord blood transplantation,TREATS,Patients
NCT00053157,Bone Marrow,LOCATION_OF,Granulocyte-Macrophage Colony-Stimulating Factor
NCT00053157,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00053157,Granulocyte-Macrophage Colony-Stimulating Factor,ASSOCIATED_WITH,Graft-vs-Host Disease
NCT00053157,Granulocyte-Macrophage Colony-Stimulating Factor,ISA,Colony-Stimulating Factors
NCT00053157,peripheral blood,LOCATION_OF,Granulocyte-Macrophage Colony-Stimulating Factor
NCT00053157,Stem cell transplant,TREATS,Aplastic Anemia
NCT00053157,Stem cell transplant,TREATS,Patients
NCT00053157,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00053157,Stem cell transplant,TREATS(INFER),Graft-vs-Host Disease
NCT00053157,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00053157,Granulocyte-Macrophage Colony-Stimulating Factor,ASSOCIATED_WITH,Graft-vs-Host Disease
NCT00053157,Stem cell transplant,TREATS,Aplastic Anemia
NCT00053157,Stem cell transplant,TREATS,Patients
NCT00053157,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00053157,Stem cell transplant,TREATS(INFER),Graft-vs-Host Disease
NCT00053157,Disease,PROCESS_OF,Patients
NCT00053157,Donor person,LOCATION_OF,Granulocyte-Macrophage Colony-Stimulating Factor
NCT00053157,host,LOCATION_OF,Disease
NCT00053157,Stem cell transplant,TREATS,Aplastic Anemia
NCT00053157,Stem cell transplant,TREATS,Hematologic Neoplasms
NCT00053157,Granulocyte-Macrophage Colony-Stimulating Factor,ADMINISTERED_TO,Donor person
NCT00053157,Blood Component Removal,TREATS,Donor person
NCT00053157,Harvest,TREATS,Donor person
NCT00053157,Behavior Therapy,ADMINISTERED_TO,Patients
NCT00053157,Stem cell transplant,TREATS,Patients
NCT00053157,Granulocyte-Macrophage Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00054236,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00054236,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00054236,umbilical cord blood transplantation,METHOD_OF,Combination Drug Therapy
NCT00054236,umbilical cord blood transplantation,TREATS,Patients
NCT00054236,umbilical cord blood transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00054236,anemia; profound,PROCESS_OF,Patients
NCT00054236,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00054236,umbilical cord blood transplantation,METHOD_OF,Combination Drug Therapy
NCT00054236,umbilical cord blood transplantation,TREATS,Patients
NCT00054236,umbilical cord blood transplantation,TREATS(INFER),anemia; profound
NCT00054236,umbilical cord blood transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00054236,Treatment Protocols,TREATS,anemia; profound
NCT00054236,Treatment Protocols,TREATS,Hematologic Neoplasms
NCT00054236,anemia; profound,PROCESS_OF,Patients
NCT00054236,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00054236,Toxic effect,OCCURS_IN,Patients
NCT00054236,Treatment Protocols,TREATS,Patients
NCT00054236,Treatment Protocols,TREATS(INFER),Chronic graft-versus-host disease
NCT00054236,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00054236,Treatment Protocols,TREATS,Patients
NCT00054236,Transplantation,TREATS,Patients
NCT00054236,Treatment Protocols,TREATS,Patients
NCT00054236,Complication,PROCESS_OF,Patients
NCT00054236,Treatment Protocols,TREATS,Patients
NCT00054236,Treatment Protocols,TREATS(INFER),Complication
NCT00054236,Treatment Protocols,TREATS,Patients
NCT00054236,Graft acceptance,PROCESS_OF,Patients
NCT00054236,umbilical cord blood transplantation,TREATS,Patients
NCT00054236,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00054236,Filgrastim,ADMINISTERED_TO,Patients
NCT00054236,Hematological Disease,PROCESS_OF,Patients
NCT00054236,anemia; profound,PROCESS_OF,Patients
NCT00054236,umbilical cord blood transplantation,TREATS,Patients
NCT00054236,umbilical cord blood transplantation,TREATS(INFER),Hematological Disease
NCT00054236,umbilical cord blood transplantation,TREATS(INFER),anemia; profound
NCT00053989,Aplastic Anemia,PROCESS_OF,Patients
NCT00053989,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00053989,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00053989,Aplastic Anemia,PROCESS_OF,Patients
NCT00053989,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00053989,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00053989,Aplastic Anemia,PROCESS_OF,Patients
NCT00053989,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00053989,Toxic effect,PROCESS_OF,Patients
NCT00053989,Treatment Protocols,TREATS,Patients
NCT00053989,Transplantation,AFFECTS,Neoplasm
NCT00053989,host,LOCATION_OF,Disease
NCT00053989,Treatment Protocols,ADMINISTERED_TO,Patients
NCT00053989,Tacrolimus,ADMINISTERED_TO,Patients
NCT00053989,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00053989,Tacrolimus,ADMINISTERED_TO,Patients
NCT00053989,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00053989,Granulocyte-Macrophage Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00053989,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00053989,Peripheral Stem Cell Transplantation,TREATS,Aplastic Anemia
NCT00053989,Peripheral Stem Cell Transplantation,TREATS,Hematologic Neoplasms
NCT02393859,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT02393859,Treatment Protocols,TREATS,Adult
NCT02393859,Consolidation Therapy,compared_with,Pharmacotherapy
NCT02141828,leukemia,PROCESS_OF,Patients
NCT02141828,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT02141828,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT02141828,leukemia,PROCESS_OF,Patients
NCT02141828,leukemia,PROCESS_OF,Patients
NCT01068301,Treatment Protocols,TREATS,Patients
NCT01068301,Treatment Protocols,TREATS(INFER),Refractory Hematologic Malignancy
NCT01068301,Refractory Hematologic Malignancy,PROCESS_OF,Patients
NCT01068301,Apoptosis,AFFECTS,Leukemic Cell
NCT01068301,MSC gene,AUGMENTS,cytotoxicity
NCT01068301,MSC gene,AUGMENTS,Leukemic Cell
NCT01068301,Chemotherapy-Oncologic Procedure,TREATS,Patients
NCT01068301,Treatment Protocols,TREATS,Child
NCT01068301,Treatment Protocols,TREATS,Young adult
NCT01068301,Procedures,TREATS,Child
NCT01068301,Procedures,TREATS,Young adult
NCT01068301,Toxic effect,PROCESS_OF,Participant
NCT02007863,leukemia,PROCESS_OF,Patients
NCT02007863,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT02007863,Transplanted organ and tissue status,PROCESS_OF,Child
NCT02007863,umbilical cord blood transplantation,TREATS,Patients
NCT02007863,umbilical cord blood transplantation,TREATS(INFER),leukemia
NCT02007863,umbilical cord blood transplantation,TREATS(INFER),Dysmyelopoietic Syndromes
NCT02007863,Marrow,LOCATION_OF,Transplanted organ and tissue status
NCT02007863,leukemia,PROCESS_OF,Patients
NCT02007863,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT02007863,Transplantation,TREATS,Patients
NCT02007863,Transplantation,TREATS(INFER),leukemia
NCT02007863,Transplantation,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00315705,Cyclophosphamide,TREATS,Child
NCT00315705,Cyclophosphamide,TREATS(INFER),Acute leukemia
NCT00315705,Etoposide,TREATS,Child
NCT00315705,Etoposide,TREATS(INFER),Acute leukemia
NCT00315705,Acute leukemia,PROCESS_OF,Child
NCT00315705,clofarabine,ISA,Injection procedure
NCT00315705,Medication Management,METHOD_OF,Therapeutic procedure
NCT00315705,clofarabine,COEXISTS_WITH,Cyclophosphamide
NCT00315705,clofarabine,COEXISTS_WITH,Etoposide
NCT00315705,Combined Modality Therapy,TREATS,Child
NCT00315705,Combined Modality Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00315705,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00315705,Cyclophosphamide,TREATS,Patients
NCT00315705,Etoposide,TREATS,Patients
NCT00022451,Growth,PROCESS_OF,Patients
NCT00022451,leukemia,PROCESS_OF,Patients
NCT00022451,tipifarnib,DISRUPTS,Growth
NCT00022451,tipifarnib,TREATS,Patients
NCT00022451,leukemia,PROCESS_OF,Patients
NCT00022451,tipifarnib,TREATS,Patients
NCT00022451,tipifarnib,TREATS(INFER),leukemia
NCT00022451,Drug Kinetics,PROCESS_OF,Patients
NCT00022451,Therapeutic procedure,USES,Pharmaceutical Preparations
NCT00022451,tipifarnib,ADMINISTERED_TO,Patients
NCT00022451,tipifarnib,ADMINISTERED_TO,Patients
NCT00022451,Toxic effect,PROCESS_OF,Patients
NCT00022451,leukemia,PROCESS_OF,Patients
NCT00022451,R115777,TREATS,Patients
NCT00022451,R115777,TREATS(INFER),leukemia
NCT00085150,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00085150,B3(Fv)-PE38KDEL recombinant immunotoxin,TREATS,Patients
NCT00085150,Adverse effects,PROCESS_OF,Patients
NCT00085150,B3(Fv)-PE38KDEL recombinant immunotoxin,TREATS,Patients
NCT00085150,Toxic effect,PROCESS_OF,Patients
NCT00085150,Drug Kinetics,PROCESS_OF,Patients
NCT00085150,Pharmaceutical Preparations,TREATS,Patients
NCT00085150,Immunoglobulins,TREATS,Patients
NCT00085150,Serum,LOCATION_OF,cytokine
NCT00085150,Cytarabine,ADMINISTERED_TO,Patients
NCT00085150,Hydrocortisone,ADMINISTERED_TO,Patients
NCT00085150,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00085150,B3(Fv)-PE38KDEL recombinant immunotoxin,ADMINISTERED_TO,Patients
NCT00085150,Toxic effect,PROCESS_OF,Patients
NCT00085150,B3(Fv)-PE38KDEL recombinant immunotoxin,TREATS,leukemia
NCT00085150,B3(Fv)-PE38KDEL recombinant immunotoxin,TREATS,Lymphoma
NCT02618109,Immunologic Factors,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
NCT02618109,"Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Neoplasms
NCT02618109,Malignant Neoplasms,PROCESS_OF,Human
NCT02618109,Tumorigenesis,COEXISTS_WITH,Malignant Neoplasms
NCT02618109,Immunologic Factors,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
NCT00020111,Pharmaceutical Preparations,DISRUPTS,"Tumor cells, malignant"
NCT00020111,leukemia,PROCESS_OF,Patients
NCT00020111,Lymphoma,PROCESS_OF,Patients
NCT00020111,arsenic trioxide,TREATS,Patients
NCT00020111,arsenic trioxide,TREATS(INFER),leukemia
NCT00020111,arsenic trioxide,TREATS(INFER),Lymphoma
NCT00020111,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00020111,Adverse effects,PROCESS_OF,Patients
NCT00020111,leukemia,PROCESS_OF,Patients
NCT00020111,Lymphoma,PROCESS_OF,Patients
NCT00020111,Toxic effect,PROCESS_OF,Patients
NCT00020111,Acute Promyelocytic Leukemia,ISA,Disease
NCT00020111,Acute Promyelocytic Leukemia,PROCESS_OF,Patients
NCT00020111,arsenic trioxide,ADMINISTERED_TO,Patients
NCT00020111,Toxic effect,PROCESS_OF,Patients
NCT00020111,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00020111,Therapeutic procedure,USES,arsenic trioxide
NCT00020111,leukemia,PROCESS_OF,Patients
NCT00020111,arsenic trioxide,ADMINISTERED_TO,Patients
NCT00020111,leukemia,PROCESS_OF,Patients
NCT00020111,Lymphoma,PROCESS_OF,Patients
NCT00020111,arsenic trioxide,TREATS,Patients
NCT00020111,arsenic trioxide,TREATS(INFER),leukemia
NCT00020111,arsenic trioxide,TREATS(INFER),Lymphoma
NCT00365768,Pharmacotherapy,CAUSES,Neuropathy
NCT00365768,Glutamine,AFFECTS,Neuropathy
NCT00365768,Glutamine,ASSOCIATED_WITH,Neuropathy
NCT00365768,Glutamine,INTERACTS_WITH(INFER),Vincristine
NCT00365768,leukemia,PROCESS_OF,Patients
NCT00365768,Lymphoma,PROCESS_OF,Patients
NCT00365768,Vincristine,CAUSES,Neuropathy
NCT00365768,Vincristine,TREATS,Patients
NCT00365768,Vincristine,TREATS(INFER),leukemia
NCT00365768,Vincristine,TREATS(INFER),Lymphoma
NCT00365768,Vincristine,TREATS(INFER),Solid tumor
NCT00365768,Solid tumor,PROCESS_OF,Patients
NCT00365768,Glutamine,ASSOCIATED_WITH,Neuropathy
NCT00365768,Glutamine,INTERACTS_WITH(INFER),Vincristine
NCT00365768,Glutamine,compared_with,Placebos
NCT00365768,Glutamine,higher_than,Placebos
NCT00365768,leukemia,PROCESS_OF,Patients
NCT00365768,Lymphoma,PROCESS_OF,Patients
NCT00365768,Vincristine,CAUSES,Neuropathy
NCT00365768,Vincristine,TREATS,Patients
NCT00365768,Vincristine,TREATS(INFER),leukemia
NCT00365768,Vincristine,TREATS(INFER),Lymphoma
NCT00365768,Vincristine,TREATS(INFER),Solid tumor
NCT00365768,Solid tumor,PROCESS_OF,Patients
NCT00365768,Glutamine,compared_with,Placebos
NCT00365768,leukemia,PROCESS_OF,Patients
NCT00365768,Lymphoma,PROCESS_OF,Patients
NCT00365768,Peripheral Neuropathy,OCCURS_IN,Patients
NCT00365768,Solid tumor,PROCESS_OF,Patients
NCT00365768,Glutamine,compared_with,Placebos
NCT00365768,Peripheral Neuropathy,PROCESS_OF,Patients
NCT00365768,Toxic effect,PROCESS_OF,Patients
NCT00365768,Supplementation,USES,Glutamine
NCT00365768,Supplementation,compared_with,Placebos
NCT00365768,Glutamine,compared_with,Placebos
NCT00365768,Placebos,TREATS,Patients
NCT00365768,Placebos,TREATS,Patients
NCT00365768,Serum,LOCATION_OF,Nerve Growth Factors
NCT00365768,Supplementation,TREATS,Patients
NCT00365768,Supplementation,USES,Glutamine
NCT00365768,Supplementation,compared_with,Placebos
NCT00365768,Pharmacotherapy,USES,Vincristine
NCT00365768,Glutamine,ADMINISTERED_TO,Patients
NCT00365768,Placebos,ADMINISTERED_TO,Patients
NCT00365768,Vincristine,ISA,Pharmacotherapy
NCT00365768,Serum,LOCATION_OF,Glutamine
NCT00365768,Glutamine,CAUSES,Malignant Neoplasms
NCT00365768,Vincristine,CAUSES,Malignant Neoplasms
NCT00365768,Neuropathy,PROCESS_OF,Patients
NCT00349024,Malignant Neoplasms,PROCESS_OF,Patients
NCT00349024,Therapeutic procedure,TREATS,Patients
NCT00349024,Therapeutic procedure,TREATS(INFER),Mouth Sore
NCT00349024,Therapeutic procedure,TREATS(INFER),Oral Mucositis
NCT00349024,Mouth Sore,PROCESS_OF,Patients
NCT00349024,Oral Mucositis,PROCESS_OF,Patients
NCT00349024,Oral pain,PROCESS_OF,Patients
NCT00349024,Oral pain,PROCESS_OF,Patients
NCT00349024,Malignant Neoplasms,PROCESS_OF,Child
NCT00349024,Malignant Neoplasms,PROCESS_OF,Persons
NCT00349024,Oral Mucositis,PROCESS_OF,Child
NCT00349024,Oral Mucositis,PROCESS_OF,Persons
NCT00713505,Functional disorder,PROCESS_OF,Survivors
NCT00713505,Functional disorder,PROCESS_OF,Cancer Survivor
NCT00713505,Malignant Childhood Neoplasm,PROCESS_OF,Survivors
NCT00713505,Functional disorder,PROCESS_OF,Cancer Survivor
NCT00713505,Intervention regimes,TREATS,parent
NCT00713505,Emotional,PROCESS_OF,Support System
NCT00713505,Malignant Childhood Neoplasm,PROCESS_OF,Survivors
NCT00713505,Late effect of,PROCESS_OF,Survivors
NCT01164163,Vitelliform dystrophy,PROCESS_OF,Patients
NCT01164163,Adverse effects,PROCESS_OF,Patients
NCT01164163,leukemia,PROCESS_OF,Patients
NCT01164163,Drug Kinetics,PROCESS_OF,Patients
NCT01164163,cytotoxicity,PROCESS_OF,Patients
NCT01164163,Toxic effect,PROCESS_OF,Patients
NCT01164163,Intrathecal Chemotherapy,ADMINISTERED_TO,Patients
NCT00991744,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00991744,Therapeutic procedure,USES,cytarabine liposomal
NCT00991744,Maintenance therapy,TREATS,Patients
NCT00991744,Maintenance therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00991744,Upper arm,LOCATION_OF,Toxic effect
NCT00991744,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00991744,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00991744,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00991744,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
NCT00991744,Upper arm,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
NCT00991744,Upper arm,LOCATION_OF,Toxic effect
NCT00991744,Toxic effect,PROCESS_OF,Child
NCT00991744,Toxic effect,PROCESS_OF,Adolescent
NCT00991744,Maintenance therapy,TREATS,Patients
NCT00991744,Maintenance therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00991744,DepoCyte,ISA,cytarabine liposomal
NCT00991744,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00991744,Maintenance therapy,TREATS,Patients
NCT00991744,Maintenance therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00004858,Malignant Neoplasms,PROCESS_OF,Patients
NCT00004858,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00004858,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00004858,Monoclonal Antibody Therapy,TREATS,Patients
NCT00004858,Monoclonal Antibody Therapy,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00004858,Monoclonal Antibody Therapy,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT00004858,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
NCT00004858,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
NCT00004858,Immunoconjugates,TREATS,Patients
NCT00004858,Immunoconjugates,TREATS(INFER),"Leukemia, B-Cell, Acute"
NCT00004858,Immunoconjugates,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT00004858,Genistein,TREATS,Patients
NCT00004858,Treatment Protocols,TREATS,Patients
NCT00004858,Immunoconjugates,ADMINISTERED_TO,Patients
NCT00004858,Toxic effect,PROCESS_OF,Patients
NCT00004858,Immunoconjugates,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
NCT00004858,Immunoconjugates,ASSOCIATED_WITH,"Lymphoma, Non-Hodgkin's"
NCT00686556,Bone Marrow,PART_OF,Patients
NCT00686556,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00686556,Multiple Myeloma,PROCESS_OF,Patients
NCT00686556,Acute leukemia,PROCESS_OF,Patients
NCT00686556,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00686556,Adverse effects,PROCESS_OF,Patients
NCT00686556,umbilical cord blood transplantation,TREATS,Patients
NCT00686556,"Radiotherapy, Intensity-Modulated",METHOD_OF,Radiation therapy
NCT00686556,Myeloablative Chemotherapy,TREATS,Patients
NCT00686556,Radiation therapy,TREATS,Patients
NCT00686556,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00686556,Filgrastim,ADMINISTERED_TO,Patients
NCT00686556,Radiation therapy,TREATS,Patients
NCT00686556,Radiation therapy,TREATS(INFER),Acute leukemia
NCT00686556,Acute leukemia,PROCESS_OF,Patients
NCT00686556,Myeloablative Chemotherapy,TREATS,Patients
NCT00686556,Myeloablative Chemotherapy,TREATS(INFER),Acute leukemia
NCT00005946,Pharmaceutical Preparations,DISRUPTS,[M]Unspecified tumor cell NOS
NCT00005946,Relapsed Hematologic Malignancy,PROCESS_OF,Patients
NCT00005946,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00005946,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00005946,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00005946,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00005946,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00005946,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00005946,Pharmacotherapy,TREATS,Hematologic Neoplasms
NCT00005946,Donor Lymphocyte Infusion,TREATS,Hematologic Neoplasms
NCT00036712,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00036712,Phototherapy,PREVENTS,Mucositis
NCT00036712,Phototherapy,TREATS,Mucositis
NCT00036712,Radiation therapy,TREATS,Mucositis
NCT00036712,Mucositis,PROCESS_OF,Child
NCT00036712,Radiation therapy,compared_with,Phototherapy
NCT00036712,Oral Mucositis,OCCURS_IN,Child
NCT00036712,Bone Marrow Transplantation,PRECEDES,Radiation therapy
NCT00036712,Bone Marrow Transplantation,PRECEDES,Myeloablative Chemotherapy
NCT00036712,Phototherapy,TREATS,Patients
NCT00036712,Bone Marrow Transplantation,PRECEDES,Pain scale
NCT00036712,Oral Mucositis,PROCESS_OF,Patients
NCT00027560,Melphalan,ISA,Pharmacotherapy
NCT00027560,Melphalan,TREATS,Patients
NCT00027560,fludarabine,TREATS,Patients
NCT00027560,alemtuzumab,DISRUPTS,Growth
NCT00027560,alemtuzumab,ISA,Monoclonal Antibodies
NCT00027560,alemtuzumab,TREATS,Patients
NCT00027560,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00027560,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00027560,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00027560,Melphalan,TREATS,Malignant Neoplasms
NCT00027560,fludarabine,TREATS,Malignant Neoplasms
NCT00027560,alemtuzumab,TREATS,Malignant Neoplasms
NCT00027560,Campath 1H,ISA,alemtuzumab
NCT00027560,Campath 1H,TREATS(SPEC),Malignant Neoplasms
NCT00020527,Pharmacotherapy,CAUSES,Neutropenia
NCT00020527,Fever,PROCESS_OF,Child
NCT00020527,Neutropenia,PROCESS_OF,Child
NCT00020527,Caspofungin acetate,TREATS,Child
NCT00020527,Caspofungin acetate,TREATS(INFER),Fever
NCT00020527,Caspofungin acetate,TREATS(INFER),Neutropenia
NCT00020527,Fever,PROCESS_OF,Child
NCT00020527,Neutropenia,PROCESS_OF,Child
NCT00020527,Drug Kinetics,PROCESS_OF,Child
NCT00020527,Caspofungin acetate,ADMINISTERED_TO,Patients
NCT00020527,Toxic effect,PROCESS_OF,Patients
NCT00020527,Fever,PROCESS_OF,Child
NCT00020527,Neutropenia,PROCESS_OF,Child
NCT00020527,Drug Kinetics,PROCESS_OF,Child
NCT00006246,Busulfan,TREATS,Child
NCT00006246,Busulfan,TREATS,Adolescent
NCT00006246,Pharmacotherapy,ADMINISTERED_TO,Child
NCT00006246,Pharmacotherapy,ADMINISTERED_TO,Adolescent
NCT00006246,Refractory Carcinoma,PROCESS_OF,Child
NCT00006246,Malignant neoplasm of central nervous system,PROCESS_OF,Child
NCT00006246,Malignant neoplasm of central nervous system,PROCESS_OF,Adolescent
NCT00006246,Toxic effect,PROCESS_OF,Child
NCT00006246,Toxic effect,PROCESS_OF,Adolescent
NCT00006246,Treatment Protocols,TREATS,Patients
NCT00006246,Treatment Protocols,TREATS,Patients
NCT00006246,Busulfan,ADMINISTERED_TO,Patients
NCT00006246,Busulfan,ADMINISTERED_TO,Patients
NCT00006246,Toxic effect,PROCESS_OF,Patients
NCT00006246,Busulfan,TREATS,Child
NCT00006246,Busulfan,TREATS(INFER),Malignant meningitis
NCT00006246,Malignant meningitis,PROCESS_OF,Child
NCT00295971,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00295971,Pancytopenia,ISA,Syndrome
NCT00295971,Stem cell transplant,TREATS,Patients
NCT00295971,Stem cell transplant,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00295971,Peripheral Stem Cell Transplant,PART_OF,Blood
NCT00295971,Bone Marrow,PART_OF,Patients
NCT00295971,Cells,LOCATION_OF,Antithymoglobulin
NCT00295971,Pancytopenia,ISA,Syndrome
NCT00295971,T-Lymphocyte,LOCATION_OF,Vitelliform dystrophy
NCT00295971,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00295971,Adverse effects,PROCESS_OF,Patients
NCT00295971,Stem cell transplant,TREATS,Immunologic Deficiency Syndromes
NCT00295971,Stem cell transplant,TREATS,leukemia
NCT00295971,Stem cell transplant,TREATS,Dysmyelopoietic Syndromes
NCT00295971,Stem cell transplant,TREATS,Syndrome
NCT00295971,Stem cell transplant,TREATS(SPEC),Pancytopenia
NCT00295971,Cytopenia,PROCESS_OF,Child
NCT00295971,Disease,PROCESS_OF,Child
NCT00295971,leukemia,PROCESS_OF,Child
NCT00295971,Dysmyelopoietic Syndromes,PROCESS_OF,Child
NCT00295971,Primary immune deficiency disorder,ISA,Disease
NCT00295971,Primary immune deficiency disorder,PROCESS_OF(SPEC),Child
NCT00295971,Toxic effect,PROCESS_OF,Child
NCT00295971,fludarabine,COEXISTS_WITH,Antithymoglobulin
NCT00295971,Toxic effect,PROCESS_OF,Patients
NCT00295971,Treatment Protocols,TREATS,Patients
NCT00295971,Graft acceptance,PROCESS_OF,Patients
NCT00295971,Antithymoglobulin,AFFECTS,Stem cells
NCT00295971,Whole-Body Irradiation,TREATS,Patients
NCT00295971,cytokine,AUGMENTS,Transplanted organ and tissue status
NCT00295971,Graft acceptance,PROCESS_OF,Patients
NCT00295971,Transplanted tissue,NEG_PART_OF,Patients
NCT00295971,host,LOCATION_OF,Disease
NCT00295971,Disease,PROCESS_OF,Child
NCT00295971,Immunologic Deficiency Syndromes,PROCESS_OF,Child
NCT00295971,leukemia,PROCESS_OF,Child
NCT00295971,Syndrome,PROCESS_OF,Child
NCT00295971,Transplantation,TREATS,Child
NCT00295971,Transplantation,TREATS(INFER),Disease
NCT00295971,Transplantation,TREATS(INFER),Immunologic Deficiency Syndromes
NCT00295971,Transplantation,TREATS(INFER),leukemia
NCT00295971,Transplantation,TREATS(INFER),Syndrome
NCT00726934,Infection,COEXISTS_WITH,Neutropenia
NCT00726934,Malignant Childhood Neoplasm,PROCESS_OF,Patients
NCT00726934,Adverse effects,PROCESS_OF,Patients
NCT00726934,Medication Management,TREATS,Immunocompromised Host
NCT00087009,rituximab,ISA,Monoclonal Antibodies
NCT00087009,rituximab,TREATS,Patients
NCT00087009,beta-Glucans,TREATS,Patients
NCT00087009,leukemia,PROCESS_OF,Patients
NCT00087009,Lymphoma,PROCESS_OF,Patients
NCT00087009,Lymphoproliferative Disorders,PROCESS_OF,Patients
NCT00087009,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00087009,rituximab,INTERACTS_WITH,beta-Glucans
NCT00087009,rituximab,TREATS,Patients
NCT00087009,rituximab,TREATS(INFER),leukemia
NCT00087009,rituximab,TREATS(INFER),Lymphoma
NCT00087009,rituximab,TREATS(INFER),Lymphoproliferative Disorders
NCT00087009,rituximab,TREATS(INFER),Vitelliform dystrophy
NCT00087009,rituximab,TREATS,Patients
NCT00087009,Toxic effect,PROCESS_OF,Patients
NCT00087009,beta-Glucans,TREATS,Patients
NCT00087009,Disease,PROCESS_OF,Patients
NCT00087009,Prophylactic treatment,ADMINISTERED_TO,Patients
NCT00087009,Prophylactic treatment,USES,rituximab
NCT00087009,beta-Glucans,ADMINISTERED_TO,Patients
NCT00087009,Toxic effect,PROCESS_OF,Patients
NCT00087009,leukemia,PROCESS_OF,Child
NCT00087009,leukemia,PROCESS_OF,Adolescent
NCT00087009,Lymphoma,PROCESS_OF,Child
NCT00087009,Lymphoma,PROCESS_OF,Adolescent
NCT00087009,Lymphoproliferative Disorders,PROCESS_OF,Child
NCT00087009,Lymphoproliferative Disorders,PROCESS_OF,Adolescent
NCT00134004,Bone Marrow Transplantation,TREATS,Patients
NCT00134004,Cyclophosphamide,DISRUPTS,Growth
NCT00134004,Cyclophosphamide,TREATS,Patients
NCT00134004,Whole-Body Irradiation,TREATS,Patients
NCT00134004,fludarabine,ISA,Pharmacotherapy
NCT00134004,fludarabine,TREATS,Patients
NCT00134004,Bone Marrow Transplantation,TREATS,Patients
NCT00134004,Bone Marrow Transplantation,TREATS,Hematologic Neoplasms
NCT00134004,Whole-Body Irradiation,TREATS,Patients
NCT00134004,Cyclophosphamide,TREATS,Hematologic Neoplasms
NCT00134004,Whole-Body Irradiation,TREATS,Hematologic Neoplasms
NCT00134004,fludarabine,TREATS,Hematologic Neoplasms
NCT00134004,Toxic effect,PROCESS_OF,Patients
NCT00134004,Whole-Body Irradiation,TREATS,Patients
NCT00134004,Transplantation,ISA,Therapeutic procedure
NCT00134004,Transplantation,TREATS,Patients
NCT00134004,Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00134004,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00806767,Antilymphocyte Globulin,DISRUPTS,Growth
NCT00806767,Busulfan,DISRUPTS,Growth
NCT00806767,Stem cells,PART_OF,Patients
NCT00806767,fludarabine,DISRUPTS,Growth
NCT00806767,Stem cell transplant,TREATS,Patients
NCT00806767,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00806767,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00806767,Globulins,PART_OF,Lymphocyte
NCT00806767,Graft-vs-Host Disease,OCCURS_IN,Patients
NCT00806767,Relapse,OCCURS_IN,Patients
NCT00806767,Hematopoietic Stem Cell Transplantation,TREATS,Hematologic Neoplasms
NCT00806767,"Transplantation, Homologous",TREATS,Patients
NCT00526292,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00526292,Pharmacotherapy,TREATS,Patients
NCT00526292,Stem cell transplant,NEG_TREATS,Hematopoietic Neoplasms
NCT00526292,Hematopoietic Neoplasms,PROCESS_OF,Research Personnel
NCT00526292,Pharmacotherapy,ADMINISTERED_TO,Research Personnel
NCT00526292,Pharmacotherapy,ISA,Therapeutic procedure
NCT00526292,Pharmacotherapy,TREATS(SPEC),Disease
NCT00526292,Therapeutic procedure,TREATS,Disease
NCT00526292,Cyclophosphamide,TREATS,Patients
NCT00526292,Cyclophosphamide,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00526292,"Leukemia, Myelocytic, Acute",ISA,Dysmyelopoietic Syndromes
NCT00526292,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00526292,Treatment Protocols,USES,Cyclophosphamide
NCT00526292,Treatment Protocols,USES,fludarabine
NCT00526292,fludarabine,PREDISPOSES,Graft-vs-Host Disease
NCT00526292,fludarabine,TREATS,Patients
NCT00526292,fludarabine,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00526292,"BCR protein, human",PART_OF,Blast Cell
NCT00526292,"BCR protein, human",PREDISPOSES,Graft-vs-Host Disease
NCT00526292,human leukocyte interferon,PART_OF,Protoplasm
NCT00526292,Allogeneic hematopoietic stem cell transplant,AFFECTS,Recovery
NCT00526292,Allogeneic hematopoietic stem cell transplant,AFFECTS,Graft acceptance
NCT00458744,Pharmaceutical Preparations,DISRUPTS,Growth
NCT00458744,leukemia,PROCESS_OF,Patients
NCT00458744,Solid tumor,PROCESS_OF,Patients
NCT00458744,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00458744,Adverse effects,PROCESS_OF,Patients
NCT00458744,leukemia,PROCESS_OF,Patients
NCT00458744,Solid tumor,PROCESS_OF,Patients
NCT00458744,Toxic effect,PROCESS_OF,Patients
NCT00458744,Toxic effect,PROCESS_OF,Patients
NCT00458744,leukemia,PROCESS_OF,Patients
NCT00458744,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00458744,Toxic effect,PROCESS_OF,Patients
NCT00458744,leukemia,PROCESS_OF,Child
NCT00458744,leukemia,PROCESS_OF,Adolescent
NCT00458744,Solid tumor,PROCESS_OF,Child
NCT00458744,Solid tumor,PROCESS_OF,Adolescent
NCT00534430,Busulfan,TREATS,Patients
NCT00534430,Etoposide,TREATS,Patients
NCT00534430,Whole-Body Irradiation,TREATS,Patients
NCT00534430,Bone Marrow,PART_OF,Patients
NCT00534430,Bone Marrow Transplantation,TREATS,Hematologic Neoplasms
NCT00534430,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00534430,Adverse effects,PROCESS_OF,Patients
NCT00534430,Bone Marrow Transplantation,TREATS,Patients
NCT00534430,Bone Marrow Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00534430,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
NCT00534430,Treatment Protocols,TREATS,Patients
NCT00534430,Treatment Protocols,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00534430,Treatment Protocols,TREATS(INFER),Toxic effect
NCT00534430,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00534430,Chemotherapy-Oncologic Procedure,METHOD_OF,Prophylactic treatment
NCT00534430,Toxic effect,PROCESS_OF,Patients
NCT00534430,Whole-Body Irradiation,TREATS,Patients
NCT00534430,Bone Marrow Transplantation,TREATS,Patients
NCT00534430,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00534430,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00534430,Treatment Protocols,METHOD_OF,Allogeneic bone marrow transplantation
NCT00534430,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00534430,Allogeneic bone marrow transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00534430,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00534430,VP-16,ISA,Etoposide
NCT00534118,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00534118,Donor Lymphocyte Infusion,TREATS,Patients
NCT00534118,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00534118,Donor Lymphocyte Infusion,ADMINISTERED_TO,Patients
NCT00369564,Vincristine,CAUSES,Nerve injury NOS
NCT00369564,Vincristine,TREATS,Patients
NCT00369564,Glutamic Acid,ASSOCIATED_WITH,Nerve injury NOS
NCT00369564,Glutamic Acid,PREVENTS,Nerve injury NOS
NCT00369564,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00369564,Vincristine,ADMINISTERED_TO,Patients
NCT00369564,Vincristine,CAUSES,Nerve injury NOS
NCT00369564,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00369564,Vincristine,TREATS,"Lymphoma, Non-Hodgkin's"
NCT00369564,Vincristine,TREATS,Nephroblastoma
NCT00369564,Vincristine,TREATS,Rhabdomyosarcoma
NCT00369564,Glutamic Acid,ASSOCIATED_WITH,Nerve injury NOS
NCT00369564,Glutamic Acid,compared_with,Placebos
NCT00369564,Glutamic Acid,higher_than,Placebos
NCT00369564,Nerve injury NOS,PROCESS_OF,Patients
NCT00369564,Placebos,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00369564,Placebos,TREATS,"Lymphoma, Non-Hodgkin's"
NCT00369564,Placebos,TREATS,Nephroblastoma
NCT00369564,Placebos,TREATS,Patients
NCT00369564,Placebos,TREATS,Rhabdomyosarcoma
NCT00369564,Glutamic Acid,TREATS,"Leukemia, Lymphocytic, Acute"
NCT00369564,Glutamic Acid,TREATS,"Lymphoma, Non-Hodgkin's"
NCT00369564,Glutamic Acid,TREATS,Nephroblastoma
NCT00369564,Glutamic Acid,TREATS,Rhabdomyosarcoma
NCT00369564,Glutamic Acid,compared_with,Placebos
NCT00369564,Glutamic Acid,TREATS,Patients
NCT00369564,Therapeutic procedure,TREATS,Patients
NCT00369564,Glutamic Acid,ADMINISTERED_TO,Patients
NCT00369564,Neurologic Examination,ADMINISTERED_TO,Patients
NCT00369564,Vincristine,ADMINISTERED_TO,Patients
NCT00369564,Neurologic Examination,ADMINISTERED_TO,Patients
NCT00369564,Malignant Neoplasms,PROCESS_OF,Child
NCT00369564,Glutamic Acid,PREVENTS,Toxic effect
NCT00369564,Toxic effect,PROCESS_OF,Child
NCT00293410,Cyclophosphamide,TREATS,Patients
NCT00293410,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00293410,clofarabine,ADMINISTERED_TO(SPEC),Patients
NCT00293410,clofarabine,DISRUPTS,Growth
NCT00293410,clofarabine,ISA,Pharmacotherapy
NCT00293410,clofarabine,TREATS,Patients
NCT00293410,Combination Drug Therapy,USES,Pharmaceutical Preparations
NCT00293410,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00293410,Adverse effects,PROCESS_OF,Patients
NCT00293410,Cyclophosphamide,TREATS,Patients
NCT00293410,"Myeloid Leukemia, Chronic",PROCESS_OF,Patients
NCT00293410,clofarabine,TREATS,Patients
NCT00293410,Blast Cell,LOCATION_OF,Toxic effect
NCT00293410,Marrow,LOCATION_OF,Toxic effect
NCT00293410,Therapeutic procedure,USES,Cyclophosphamide
NCT00293410,Therapeutic procedure,USES,clofarabine
NCT00293410,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00293410,clofarabine,ADMINISTERED_TO,Patients
NCT00293410,Toxic effect,PROCESS_OF,Patients
NCT00293410,Cyclophosphamide,TREATS,Adult
NCT00293410,Cyclophosphamide,TREATS,Child
NCT00112619,Pharmaceutical Preparations,DISRUPTS,Cells
NCT00112619,leukemia,CAUSES,Malignant meningitis
NCT00112619,Lymphoma,CAUSES,Malignant meningitis
NCT00112619,Topotecan,DISRUPTS,Growth
NCT00112619,Topotecan,ISA,Pharmacotherapy
NCT00112619,Topotecan,TREATS,Patients
NCT00112619,Topotecan,TREATS(INFER),Malignant meningitis
NCT00112619,Malignant meningitis,PROCESS_OF,Patients
NCT00112619,Solid tumor,CAUSES,Malignant meningitis
NCT00112619,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00112619,Adverse effects,PROCESS_OF,Patients
NCT00112619,Topotecan,TREATS,Patients
NCT00112619,Topotecan,TREATS(INFER),Malignant meningitis
NCT00112619,Malignant meningitis,PROCESS_OF,Patients
NCT00112619,Toxic effect,PROCESS_OF,Patients
NCT00112619,Cerebrospinal Fluid,LOCATION_OF,Lactones
NCT00112619,Pharmaceutical Preparations,TREATS,Patients
NCT00112619,Lactones,ISA,Pharmaceutical Preparations
NCT00112619,Cerebrospinal Fluid,PART_OF,Patients
NCT00112619,Topotecan,ADMINISTERED_TO,Patients
NCT00112619,Topotecan,ADMINISTERED_TO,Patients
NCT00112619,Topotecan,ADMINISTERED_TO,Patients
NCT00112619,Topotecan,ADMINISTERED_TO,Patients
NCT00112619,Toxic effect,PROCESS_OF,Patients
NCT00112619,Topotecan,TREATS,Child
NCT00112619,Topotecan,TREATS(INFER),Malignant meningitis
NCT00112619,Malignant meningitis,PROCESS_OF,Child
NCT00891137,Myeloid Progenitor Cells,PART_OF,Human
NCT00891137,Myeloid Progenitor Cells,PART_OF,Human
NCT00891137,umbilical cord blood transplantation,TREATS,Hematologic Neoplasms
NCT00004132,Pharmacotherapy,TREATS,Hematologic Neoplasms
NCT00004132,Radiation therapy,ADMINISTERED_TO,Patients
NCT00004132,Radiation therapy,TREATS,Hematologic Neoplasms
NCT00004132,Fibroblast Growth Factor 7,ASSOCIATED_WITH,Oral Mucositis
NCT00004132,Mucositis,PROCESS_OF,Patients
NCT00004132,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00004132,Oral Mucositis,PROCESS_OF,Patients
NCT00004132,Whole-Body Irradiation,CAUSES,Oral Mucositis
NCT00004132,Whole-Body Irradiation,TREATS,Patients
NCT00004132,Whole-Body Irradiation,TREATS(INFER),Hematologic Neoplasms
NCT00004132,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00004132,high-dose chemotherapy,CAUSES,Oral Mucositis
NCT00004132,high-dose chemotherapy,TREATS,Patients
NCT00004132,high-dose chemotherapy,TREATS(INFER),Hematologic Neoplasms
NCT00004132,Recombinant Growth Factor,PART_OF,keratinocyte
NCT00004132,Diarrhea,OCCURS_IN,Patients
NCT00004132,Febrile neutropenia,OCCURS_IN,Patients
NCT00004132,Oral Mucositis,OCCURS_IN,Patients
NCT00004132,Antibiotics,TREATS,Infection
NCT00004132,Antibiotics,TREATS,Febrile neutropenia
NCT00004132,Antifungal Agents,TREATS,Infection
NCT00004132,Antifungal Agents,TREATS,Febrile neutropenia
NCT00004132,Infection,PROCESS_OF,Patients
NCT00004132,Febrile neutropenia,PROCESS_OF,Patients
NCT00004132,Palifermin,ADMINISTERED_TO,Patients
NCT00004132,Palifermin,ADMINISTERED_TO,Patients
NCT00004132,Placebos,ADMINISTERED_TO,Patients
NCT00004132,Placebos,ADMINISTERED_TO,Patients
NCT00004132,Palifermin,ADMINISTERED_TO,Patients
NCT00004132,Etoposide,ADMINISTERED_TO,Patients
NCT00004132,Peripheral Stem Cell Transplantation,ADMINISTERED_TO,Patients
NCT00004132,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00004132,Placebos,ADMINISTERED_TO,Patients
NCT00004132,Palifermin,ADMINISTERED_TO,Patients
NCT00004132,Whole-Body Irradiation,TREATS,Hematologic Neoplasms
NCT00004132,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00004132,Palifermin,TREATS,Patients
NCT00004132,Palifermin,TREATS(INFER),Hematologic Neoplasms
NCT00028730,Bone Marrow Transplantation,METHOD_OF,Pharmacotherapy
NCT00028730,Bone Marrow Transplantation,METHOD_OF,Whole-Body Irradiation
NCT00028730,Bone Marrow Transplantation,TREATS,Patients
NCT00028730,Bone Marrow,PART_OF,Patients
NCT00028730,Cells,LOCATION_OF,Antithymoglobulin
NCT00028730,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00028730,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00028730,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT00028730,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
NCT00028730,"Myeloid Leukemia, Chronic",PROCESS_OF,Child
NCT00028730,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT00028730,Dysmyelopoietic Syndromes,PROCESS_OF,Child
NCT00028730,Allogeneic bone marrow transplantation,METHOD_OF,Whole-Body Irradiation
NCT00028730,Allogeneic bone marrow transplantation,TREATS,Child
NCT00028730,Allogeneic bone marrow transplantation,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT00028730,Allogeneic bone marrow transplantation,TREATS(INFER),"Leukemia, Myelocytic, Acute"
NCT00028730,Allogeneic bone marrow transplantation,TREATS(INFER),"Myeloid Leukemia, Chronic"
NCT00028730,Allogeneic bone marrow transplantation,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT00028730,Allogeneic bone marrow transplantation,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00028730,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00028730,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00028730,Allogeneic bone marrow transplantation,TREATS,Patients
NCT00028730,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00028730,Filgrastim,ADMINISTERED_TO,Patients
NCT00028730,Antigens,PART_OF,Donor person
NCT00028730,HLA Antigens,PART_OF,Donor person
NCT00028730,Cyclophosphamide,TREATS,Patients
NCT00028730,Thiotepa,TREATS,Patients
NCT00028730,Treatment Protocols,PRECEDES,Hemopoietic stem cell transplant
NCT00608517,Bone Marrow,PART_OF,Patients
NCT00608517,Cells,PART_OF,Umbilical Cord Blood
NCT00608517,Tacrolimus,TREATS,Persons
NCT00608517,mycophenolate mofetil,TREATS,Persons
NCT00608517,Bone Marrow,PART_OF,Patients
NCT00608517,Cells,PART_OF,Umbilical Cord Blood
NCT00608517,Tacrolimus,TREATS,Persons
NCT00608517,mycophenolate mofetil,TREATS,Persons
NCT00608517,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00608517,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00608517,Acute graft-versus-host disease,ISA,Graft-vs-Host Disease
NCT00608517,Acute graft-versus-host disease,PROCESS_OF(SPEC),Patients
NCT00608517,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00608517,Stem cell transplant,TREATS,Patients
NCT00608517,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00608517,Whole-Body Irradiation,TREATS,Patients
NCT00608517,Whole-Body Irradiation,TREATS,Patients
NCT00608517,Whole-Body Irradiation,TREATS,Patients
NCT00608517,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00608517,Filgrastim,ADMINISTERED_TO,Patients
NCT00608517,Prophylactic treatment,METHOD_OF,Therapeutic procedure
NCT00608517,Prophylactic treatment,METHOD_OF,umbilical cord blood transplantation
NCT00608517,Prophylactic treatment,USES,Tacrolimus
NCT00608517,Prophylactic treatment,USES,mycophenolate mofetil
NCT00376480,Disease,PROCESS_OF,Patients
NCT00376480,Thiotepa,DISRUPTS,Growth
NCT00376480,fludarabine,DISRUPTS,Growth
NCT00376480,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00376480,Stem cell transplant,TREATS,Patients
NCT00376480,Stem cell transplant,TREATS(INFER),Disease
NCT00376480,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00376480,Bone Marrow,PART_OF,Patients
NCT00376480,Disease,ISA,Hematologic Neoplasms
NCT00376480,Disease,PROCESS_OF,Patients
NCT00376480,Disease,PROCESS_OF(SPEC),Patients
NCT00376480,Vitelliform dystrophy,PROCESS_OF,Patients
NCT00376480,Hematologic Neoplasms,ISA,Disease
NCT00376480,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00376480,Hematologic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00376480,Adverse effects,PROCESS_OF,Patients
NCT00376480,Stem cell transplant,TREATS,Vitelliform dystrophy
NCT00376480,Stem cell transplant,TREATS,Adverse effects
NCT00376480,Disease,ISA,Hematopoietic Neoplasms
NCT00376480,Disease,PROCESS_OF,Patients
NCT00376480,Disease,PROCESS_OF(SPEC),Patients
NCT00376480,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00376480,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Disease
NCT00376480,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Hematopoietic Neoplasms
NCT00376480,Hematopoietic Neoplasms,ISA,Disease
NCT00376480,Hematopoietic Neoplasms,PROCESS_OF,Patients
NCT00376480,Hematopoietic Neoplasms,PROCESS_OF(SPEC),Patients
NCT00376480,Anergy,PROCESS_OF,Patients
NCT00376480,Induction,TREATS,Patients
NCT00376480,Whole-Body Irradiation,TREATS,Patients
NCT00376480,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00376480,host,LOCATION_OF,Disease
NCT00376480,Toxic effect,PROCESS_OF,Patients
NCT00376480,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00376480,Acute leukemia,PROCESS_OF,Patients
NCT00376480,Peripheral Stem Cell Transplantation,TREATS,Patients
NCT00376480,Peripheral Stem Cell Transplantation,TREATS(INFER),Dysmyelopoietic Syndromes
NCT00376480,Peripheral Stem Cell Transplantation,TREATS(INFER),Acute leukemia
NCT00047021,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00047021,Combination Drug Therapy,TREATS,Patients
NCT00047021,Cytarabine,TREATS,Patients
NCT00047021,Mitoxantrone,TREATS,Patients
NCT00047021,leukemia,PROCESS_OF,Patients
NCT00047021,Lymphoma,PROCESS_OF,Patients
NCT00047021,Toxic effect,PROCESS_OF,Patients
NCT00047021,Granulocyte-Macrophage Colony-Stimulating Factor,ADMINISTERED_TO,Patients
NCT00410657,Glucocorticoids,ISA,Therapeutic procedure
NCT00410657,Methylprednisolone,ISA,Glucocorticoids
NCT00410657,Methylprednisolone,ISA,Therapeutic procedure
NCT00410657,Prednisone,ISA,Glucocorticoids
NCT00410657,Prednisone,ISA,Therapeutic procedure
NCT00410657,alemtuzumab,TREATS,Acute graft-versus-host disease
NCT00410657,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00410657,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT00410657,alemtuzumab,ADMINISTERED_TO,Patients
NCT00410657,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00410657,Therapeutic procedure,ADMINISTERED_TO,Patients
NCT00410657,Therapeutic procedure,USES,Pharmaceutical Preparations
NCT00410657,Transplantation,PRECEDES,Therapeutic procedure
NCT00410657,Agent,TREATS,Acute graft-versus-host disease
NCT00290641,Cyclophosphamide,DISRUPTS,Growth
NCT00290641,fludarabine,DISRUPTS,Growth
NCT00290641,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00290641,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00290641,Transplanted organ and tissue status,PROCESS_OF,Patients
NCT00290641,Cyclosporine,TREATS,Patients
NCT00290641,Treatment Protocols,TREATS,Patients
NCT00290641,mycophenolate mofetil,TREATS,Patients
NCT00290641,Graft acceptance,PROCESS_OF,Patients
NCT00290641,Treatment Protocols,TREATS,Patients
NCT00290641,Treatment Protocols,TREATS(INFER),Chronic graft-versus-host disease
NCT00290641,Chronic graft-versus-host disease,PROCESS_OF,Patients
NCT00290641,Relapse,OCCURS_IN,Patients
NCT00290641,Treatment Protocols,TREATS,Patients
NCT00290641,Treatment Protocols,TREATS,Patients
NCT00290641,Treatment Protocols,TREATS,Patients
NCT00290641,umbilical cord blood transplantation,TREATS,Patients
NCT00290641,Whole-Body Irradiation,TREATS,Patients
NCT00290641,Cyclosporine,ADMINISTERED_TO,Patients
NCT00290641,Graft-vs-Host Disease,ISA,Disease
NCT00290641,host,LOCATION_OF,Disease
NCT00290641,host,LOCATION_OF(SPEC),Graft-vs-Host Disease
NCT00290641,mycophenolate mofetil,ADMINISTERED_TO,Patients
NCT00290641,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00290641,Filgrastim,ADMINISTERED_TO,Patients
NCT00290641,Treatment Protocols,TREATS,Patients
NCT00290641,Treatment Protocols,TREATS(INFER),Hematologic Neoplasms
NCT00290641,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00245115,Bone Marrow,LOCATION_OF,Colony-Stimulating Factors
NCT00245115,Bone Marrow,LOCATION_OF,Granulocyte Colony-Stimulating Factor
NCT00245115,Bone Marrow Transplantation,TREATS,Patients
NCT00245115,Blood,PART_OF,Patients
NCT00245115,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00245115,Radiation therapy,ADMINISTERED_TO,Patients
NCT00245115,Bone Marrow Transplantation,TREATS,Patients
NCT00245115,Bone Marrow Transplantation,TREATS(INFER),Acute leukemia
NCT00245115,Acute leukemia,PROCESS_OF,Patients
NCT00245115,Bone Marrow Transplantation,TREATS,Patients
NCT00245115,Bone Marrow Transplantation,TREATS(INFER),Acute leukemia
NCT00245115,Acute leukemia,PROCESS_OF,Patients
NCT00245115,Treatment Protocols,TREATS,Patients
NCT00245115,Treatment Protocols,TREATS(INFER),"Aplasia, NOS"
NCT00245115,"Aplasia, NOS",PROCESS_OF,Patients
NCT00245115,Leukapheresis,METHOD_OF,Therapeutic Mobilization
NCT00245115,Filgrastim,ISA,Granulocyte Colony-Stimulating Factor
NCT00245115,Granulocyte Colony-Stimulating Factor,PART_OF,Cells
NCT00245115,Stem Cell Factor,PART_OF,Cells
NCT00245115,recombinant human thrombopoietin,PART_OF,Cells
NCT00245115,Busulfan,ADMINISTERED_TO,Patients
NCT00245115,Cyclophosphamide,ADMINISTERED_TO,Patients
NCT00245115,"Transplantation, Autologous",TREATS,Patients
NCT00245115,Acute leukemia,PROCESS_OF,Patients
NCT00244829,Imatinib mesylate,DISRUPTS,Growth
NCT00244829,Stem cell transplant,TREATS,Patients
NCT00244829,leukemia,PROCESS_OF,Patients
NCT00244829,Adverse effects,PROCESS_OF,Patients
NCT00244829,Pharmaceutical Preparations,TREATS,Patients
NCT00244829,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00244829,Transplantation,PRECEDES,Stem cell transplant
NCT00244829,Imatinib mesylate,ADMINISTERED_TO,Patients
NCT00244829,Therapeutic procedure,TREATS,leukemia
NCT00054327,Stem cell transplant,TREATS,Patients
NCT00054327,Blood,PART_OF,Patients
NCT00054327,Bone Marrow,PART_OF,Patients
NCT00054327,Pharmacotherapy,ADMINISTERED_TO,Patients
NCT00054327,Radiation therapy,ADMINISTERED_TO,Patients
NCT00054327,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00054327,Stem cell transplant,TREATS,Patients
NCT00054327,Stem cell transplant,TREATS(INFER),Hematologic Neoplasms
NCT00054327,Hematopoietic Stem Cell Transplantation,TREATS,Patients
NCT00054327,Hematopoietic Stem Cell Transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00054327,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00054327,Toxic effect,PROCESS_OF,Patients
NCT00054327,Treatment Protocols,TREATS,Patients
NCT00054327,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT00054327,Whole-Body Irradiation,TREATS,Patients
NCT00054327,Whole-Body Irradiation,TREATS,Patients
NCT00054327,Whole-Body Irradiation,ADMINISTERED_TO,Patients
NCT00054327,Whole-Body Irradiation,ADMINISTERED_TO,Patients
NCT00054327,Etoposide,ADMINISTERED_TO,Patients
NCT00054327,Stem cell transplant,TREATS,Patients
NCT00930098,clofarabine,TREATS,Patients
NCT00930098,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT00930098,clofarabine,TREATS,Patients
NCT00930098,clofarabine,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03236857,x,x,x
NCT02410252,"Support, device",TREATS,Patients
NCT02410252,Myelosuppressive Therapy,TREATS,Acute leukemia
NCT02410252,Myelosuppressive Therapy,TREATS,Malignant Childhood Neoplasm
NCT02410252,Therapeutic procedure,CAUSES,Neutropenia
NCT02410252,Fever,ISA,Physical findings
NCT02410252,Empirical therapy,TREATS,Septicemia
NCT02410252,Empirical therapy,USES,Microbicides
NCT02410252,Neutropenia,COEXISTS_WITH,Fever
NCT02410252,Therapeutic procedure,USES,Microbicides
NCT02410252,Fever,PROCESS_OF,Patients
NCT02410252,Neutropenia,PROCESS_OF,Patients
NCT02410252,Monitoring of patient temperature,TREATS,Patients
NCT02410252,Myelosuppressive Therapy,TREATS,Patients
NCT02410252,Myelosuppressive Therapy,TREATS,Acute leukemia
NCT02410252,Myelosuppressive Therapy,TREATS,Malignant Childhood Neoplasm
NCT02410252,Therapeutic procedure,TREATS,Patients
NCT02410252,Therapeutic procedure,TREATS,Acute leukemia
NCT02410252,Therapeutic procedure,TREATS,Malignant Childhood Neoplasm
NCT02410252,Myelosuppressive Therapy,TREATS,Acute leukemia
NCT02410252,Myelosuppressive Therapy,TREATS,Malignant Childhood Neoplasm
NCT02410252,Research Personnel,TREATS,Patients
NCT02410252,Fever,PROCESS_OF,Patients
NCT02410252,Therapeutic procedure,TREATS,Acute leukemia
NCT02410252,Therapeutic procedure,TREATS,Malignant Childhood Neoplasm
NCT02650414,T-Lymphocyte,PRODUCES,CD22 antigen
NCT02650414,CD22 antigen,PRODUCES,T-Cell Receptor
NCT02650414,Screening Tests,TREATS,Patients
NCT02650414,T-Cell Receptor,PART_OF,Cells
NCT02650414,Pharmacotherapy,TREATS,Patients
NCT02650414,Physical assessment,ADMINISTERED_TO,Patients
NCT02650414,follow-up,METHOD_OF,Assessment procedure
NCT02650414,Patients,LOCATION_OF,CD22 antigen
NCT01036009,Acute leukemia,PROCESS_OF,Patients
NCT01036009,Graft-vs-Host Disease,NEG_PROCESS_OF,Patients
NCT01036009,Graft-vs-Host Disease,PROCESS_OF,Patients
NCT01036009,Hematologic Neoplasms,PROCESS_OF,Child
NCT01036009,Donor Lymphocyte Infusion,TREATS,Child
NCT01036009,Donor Lymphocyte Infusion,TREATS(INFER),Hematologic Neoplasms
NCT01036009,Intervention regimes,ADMINISTERED_TO,Patients
NCT01036009,Donor Lymphocyte Infusion,TREATS,Patients
NCT01036009,"Neoplasm, Residual",PROCESS_OF,Patients
NCT01036009,Chronic graft-versus-host disease,ISA,Graft-vs-Host Disease
NCT01036009,Donor Lymphocyte Infusion,TREATS,Chimerism
NCT02723994,Pharmacotherapy,TREATS,Child
NCT02723994,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, B-Cell, Acute"
NCT02723994,Pharmacotherapy,TREATS,Child
NCT03117751,Pharmaceutical Preparations,TREATS,Patients
NCT03117751,Pharmaceutical Preparations,TREATS(INFER),leukemia
NCT03117751,Pharmaceutical Preparations,TREATS(INFER),"Leukemia, Lymphocytic, Acute"
NCT03117751,leukemia,PROCESS_OF,Patients
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT03117751,Vincristine,ISA,Therapeutic procedure
NCT03117751,pegaspargase,STIMULATES,Vincristine
NCT03117751,Therapeutic procedure,USES,Vincristine
NCT03117751,Lesion,PROCESS_OF,Patients
NCT03117751,rituximab,ADMINISTERED_TO,Child
NCT03117751,bortezomib,ISA,Proteasome inhibitor
NCT03117751,bortezomib,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03117751,bortezomib,TREATS,Lesion
NCT03117751,Protein-tyrosine kinase inhibitor,TREATS,"Leukemia, Lymphocytic, Acute"
NCT03117751,Protein-tyrosine kinase inhibitor,TREATS,Lesion
NCT03117751,Remission Induction Therapy,PREVENTS,Allergic Reaction
NCT03117751,Allergic Reaction,PROCESS_OF,Patients
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
NCT03117751,Drug resistance,AFFECTS,Evolution
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT03117751,Lesion,NEG_PROCESS_OF,Patients
NCT03117751,"Neoplasm, Residual",NEG_PROCESS_OF,Patients
NCT03117751,bortezomib,ADMINISTERED_TO,Patients
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT03117751,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT03117751,Lesion,NEG_PROCESS_OF,Patients
NCT03117751,"Neoplasm, Residual",NEG_PROCESS_OF,Patients
NCT03117751,bortezomib,TREATS,Patients
NCT03117751,bortezomib,TREATS(INFER),Large Cell Lymphoblastic Lymphoma
NCT03117751,pegaspargase,ADMINISTERED_TO,Patients
NCT03117751,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT03117751,Immunotherapy,PRECEDES,Therapeutic procedure
NCT03117751,"Neoplasm, Residual",PROCESS_OF,Patients
NCT03117751,Acute T Cell Leukemia,PROCESS_OF,Patients
NCT03117751,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT03117751,Dexamethasone,ADMINISTERED_TO,Patients
NCT03117751,Vincristine,ADMINISTERED_TO,Patients
NCT03117751,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
NCT03117751,Lymphoma,PROCESS_OF,Patients
NCT03301168,Blood Cells,LOCATION_OF,Disease
NCT03301168,Genes,AFFECTS,Cells
NCT03301168,Genes,AFFECTS,T-Lymphocyte
NCT03301168,alpha-beta T-Cell Receptor,INHIBITS,T-Cell Receptors alpha-Chain
NCT03301168,Laboratory,LOCATION_OF,Clinical Research
NCT03301168,Hemopoietic stem cell transplant,TREATS,Patients
NCT03301168,Hematological Disease,PROCESS_OF,Patients
NCT03301168,Infusion procedures,TREATS,Graft-vs-Host Disease
NCT03301168,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT03301168,Hematological Disease,AFFECTS,Patients
NCT02065869,Blood Cells,LOCATION_OF,Disease
NCT02065869,Genes,AFFECTS,Cells
NCT02065869,Genes,AFFECTS,T-Lymphocyte
NCT02065869,T-Cell Receptor,INHIBITS,T-Cell Receptors alpha-Chain
NCT02065869,Laboratory,LOCATION_OF,Clinical Research
NCT02065869,Hemopoietic stem cell transplant,TREATS,Patients
NCT02065869,Hematological Disease,PROCESS_OF,Patients
NCT02065869,Infusion procedures,TREATS,Graft-vs-Host Disease
NCT02065869,Acute graft-versus-host disease,PROCESS_OF,Patients
NCT02065869,Hematological Disease,AFFECTS,Patients
NCT01842672,Mitoxantrone,TREATS,Acute leukemia
NCT01842672,Mitoxantrone,TREATS,Non-Hodgkin's lymphoma recurrent
NCT01842672,Acute leukemia,PROCESS_OF,Child
NCT01842672,Acute leukemia,PROCESS_OF,Adolescent
NCT01842672,Acute leukemia,PROCESS_OF,Young adult
NCT01842672,Therapeutic procedure,TREATS,Child
NCT01842672,Therapeutic procedure,TREATS,Adolescent
NCT01842672,Therapeutic procedure,TREATS,Young adult
NCT01842672,Therapeutic procedure,TREATS(INFER),Acute leukemia
NCT01842672,clofarabine,TREATS,Acute leukemia
NCT01842672,clofarabine,TREATS,Non-Hodgkin's lymphoma recurrent
NCT01842672,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
NCT01842672,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Adolescent
NCT01842672,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Young adult
NCT01842672,Acute leukemia,PROCESS_OF,Child
NCT01842672,Acute leukemia,PROCESS_OF,Adolescent
NCT01842672,Acute leukemia,PROCESS_OF,Young adult
NCT01842672,clofarabine,TREATS,Child
NCT01842672,clofarabine,TREATS,Adolescent
NCT01842672,clofarabine,TREATS,Young adult
NCT01842672,clofarabine,TREATS(INFER),"Lymphoma, Non-Hodgkin's"
NCT01842672,clofarabine,TREATS(INFER),Acute leukemia
NCT00412360,leukemia,PROCESS_OF,Child
NCT00412360,Dysmyelopoietic Syndromes,PROCESS_OF,Child
NCT00412360,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00412360,umbilical cord blood transplantation,TREATS,Patients
NCT00412360,umbilical cord blood transplantation,TREATS(INFER),Hematologic Neoplasms
NCT00412360,Hematologic Neoplasms,PROCESS_OF,Patients
NCT00412360,leukemia,PROCESS_OF,Patients
NCT00412360,Dysmyelopoietic Syndromes,PROCESS_OF,Patients
NCT00412360,Transplantation,TREATS,Patients
NCT00412360,Transplantation,TREATS(INFER),leukemia
NCT00412360,Transplantation,TREATS(INFER),Dysmyelopoietic Syndromes
